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Abstract 
Toxin-antitoxin (TA) systems were identified more than 20 years ago on the 
mini-F plasmid of Escherichia coli as plasmid stability elements; components 
responsible for purging bacterial cells that lack the plasmid from the population. 
More recent discovery of TA systems spanning a wide diversity of prokaryotic 
chromosomes, including that of Mycobacterium tuberculosis (M. tb), suggests a 
broader biochemical role. TA systems can be classified into a number of families, 
with the vapBC systems being by far the largest. The biochemical role of vapBC 
systems in M. tb remains unclear despite their abundance within the genome.  
This thesis describes the biochemical and functional characterisation of two 
vapBC systems encoded by operons Rv0065a/c and Rv0617a/c in the M. tb 
genome. VapCRv0617 overexpression had a bacteriostatic effect on the growth of 
Mycobacterium smegmatis cultures. Therefore, the biochemistry underlying this 
phenotype was investigated, along with that of the Rv0065a/c system. VapCRv0065 
and VapCRv0617 are Mg
2+
-dependent, sequence-specific ribonucleases targeting 
GC-rich 4-mers. Ribonuclease assays with in vitro synthesised RNA transcripts 
suggested an additional layer of target recognition resides in RNA secondary 
structure, and revealed that both VapC proteins exhibit high activity against 
isolated M. smegmatis 16S and 23S rRNA. Electrophoretic mobility shift assays 
with purified VapBC protein and labelled DNA demonstrated an autoregulatory 
function for the VapBCRv0617a/c complex and not the VapBCRv0065a/c complex. 
VapBCRv0617a/c bound specifically to a near-perfect inverted repeat in the 
Rv0617a/c promoter region that overlaps an annotated -10 M. tb promoter 
element. In contrast, the VapBCRv0065a/c complex exhibited no DNA binding 
activity against a putative Rv0065a/c promoter region. Individualised vapBC 
transcriptional regulation mechanisms may help explain the persistence of such an 
expanded number of these systems in the genome. 
Knowledge of the physiological role of vapBC systems in M. tb will enable a 
better understanding of how they contribute to the pathogenicity of this bacterium. 
This would serve as the basis for the design of drugs which interfere with vapBC 
system functioning and in turn the ability of M. tb cells to enter the persistent 
state.  
  
iii 
 
Acknowledgements 
First and foremost I would like to acknowledge Professor Vic Arcus for the 
guidance, support and opportunities that he has provided throughout the duration 
of my MSc degree. I valued his enthusiasm both in the toxin-antitoxin project and 
in my progression as a research scientist. 
I’d like to thank everybody in the Proteins & Microbes lab for making my 
research year by far the most enjoyable year of my tertiary study. I was very 
fortunate to be working in a lab with such great people who are also such talented 
researchers.  
A special mention needs to go out to all the mycobacterial girls, past and present, 
for introducing me to the toxin-antitoxin world and helping me along my way. 
This includes Jo M, Emily, Ali, Emma A and Chelsea. I’d also like to thank the 
remainder of those who have been a part of the Proteins & Microbes team whilst I 
completed my research; Judith, Jo H, Jo D, Mark, Emma S, Tifany, Joel, Kirsty, 
Vikas and Erica. 
A big thank you to those who provided financial support throughout my degree; 
including the University of Waikato, the Brian Perry Charitable Trust, the Nancy 
Caiger Graduate Trust and the NZ Federation of Graduate Women. 
I’d finally like to thank my family, non-scientific friends and Jono for their love 
and unwavering support throughout my studies, with a special thank you to Keith 
whose scientific knowledge and proof-reading skills were very much appreciated!  
 
  
  
iv 
 
Table of Contents 
Abstract .................................................................................................................. ii 
Acknowledgements ............................................................................................... iii 
Table of Contents ................................................................................................. iv 
List of Figures ....................................................................................................... xi 
List of Tables ...................................................................................................... xiv 
List of Abbreviations .......................................................................................... xv 
Chapter One: Introduction .................................................................................. 1 
1.1 Tuberculosis ............................................................................................. 1 
1.2 Toxin-Antitoxin Systems ......................................................................... 2 
1.2.1 First Identification ............................................................................. 2 
1.2.2 Toxin-Antitoxin System Classification ............................................. 4 
1.2.3 Cellular Targets and Activity of Toxin Proteins ............................... 6 
1.2.4 Regulation of Toxin-Antitoxin systems ............................................ 7 
1.2.4.1 Operon Organisation ..................................................................... 7 
1.2.4.2 Antitoxin Auto-Regulation of Transcription ................................. 7 
1.2.4.3 Ratio of Toxin to Antitoxin ........................................................... 8 
1.2.5 Proposed Physiological Roles of Toxin-Antitoxin Systems ............. 8 
1.2.5.1 Persistence ..................................................................................... 8 
1.2.5.2 Programmed Cell Death ................................................................ 9 
1.2.5.3 Cellular Stress Response ............................................................... 9 
1.2.6 Distribution of Toxin-Antitoxin Systems in Mycobacteria ............ 10 
1.3 The VapBC Toxin-Antitoxin Family ..................................................... 11 
1.3.1 PIN-domain Proteins ....................................................................... 12 
1.3.2 Ribonuclease Activity of VapC Proteins ........................................ 13 
1.3.2.1 Proposed Catalytic Mechanism of VapC .................................... 13 
1.3.2.2 Screening for VapC Sequence-Specificity using Pentaprobes .... 14 
1.3.2.3 The Impact of Secondary Structure on RNase-Specificity ......... 15 
1.3.3 Characterised Autoregulation in vapBC Toxin-Antitoxin Systems 16 
  
v 
 
1.3.3.1 The fitAB System of Neisseria gonorrhoeae ............................... 16 
1.3.3.2 The vapBC2 System of Rickettsia felis ....................................... 17 
1.3.3.3 The ntPR System of Sinorhizobium meliloti ............................... 18 
1.3.3.4 The vapBC-1 System of Nontypeable Haemophilus influenza ... 19 
1.4 The vapBC Toxin-Antitoxin Systems in Mycobacteria ......................... 19 
1.4.1 The vapBC System of Mycobacterium smegmatis ......................... 19 
1.4.1.1 VapC Toxicity ............................................................................. 19 
1.4.1.2 VapC RNase-Specificity ............................................................. 20 
1.4.1.3 Intracellular Roles of VapB and the VapBC Complex ............... 21 
1.4.2 The vapBC Systems of Mycobacterium tuberculosis ..................... 21 
1.4.2.1 VapC Toxicity ............................................................................. 22 
1.4.2.2 The Rv0065a/c and Rv0617a/c vapBC Systems .......................... 23 
1.5 Research Objectives ............................................................................... 26 
Chapter Two: Materials & Methods ................................................................. 27 
2.1 General Materials and Methods.............................................................. 27 
2.1.1 DNA Manipulations ........................................................................ 27 
2.1.1.1 Mycobacterium tuberculosis Genomic DNA .............................. 27 
2.1.1.2 Escherichia coli Plasmid DNA Extraction .................................. 27 
2.1.1.3 Agarose Gel Electrophoresis ....................................................... 27 
2.1.1.4 DNA Extraction from an Agarose Gel ........................................ 27 
2.1.1.5 DNA Purification from Solution ................................................. 28 
2.1.1.6 DNA Quantification .................................................................... 28 
2.1.1.7 Restriction Enzyme Digest .......................................................... 28 
2.1.1.8 DNA Ligation .............................................................................. 28 
2.1.1.9 Annealing of DNA Oligonucleotides .......................................... 28 
2.1.1.10 Two Halves Mutagenesis ......................................................... 29 
2.1.1.11 Preparation of Electrocompetent Escherichia coli .................. 29 
2.1.1.12 Electroporation of Escherichia coli ......................................... 30 
2.1.1.13 Preparation of Electrocompetent Mycobacterium smegmatis . 30 
2.1.1.14 Electroporation of Mycobacterium smegmatis ........................ 31 
2.1.2 RNA Manipulation .......................................................................... 31 
2.1.2.1 Total RNA Extraction from Mycobacterium smegmatis ............. 31 
  
vi 
 
2.1.2.2 RNA Precipitation ....................................................................... 32 
2.1.2.3 Purification of 16S and 23S rRNA from Total RNA .................. 33 
2.1.2.4 RNA Quantification .................................................................... 33 
2.1.3 Polymerase Chain Reaction ............................................................ 33 
2.1.3.1 Primers ......................................................................................... 33 
2.1.3.2 PCR for Amplification of Genomic DNA and Plasmid Inserts .. 33 
2.1.3.3 Platinum Pfx PCR ........................................................................ 34 
2.1.3.4 Taq PCR ...................................................................................... 34 
2.1.3.5 iProof PCR .................................................................................. 34 
2.1.3.6 Touchdown PCR ......................................................................... 35 
2.1.3.7 Colony PCR ................................................................................. 35 
2.2 Methods relating to Mycobacterium smegmatis Growth Experiments .. 35 
2.2.1 Construction of Tetracycline Inducible Constructs......................... 35 
2.2.2 Conditional VapC and VapBC Protein Expression ........................ 36 
2.3 Methods Relating to Protein Expression and Purification ..................... 37 
2.3.1 Small Scale Protein Expression in Mycobacterium smegmatis ...... 37 
2.3.1.1 Small Scale Protein Expression ................................................... 37 
2.3.1.2 His-tag Binding Tests .................................................................. 38 
2.3.2 Large Scale Protein Expression in Mycobacterium smegmatis ...... 38 
2.3.2.1 Streaking Plates ........................................................................... 38 
2.3.2.2 Seeder Cultures ............................................................................ 39 
2.3.2.3 Expression Cultures ..................................................................... 39 
2.3.2.4 Glycerol Stocks ........................................................................... 39 
2.3.2.5 Harvesting Cells from Expression Cultures ................................ 39 
2.3.3 Purification of the VapBC complex ................................................ 39 
2.3.3.1 Fast Performance Liquid Chromatography (FPLC) .................... 39 
2.3.3.2 Purification of His-tagged Proteins through IMAC .................... 39 
2.3.3.3 Size Exclusion Chromatography of the VapBC Complex .......... 40 
2.3.3.4 Dialysis of the VapBC Complex ................................................. 40 
2.3.4 Tryptic Digest of the VapBC Complex ........................................... 41 
2.3.5 Purification of VapC ....................................................................... 41 
2.3.5.1 Anion Exchange Chromatography .............................................. 41 
  
vii 
 
2.3.5.2 Concentration of Protein ............................................................. 41 
2.3.5.3 Measurement of Protein Concentration ....................................... 41 
2.3.5.4 SDS-Polyacrylamide Gel Electrophoresis ................................... 42 
2.3.5.5 Coomasie Blue Stain for SDS-PAGE ......................................... 42 
2.4 Methods relating to RNase Assays and their Analysis ........................... 42 
2.4.1 932 Pentaprobe RNA Fragments .................................................... 42 
2.4.1.1 Design of 932 Pentaprobe Fragments ......................................... 42 
2.4.1.2 PCR Amplification of 932 Pentaprobe Fragments ...................... 43 
2.4.1.3 In Vitro Transcription of 932 Pentaprobe Fragments .................. 43 
2.4.2 RNA Secondary Structure Predictions ............................................ 44 
2.4.3 General VapC Ribonuclease Assay Method ................................... 44 
2.4.3.1 Pyrobaculum aerophilum VapC Ribonuclease Assay ................ 44 
2.4.3.2 Mycobacterium tuberculosis VapC Ribonuclease Assay ............ 45 
2.4.4 Urea Denaturing Polyacrylamide Gel Electrophoresis RNA Analysis 
(Urea Denaturing-PAGE).............................................................................. 45 
2.4.5 Visualisation of RNA ...................................................................... 46 
2.4.6 MALDI TOF Mass Spectrometry of RNA Oligonucleotides ......... 46 
2.4.6.1 Sample Purification and Preparation ........................................... 46 
2.4.6.2 MALDI TOF Set Up and Spectra Analysis ................................. 46 
2.4.7 Developed Protocol for Identification of In Vivo VapC Targets .... 47 
2.4.7.1 VapCPAE0151 Ribonuclease Assay ................................................ 47 
2.4.7.2 Poly(A)-tailing of RNA ............................................................... 47 
2.4.7.3 Ligation of Acceptor Oligo ......................................................... 47 
2.4.7.4 cDNA synthesis ........................................................................... 48 
2.5 Methods relating to VapBC DNA Binding Experiments ....................... 48 
2.5.1 Amplification of Rv0065a/c and Rv0617a/c Promoter DNA ......... 49 
2.5.2 Amplification of the mazEF Promoter ............................................ 49 
2.5.3 Creation of Perfect IR Mutations .................................................... 50 
2.5.4 Design of Promoter Oligonucleotides ............................................. 50 
2.5.5 Electrophoretic Mobility Shift Assays (EMSAs) ............................ 51 
2.5.5.1 Labelling Target DNA ................................................................. 51 
  
viii 
 
2.5.5.2 Preparation of VapBC for EMSA ............................................... 51 
2.5.5.3 EMSA Reactions ......................................................................... 52 
2.5.5.4 EMSA Controls ........................................................................... 53 
2.5.5.5 Native TBE Polyacrylamide Gel Electrophoresis ....................... 53 
2.5.5.6 Contact-Blotting and Crosslinking of Oligonucleotides ............. 53 
2.5.5.7 Chemiluminescent Detection ...................................................... 53 
Chapter Three: Results....................................................................................... 55 
3.1 The Effects of Conditional Expression of VapCRv0617 on 
Mycobacterium smegmatis Growth and Morphology ....................................... 55 
3.1.1 The Effect of VapCRv0617 on Cell Growth and Viability ................. 55 
3.1.2 The Effect of VapCRv0617  on Cell Morphology .............................. 60 
3.2 Protein Expression and Purification ....................................................... 61 
3.2.1 Protein Expression in Mycobacterium smegmatis .......................... 61 
3.2.2 Cloning of Rv0065a/c and Rv0617a/c Operons into pYUB28b ..... 62 
3.2.3 Small Scale Protein Expression Trials ............................................ 62 
3.2.4 IMAC Purification of VapBC ......................................................... 62 
3.2.5 Size Exclusion Purification of VapBC ............................................ 64 
3.2.6 Isolation of VapC ............................................................................ 66 
3.3 VapC Ribonuclease Activity .................................................................. 69 
3.3.1 The Importance of RNA Secondary Structure in VapC Ribonuclease 
Activity.. ...................................................................................................... ..69 
3.3.1.1 932 Pentaprobe RNA VapC Ribonuclease Activity Assays ....... 69 
3.3.1.2 932 Pentaprobe RNA Fragments VapC Ribonuclease Activity 
Assays.........................................................................................................70 
3.3.2 VapC Ribonuclease Activity Against In Vivo Substrates ............... 76 
3.3.2.1 Mycobacterial Total RNA Ribonuclease Activity Assays .......... 77 
3.3.2.2 Mycobacterium smegmatis rRNA Ribonuclease Activity 
Assays.... ................................................................................................... .78 
3.3.3 Proposed Protocol for the Identification of In Vivo VapC Targets . 81 
3.3.3.1 Development of Protocol with VapCPAE0151 and the 924 
Pentaprobe .................................................................................................. 82 
  
ix 
 
3.4 VapBC Transcriptional Autoregulation through DNA Binding ............ 85 
3.4.1 Identification of Promoter Regions ................................................. 85 
3.4.2 VapBCRv0065a/c EMSAs with Putative Rv0065a/c Promoter DNA .. 87 
3.4.3 Cross-talk between VapBC Complexes and Promoter DNA .......... 88 
3.4.4 VapBCRv0617a/c EMSAs with Putative Rv0617a/c Promoter DNA .. 88 
3.4.4.1 EMSAs with Perfect Inverted Repeat Mutants ........................... 89 
3.4.4.2 Identification of Near-Perfect Inverted Repeats within the 
Rv0617a/c Promoter ................................................................................... 90 
3.4.4.3 EMSAs with Rv0617a/c Promoter Oligos and Oligo Mutants .... 93 
Chapter Four: Discussion & Future Research ................................................. 96 
4.1 Discussion .............................................................................................. 96 
4.1.1 General Background........................................................................ 96 
4.1.2 VapCRv0617 Overexpression is Toxic and Bacteriostatic to 
Mycobacterium smegmatis Strains ................................................................ 96 
4.1.3 Mycobacterium tuberculosis and Mycobacterium smegmatis TA 
Elements Exhibit No Cross-talk .................................................................... 98 
4.1.4 VapCRv0065 and VapCRv0617 are Ribonucleases Targeting a 
Combination of RNA Sequence and Structure ............................................. 99 
4.1.5 VapCRv0065 and VapCRv0617 Display Ribonuclease Activity Against 
16S and 23S rRNA Isolated from Mycobacterium smegmatis ................... 102 
4.1.6 VapBCRv0617a/c Binds a NPIR in the Rv0617a/c Promoter ............ 103 
4.1.7 VapBC Systems’ Theorised Physiological Role in Mycobacterium 
tuberculosis ................................................................................................. 104 
4.2 Future Research .................................................................................... 106 
4.2.1 Determine the Toxicity of VapCRv0065 to Mycobacterium smegmatis 
Strains...........................................................................................................106 
4.2.2 Microarray Analysis of VapCRv0065 and VapCRv0617 Overexpression 
.....................................................................................................................106 
4.2.3 Further Examine the Specificity of Mycobacterium tuberculosis 
VapC Ribonucleases ................................................................................... 106 
  
x 
 
4.3 Conclusions .......................................................................................... 107 
Appendices ......................................................................................................... 108 
Appendix A: Reagents .................................................................................... 108 
A1: Bacterial Strains and Plasmids ............................................................. 108 
A2: Buffers, Solutions and Media ............................................................... 109 
Appendix B: Sequencing Results .................................................................... 112 
B1: Perfect IR Mutagenesis ........................................................................ 112 
Appendix C: Protein and RNA Information ................................................... 113 
C1: Mycobacterium Protein Information .................................................... 113 
C2: Pyrobaculum Protein Information ........................................................ 113 
C3: Pentaprobe RNA and Flanking Sequences ........................................... 114 
C4: Predicted Secondary Structure of 932 RNA Fragments ....................... 114 
C5: Predicted Secondary Structure of 932 RNA Oligonucleotides ............ 115 
References .......................................................................................................... 116 
 
  
  
xi 
 
List of Figures 
Figure 1.1  Schematic diagram of plasmid addiction showing presence (or 
absence) of the toxin (T) and antitoxin (A) within the cytoplasm .......................... 3 
Figure 1.2 Schematic diagram of interactions in a generalised toxin-antitoxin 
system ...................................................................................................................... 4 
Figure 1.3 The Hidden Markov Model which defines the PIN-domain family of 
proteins .................................................................................................................. 12 
Figure 1.4 Structure of the PIN-domain ................................................................ 13 
Figure 1.5 Proposed catalytic mechanism of PIN-domains .................................. 14 
Figure 1.6 Schematic diagram of VapC purification and sequence specificity 
analysis .................................................................................................................. 15 
Figure 1.7 Secondary structure characterisation of VapC targets ......................... 16 
Figure 1.8 Structure of the FitAB-IR36 complex ................................................. 17 
Figure 1.9 The VapBC2-DNA complex ............................................................... 18 
Figure 2.1 Schematic diagram of two halves mutagenesis ................................... 29 
Figure 3.1. The effect of VapCRv0617 overexpression on the growth of 
M. smegmatis mc
2
155 and ΔvapBC strains ........................................................... 57 
Figure 3.2 Colonies resulting from 5 µl spots of culture dilution series of 10
-2
, 10
-4 
and 10
-6 
after three days incubation at 37 ⁰C ........................................................ 58 
Figure 3.3 The effect of VapCRv0617 overexpression on the viability of 
M. smegmatis mc
2
155 and ΔvapBC strains ........................................................... 59 
Figure 3.4 The effect of conditional expression of VapBC, VapC, and empty 
pMind vector on the growth of M. smegmatis mc
2
155 and ΔvapBC strains ........ 60 
Figure 3.5 VapBCRv0065a/c IMAC purification and corresponding 16.5% 
SDS-PAGE gel ...................................................................................................... 63 
Figure 3.6 VapBCRv0617a/c IMAC purification and corresponding 16.5% 
SDS-PAGE gel. The chromatogram depicts the UV absorbance and elution profile 
of VapBCRv0617a/c. Lanes in the SDS-PAGE gel ................................................... 64 
Figure 3.7 VapBCRv0065a/c size exclusion column purification and corresponding 
16.5% SDS-PAGE gel .......................................................................................... 65 
Figure 3.8 VapBCRv0617a/c size exclusion column purification and corresponding 
16.5% SDS-PAGE gel .......................................................................................... 66 
  
xii 
 
Figure 3.9 Anion exchange purification of a trypsin digest of VapBCRv0065a/c and 
corresponding 16.5% SDS-PAGE gel................................................................... 67 
Figure 3.10 Anion exchange purification of a trypsin digest of VapBCRv0617a/c and 
corresponding 16.5% SDS-PAGE gel................................................................... 68 
Figure 3.11 VapCRv0065 and VapCRv0617  ribonuclease assays against 932 
Pentaprobe RNA ................................................................................................... 69 
Figure 3.12 The 932 Pentaprobe and subset fragments ........................................ 71 
Figure 3.13 VapCRv0065  ribonuclease assay against 932 Pentaprobe fragments ... 72 
Figure 3.14 VapCRv0617 ribonuclease assay against 932 Pentaprobe fragments .... 73 
Figure 3.15 932 109-126 RNA, VapCRv0617 and VapCRv0065 MALDI TOF MS 
results .................................................................................................................... 74 
Figure 3.16 MFE secondary structure predictions for the 932 94-126 and 109-126 
RNA ...................................................................................................................... 75 
Figure 3.17 Ribonuclease activity of VapCRv0065 and VapCRv0617 from M. tb using 
M. smegmatis total RNA as a substrate ................................................................. 77 
Figure 3.18 Ribonuclease activity of VapCRv0617 from M. tb using M. bovis total 
RNA as a substrate ................................................................................................ 78 
Figure 3.19 Isolation of total RNA from M. smegmatis ....................................... 79 
Figure 3.20 Ribonuclease activity of VapCRv0065 and VapCRv0617 from M. tb 
against isolated M. smegmatis 16S rRNA ............................................................. 80 
Figure 3.21 Ribonuclease Activity of VapCRv0065 and VapCRv0617 from M. tb 
against isolated M. smegmatis 23S rRNA ............................................................. 80 
Figure 3.22 Proposed protocol for identification of in vivo M. tb VapC mRNA 
targets. ................................................................................................................... 82 
Figure 3.23 Ribonuclease activity of VapCPAE0151 from Pyrobaculum aerophilum 
against the 924 Pentaprobe.................................................................................... 83 
Figure 3.24 2% TAE agarose gel of PCR amplified and tagged RNase assay 
products/Pentaprobe 924 RNA ............................................................................. 83 
Figure 3.25 Putative Rv0065a/c and Rv0617a/c promoter elements .................... 87 
Figure 3.26 VapBCRv0065a/c does not bind to a 101 bp region of the Rv0065a/c 
promoter ................................................................................................................ 87 
Figure 3.27 VapBCRv0065a/c does not bind to a 150 bp region of the Rv0065a/c 
promoter ................................................................................................................ 88 
  
xiii 
 
Figure 3.28 VapBCRv0617a/c binds specifically to a 130 bp region of the Rv0617a/c 
promoter ................................................................................................................ 89 
Figure 3.29 VapBCRv0617a/c does not bind to the perfect IR in the Rv0617a/c 
130 bp promoter region ......................................................................................... 90 
Figure 3.30 Putative Rv0617a/c promoter region indicating NPIRs and designed 
oligo positioning ................................................................................................... 92 
Figure 3.31 VapBCRv0617a/c binds specifically to the 50 bp region of DNA directly 
preceding the TSP ................................................................................................. 93 
Figure 3.32 Testing VapBCRv0617a/c binding against four oligo 5 variants ............ 94 
Figure 3.33 VapBCRv0617a/c requires NPIR J for binding to the Rv0617a/c promoter 
region..................................................................................................................... 94 
Figure 3.34 VapBCRv0617a/c gel shift competition experiments ............................. 95 
 
  
  
xiv 
 
List of Tables 
Table 1.1 The nine toxin-antitoxin families ............................................................ 7 
Table 1.2 Sequence-specificity of three characterised VapC proteins .................. 24 
Table 2.1 Primers used for cloning into pMind vector ......................................... 37 
Table 2.2 Primers used for amplification of Pentaprobe 932 fragments............... 43 
Table 2.3 Primers used in VapC target identification protocol ............................. 48 
Table 2.4 Primers used for investigation of VapBC-promoter binding activity ... 50 
Table 2.5 Properties of designed Rv0617a/c promoter oligonucleotides .............. 51 
Table 2.6 Primers used in creation of Rv0617a/c promoter oligos. ...................... 52 
Table 3.1 Minimum free energy values at 37 ⁰C for each RNA substrate as 
calculated by RNAfold WebServer ....................................................................... 75 
Table 3.2 Properties of NPIRs in the 130 bp Rv0617a/c putative promoter region
 ............................................................................................................................... 91 
Table A1.1 Bacterial Strains ............................................................................... 108 
Table A1.2 Plasmids ........................................................................................... 108 
Table A2.1 Buffers and Solutions ....................................................................... 109 
Table A2.2 Liquid Media .................................................................................... 110 
Table A2.3 Solid Media ...................................................................................... 111
  
xv 
 
List of Abbreviations 
Systeme International d’Unités (SI) abbreviations for units and standard notations 
for chemical formulae and elements are used throughout this thesis. Additional 
abbreviations used are listed below. 
Ω   Ohms 
µg   microgram (10
-6 
g) 
µl   microliter (10
-6 
L) 
µm   micrometer (10
-6 
m) 
µM   micromolar (10
-6 
M) 
3-HPA   3-hydroxypicolinic acid 
A   adenine 
ACN   acetonitrile 
ADC   albumin dextrose catalase 
ATP   adenosine triphosphate 
APS   ammonium persulfate 
bp   base pair(s) 
BSA   bovine serum albumin 
C   cytosine 
cDNA   complementary DNA 
CFU   colony forming units 
Da   Daltons 
DEPC   diethyl pyruvate carbonate 
DIG   digoxigenin 
DNA   deoxyribose nucleic acids 
DNase   deoxyribonuclease 
ds   double-stranded 
EDTA   ethylene diamine tetraacetic acid (disodium salt) 
EMSA   electrophoretic mobility shift assay 
FPLC   fast performance liquid chromatography 
g   times the force of gravity 
G   guanine 
HdB   Hartmans-de Bont 
HGT   horizontal gene transfer 
  
xvi 
 
His-tag  poly-histidine tag 
HPLC   high performance liquid chromatography 
IMAC   immobilising metal affinity chromatography 
IR   inverted repeat 
kb   kilobase 
kDa   kilo Dalton 
kV   kilo Volt 
LB   Luria Bertani 
LBT   Luria Bertani plus Tween-80 
MALDI TOF   matrix assisted laser desorption ionisation time of flight 
mAU   milli-absorbance units 
MDT   multi-drug tolerant 
MS   mass spectrometry 
mg   milligram (10
-3 
g) 
ml   millilitre (10
-3 
L) 
mM   (10
-3 
M) 
mRNA   messenger RNA 
MS   mass spectrometry 
MW   molecular weight 
NPIR   near-perfect inverted repeat 
NRP   non-replicating persistence 
OD600   optical density at 600 nm wavelength 
ORF   open reading frame 
PAGE   poly acrylamide gel electrophoresis 
PCR   polymerase chain reaction 
pI   isoelectric point 
PIN   PilT N-terminal domain 
PSK   post segregational killing 
RHH   ribbon-helix-helix 
R-M   restriction modification 
RNase   ribonuclease 
rpm   revolutions per minute 
rRNA   ribosomal RNA 
SDS   sodium dodecyl sulphate 
  
xvii 
 
SOC   super optimal broth with catabolite repression 
sRNA   small RNA 
Ss   single stranded 
T   thymine 
TA   toxin-antitoxin 
TAE   tris-acetate-EDTA 
TB   tuberculosis 
TE   tris EDTA buffer 
TEMED  N, N, N, N,-tetramethylethylenediamine 
Tm   melting temperature 
TOF   time of flight 
Tris   tris-hydroxymethyl aminomethane 
tRNA   transfer ribonucleic acid 
TSP   transcriptional start point 
U   uracil 
uF   micro Faraday 
UTR   untranslated region 
UV   ultra violet 
Vap   virulence associated protein 
VapBCRv0065a/c  VapBC encoded from the Rv0065a/c operon of M. tb 
VapBCRv0617a/c  VapBC encoded from the Rv0617a/c operon of M. tb 
VapCRv0065   VapC encoded from the Rv0065 gene of M. tb 
VapCRv0617  VapC encoded from the Rv0617 gene of M. tb 
VapCMS1284  VapC from M. smegmatis 
VapBMS1283  VapB from M. smegmatis 
v/v   volume per volume 
WHO   World Health Organisation 
w/v   weight per volume 
w/w   weight per weight 
XDR   extensively drug resistant
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1. Chapter One: Introduction 
1.1 Tuberculosis 
The disease tuberculosis (TB), caused by Mycobacterium tuberculosis (M. tb), 
remains one of the most lethal infectious diseases despite the availability of 
chemotherapy and the BCG vaccine (Babajan et al. 2011). One-third of all 
humans world-wide are estimated to currently carry this microorganism, 
responsible for killing approximately 2 million people each year (Ramage et al. 
2009). The World Health Organization reports that in 2011 an estimated 8.7 
million new TB cases emerged (13% co-infected with HIV), with 1.4 million 
resulting in mortality. Geographically, the TB burden is greatest in Asia and 
Africa; India and China account for approximately 40% of the world’s reported 
TB cases, while the African region, contributing 24%, exhibits the highest rate of 
cases and deaths per capita (WHO 2012). 
M. tb is an intracellular bacterial pathogen, belonging to the genus Mycobacterium 
and the order Actinomycetales. Due to the unique structure of the mycobacterial 
cell wall, M. tb does not fall into the classic Gram negative/Gram positive 
classification. While still containing peptidoglycan, over 60% of the cell wall 
consists of complex lipids such as mycolic acids, cord factor and wax-D (Rajni et 
al. 2011). The unique cell wall structure plays an important role in virulence, 
contributing to resistance against antibiotics and lethal oxidants while assisting 
persistence within host cell environments such as within the macrophage (Rajni et 
al. 2011). The hardy cell wall also retards the passage of nutrients in and out of 
the cell, contributing to mycobacterial species’ characteristically slow growth rate. 
Persistence presents a significant hurdle for the successful treatment of M. tb 
infections, due to the ability of M. tb cells to enter into a ‘dormant’ state of 
growth. In vivo, dormancy is characterised by near zero growth, a state referred to 
as nonreplicating persistence (NRP) (Gill et al. 2009). Adopting a dormant phase 
of marginal growth renders cells refractory to antibiotic treatments that target 
rapidly dividing cells, while preserving energy and nutrients for survival in 
stressful environments. Subpopulations of the bacterial infection, termed 
multidrug tolerant (MDT) persisters, may exhibit resistance to a number of 
antimicrobial therapies. Alarmingly, 20% of previously treated cases and 3.7 % of 
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new cases are estimated to exhibit such resistance (WHO 2012). Equipped with 
the ability to selectively downregulate metabolism to the dormant level when 
required, M. tb is known to thrive in both nutrient rich and poor environments. 
Persistence within nutrient poor host macrophages (Pieters 2008) renders the  
immune system blind to the infection, allowing TB cases to be asymptomatic until 
cells emerge from dormancy, sometimes decades later (Murphy & Brown 2007). 
Out of the approximately 1.8 billion people currently infected with M. tb, the vast 
majority of cases display such clinical latency (Gill et al. 2009). To date, the 
physiology of bacteria in the dormant state, and the factors that establish and 
maintain this metabolic plasticity, are not well understood. 
As the number of MDT TB cases increases, finding weaknesses in the pathogen 
that can be exploited in new treatments has become the main research thrust. 
Ultimately, studies aim to fully understand mechanisms by which M. tb is able to 
selectively and reversibly regulate growth when exposed to a variety of stresses. 
Characterizing the components involved in these mechanisms may lead to new 
targets for drug therapy, as interference with these pathways that permit M. tb 
cells to enter the dormant state may increase the effectiveness of existing drug 
treatments.  
Entry into dormancy when faced with environmental stresses is a widely observed 
trait among pathogenic bacteria. Through adaptive evolution, multiple systems to 
ensure survival through dormancy have been developed, such as the 
toxin-antitoxin (TA) systems (Blower et al. 2012). The expansion and multiplicity 
of these systems in the M. tb genome implies they have significant a role in 
survival, making them of particular interest in the study of M. tb pathology. 
1.2 Toxin-Antitoxin Systems 
1.2.1 First Identification 
TA systems residing on bacterial plasmids were first noted more than 20 years 
ago on the mini-F plasmid of Escherichia coli and were denoted as elements that 
protect low copy number plasmids in bacteria from loss during segregation 
(Ogura & Hiraga 1983). As replication of F and oriC plasmids is not coupled to 
cell division, a small population of cells would lack a plasmid after each 
divisional round. In order to minimize the production of plasmid-free segregants, 
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a genetic system encoded on the mini-F plasmid (later termed the ccdAB TA 
system) is employed to temporarily block cell division. Interplay between the two 
genes within this system (ccdB and ccdA) was found to be essential for 
maintaining the balance of such inhibition. The ccdB gene inhibits cell division by 
encoding a ‘toxin’ protein component while the ccdA gene lifts the inhibition 
through production of an ‘antitoxin’ protein component (Ogura & Hiraga 1983). If 
the plasmid is lost through segregation during cell division, the stoichiometric 
balance of toxin : antitoxin is thrown off due to a shorter antitoxin half-life. This 
results in bacteriostasis or cell death, purging plasmid-less cells from the 
population (Rankin et al. 2012). This strategy of plasmid-maintenance, outlined in 
Figure 1.1, is referred to as ‘post-segregational killing’ (PSK). As such, the 
underlying TA systems are often referred to as ‘addiction modules’, based on the 
observation that they function to ‘addict’ cell lines to the TA complex and loss of 
the TA system may result in PSK (Gerdes et al. 1986; Engelberg-Kulka & Glaser 
1999). The interplay of a toxic component and a cognate toxicity quencher, as 
initially observed in the ccdAB system, is now known to be characteristic of all 
classified TA systems (Rankin et al. 2012).  
 
Figure 1.1  Schematic diagram of plasmid addiction showing presence (or absence) of the 
toxin (T) and antitoxin (A) within the cytoplasm. If cell division results in loss of the plasmid, 
the antitoxin will be degraded more quickly leaving an unmasked toxin. As a result the daughter 
cell is killed. Figure adapted from Rankin et al (2012). 
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Genetic systems exhibiting similar interactions to the ccdAB system were later 
identified on the plasmids of a variety of other bacterial species (Gerdes et al. 
1986), and the discovery of chromosomally-encoded TA systems in disparate 
prokaryotic and archaic taxa suggested they play a broader role in bacterial 
biology. Interestingly, a number of pathogenic bacterial species exhibit large 
expansions in the number of TA systems encoded in their genomes, for example 
E. coli 0157 and CFT073, Streptococcus pneumoniae, Vibrio cholera and M. tb 
(Pandey & Gerdes 2005).  
1.2.2 Toxin-Antitoxin System Classification 
TA systems are bicistronic operons identified by their characteristic protein 
interactions (Anantharaman & Aravind 2003). One gene in the operon encodes a 
‘toxic’ component that targets an essential cellular function such as replication or 
translation. Ectopic overexpression of the toxin may result in cell death or stasis. 
The other, generally smaller, gene encodes a cognate ‘antitoxin’ component that 
quenches the toxin’s deleterious effect. This interaction is depicted in Figure 1.2. 
A balance of toxicity is achieved through differential stability of the stable toxin 
and the more unstable antitoxin (Fineran et al. 2009). Greater lability of the 
antitoxin requires it to be produced at a higher rate in order to maintain constant 
suppression of the toxin’s effects (McKenzie 2011).     
 
TA systems have been currently classified into five types based on the nature of 
the interaction between the toxin and antitoxin components (Brantl 2012). 
benign protein 
complex
protease growth 
arrest
Antitoxin Toxin
(DNA Binding) (toxic)
Figure ‎1.2 Schematic diagram of interactions in a generalised toxin-antitoxin system. Toxin 
and antitoxin genes are encoded in a two-gene operon. The toxin protein exhibits deleterious 
effects such as growth arrest when not bound in a benign complex with the antitoxin. The antitoxin 
alone, and in complex with the toxin, binds to the promoter region of the TA operon. The antitoxin 
has greater lability and is more susceptible to proteolytic degradation. Figure adapted from 
McKenzie  (2011). 
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Type I systems have been identified in both Gram-negative and Gram-positive 
bacteria and are characterised by the antitoxin component acting as a small RNA 
(sRNA). The antitoxin and toxin gene-pair is either overlapping and convergently 
transcribed, where the antitoxin is an antisense RNA, or divergently transcribed, 
where the antitoxin is a trans-encoded sRNA. The antitoxin RNA specifically 
binds to and inhibits translation of the toxic protein mRNA transcript. 
Complementary base-pairing between the antitoxin and toxin mRNA forms a 
double-stranded (ds) RNA region across the ribosomal binding site, which blocks 
translation initiation and recruits endoribonuclease III for toxin RNA degradation 
(Brantl 2012).  Examples of type I TA systems include the ldr/rdl and tisB/istR-1 
systems of E. coli (Kawano 2012; Wagner & Unoson 2012). 
Type II TA systems are characterised by a smaller, unstable antitoxin protein that 
sequesters the toxin protein in a benign heterodimeric protein complex. A type II 
operon normally consists of two genes, where the upstream gene encodes the 
antitoxin (Van Melderen & Saavedra De Bast 2009). The vapBC and mazEF 
systems fall into the class of type II TA systems. 
While type I and II TA systems were discovered on plasmids in the 1980s, type III 
systems weren’t identified until 2009 (Fineran et al. 2009). In type III systems, the 
antitoxin is an RNA containing a pseudoknot motif that directly binds to and 
inhibits the toxin protein. The antitoxin is encoded by a number of short tandem 
repeat sequences upstream of the toxin gene. These repeats serve as a 
transcriptional terminator to regulate the ratio of antitoxic to toxic RNA 
transcripts (Fineran et al. 2009; Blower et al. 2012). The toxIN locus in 
phytopathogen Pectobacterium atrosepticum encodes the first identified type III 
TA system. Here, the toxin protein, ToxN, is encoded downstream of a 36 bp 
ToxI antitoxin region encompassing an array of 5.5 tandem repeats (Fineran et al. 
2009). 
Recently proposed type IV TA systems involve the antitoxin protein quenching 
the toxin’s activity through interfering with the toxin’s ability to bind its target. 
This is most recently observed in the yeeU-yeeV system of E. coli (Masuda et al. 
2012). 
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The antitoxin component of type V TA systems acts as a ribonuclease (RNase) to 
cleave the toxin-encoding mRNA. To date, only the ghoS/ghoT system falls into 
this class, and provides the only example of an antitoxin which functions by 
cleaving toxin mRNA (Wang et al. 2012).  
Other possible classes of TA systems include restriction modification (R-M) 
systems. These systems similarly act as selfish genetic elements and consist of 
two genes encoding a restriction endonuclease and a DNA methyltransferase. The 
endonuclease acts as the toxic component, introducing double-strand breaks at 
short recognition sequences in the DNA provided that these are devoid of 
methylation. The methyltransferase acts as the cognate antitoxin, methylating and 
in turn protecting regions of the genome targeted by the endonuclease (Naito et al. 
1995). As seen with classical TA systems, there is a degree of multiplicity in the 
R-M systems encoded in various genomes (Magnuson 2007). For example, the 
Helicobacter pylori J99 genome encodes approximately two dozen R-M loci 
(Kong et al. 2000). 
1.2.3 Cellular Targets and Activity of Toxin Proteins 
At present, nine TA families have been classified based on amino acid sequence 
homology of the toxin component (Van Melderen & Saavedra De Bast 2009). The 
toxins have a range of targets within the cell, including DNA gyrases (ccdAB and 
parDE loci), the translating ribosome (relBE loci) and RNA (mazEF and vapBC 
loci) (Bahassi et al. 1999). Thus far, the most common means of toxicity is 
observed to be non-specific or site-specific mRNA cleavage which, in turn, results 
in  translational inhibition of target transcripts (Van Melderen & Saavedra De 
Bast 2009). Several toxins displaying RNase activity contain PIN domains, a 
motif thought to be associated with such a function (Clissold & Ponting 2000). 
Selective activation of mRNases may allow the bacteria to adapt to stress by 
altering the transcriptome, allowing rapid changes in metabolic processes 
(Ramage 2010). Toxin-mediated inhibition of protein synthesis through 
interaction with RNA has also been observed via an mRNA-cleavage independent 
route. Here, selective, stable binding of the toxin to the transcript is sufficient for 
translational inhibition (Sharp et al. 2012). Table 1.1 provides a summary of 
annotated TA families and the proposed activity of their toxin within the cell. 
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 Table 1.1 The nine toxin-antitoxin families 
TA 
Family 
Toxin Target Activity Cellular Process 
CcdAB DNA Gyrase Generates dsDNA breaks Replication 
RelBE Translating 
Ribosome 
Induces mRNA cleavage Translation 
MazEF mRNAs Endoribonuclease Translation 
ParDE DNA Gyrase Generates double-stranded DNA 
breaks 
Replication 
Phd/doc Translating 
Ribosome 
Induces mRNA cleavage Translation 
VapBC mRNAs Endoribonuclease Translation 
HipBA EF-Tu Protein Kinase Translation 
HicRA 
ω-ε-ζ 
ND 
ND 
mRNA cleavage 
Phosphotransferase 
Translation 
ND 
Abbreviations: ND, not determined; Ccd, coupled cell division; Par, partitioning; doc, death on 
curing; Vap, virulence associated protein; Hip, high persistence. Table adapted from Van 
Melderen & Saavedra De Bast (2009).  
 
1.2.4 Regulation of Toxin-Antitoxin systems 
1.2.4.1 Operon Organisation 
In order to orchestrate tight control of toxin activity within the cell, many levels of 
regulation are proposed to control the expression of TA operons. In bicistronic TA 
operons, organisation of the antitoxin upstream of the toxin may be an adaption 
resulting in a gene dosage effect, where the antitoxin is produced in a higher dose. 
In agreement with this, a study of the ccdAB type II TA system confirmed higher 
levels of the antitoxin compared to the toxin in E. coli (Afif et al. 2001). The 
authors noted, however, that this observation may have been partially attributed to 
a post-transcriptional regulation mechanism of 3’-degradation of the TA 
transcript, as is seen for kid/kis mRNA (Ruiz-Echevarría et al. 1995). 
1.2.4.2 Antitoxin Auto-Regulation of Transcription 
A characteristic feature of most TA systems examined is the interaction between 
the antitoxin/benign TA complex, and the TA operon promoter (Christensen et al. 
2004). This interaction serves to sterically block access of RNA polymerase to the 
promoter, thereby down-regulating the production of TA operon transcripts and in 
turn the protein products. Two-component TA systems, such as the mazEF and 
vapBC systems, exhibit a characteristic autoregulation interaction where binding 
occurs between DNA-binding motifs at the antitoxin N-termini, and 
palindromic/repeat sequences in the promoter DNA. 
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1.2.4.3 Ratio of Toxin to Antitoxin 
The ratio of toxin to antitoxin can play an important role in regulating TA operon 
transcription. While the antitoxin alone is usually sufficient for repression, in most 
cases the toxin acts as a co-repressor and enhances binding through strengthening 
the antitoxin-DNA interaction (Afif et al. 2001; Christensen et al. 2001; Garcia-
Pino et al. 2010; Ramage 2010).  For example, the FitA antitoxin binds to a target 
inverted repeat (IR) sequence in its promoter with relatively low affinity 
(Kd=178 nM), which increases by 38-fold when the FitB toxin forms a 
heteromeric complex with FitA (Kd=4.5 nM) (Wilbur et al. 2005). ‘Conditional 
cooperativity’ describes the phenomenon whereby TA complexes only repress 
transcription from their cognate promoter when the antitoxin and toxin are present 
in the correct stoichiometric amounts (Brown et al. 2013). This is the case for the 
ccdAB TA system, where the levels of CcdB toxin can either enhance or inhibit 
the DNA-binding activity of the antitoxin. When present in equal amount to the 
CcdA antitoxin, CcdB significantly enhances the affinity of CcdA for DNA. 
Surpassing this equimolar CcdB:CcdA ratio causes destabilision of the 
antitoxin-DNA complex (Afif et al. 2001). Conversely, it was recently revealed in 
the mqsAR TA system of E. coli that the toxin, MqsR, functions to destabilize the 
MsqA antitoxin-promoter DNA complex under all conditions and at all 
toxin:antitoxin stoichiometries. This is the first identified TA system where under 
no conditions does the toxin act as a transcriptional co-repressor, and instead, 
actively destabilizes the antitoxin-DNA interaction (Brown et al. 2013). 
1.2.5 Proposed Physiological Roles of Toxin-Antitoxin Systems 
While the mechanisms of bacterial TA systems have been extensively studied, the 
physiological roles they play are not universally understood. Widely suggested 
involvements include in bacterial persistence, programmed cell death and the 
cellular stress response (Amitai et al. 2004; Pandey & Gerdes 2005; McKenzie 
2011). TA-mediated stabilisation of integrons (Christensen-Dalsgaard & Gerdes 
2006) and contribution to the biofilm formation process (Garcia-Contreras et al. 
2008) have also been proposed. 
1.2.5.1 Persistence 
It is observed that the majority of bacteria encoding TA operons exhibit a 
common metabolic state of dormancy or slow growth (Miallau et al. 2009). As 
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such, TA systems are suspected to play a role in the formation of MDT persister 
subpopulations. (Balaban et al. 2004; Keren et al. 2004). Studies conducted in 
E. coli demonstrated that deletion of a hipBA TA operon resulted in a decrease in 
MDT formation, while over-expression of the toxin HipA dramatically increased 
the persister population. Similarly, over-expression of the RelE toxin of the relBE 
TA operon  resulted in a 10,000 fold increase in persisters in an E. coli bacterial 
culture post-antibiotic treatment (Keren et al. 2004). Studies of TA systems in 
M. tb have drawn comparable conclusions, for example the expression of an M. tb 
chromosomally encoded TA system (Rv1102c - Rv1103c) in M. smegmatis was 
seen to induce growth stasis and led to a significant increase in the persister cell 
population (Han et al. 2010). 
Persistence may result from TA systems conferring a competitive advantage to the 
genetic element they are located on, as Cooper & Heinemann (2000) observed 
that plasmids containing a TA system outcompeted the same plasmid lacking the 
TA over hundreds of generations (Cooper & Heinemann 2000). Alternatively, the 
toxin’s action within the cell may permit entry into a reversible bacteriostatic state 
in which energy conservation is achieved for persisting through unfavourable 
environments and/or harsh conditions (Miallau et al. 2009; Rotem et al. 2010).  
1.2.5.2 Programmed Cell Death 
This theory suggests toxin-induced programmed suicide of a sub-population of 
cells. The proposal is contested by many, as it is deemed unlikely from an 
evolutionary stand-point that a single-celled organism would encode a multitude 
of suicide elements as observed in organisms such as M. tb (Pandey & Gerdes 
2005). Nonetheless, Mutschler et al (2011) suggest a mechanism of programmed 
cell death employed by zeta toxins, members of the epsilon/zeta TA family, in 
E. coli. The mechanism involves interference with MurA, an enzyme involved in 
peptidoglycan synthesis for bacterial cell wall production. The interaction was 
confirmed on solving the crystal structure of the zeta toxin bound to MurA 
(Mutschler et al. 2011). 
1.2.5.3 Cellular Stress Response 
Multiple studies have concluded that TA systems function in response to stressors 
to induce the NRP state when environmental conditions are unfavourable (Gerdes 
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2000; Gerdes et al. 2005). In response to stress signals, bacterial cells may trigger 
toxin activity in order to manipulate expression within the cell, tailoring the 
transcriptome to include only transcripts required for the current stress. This 
metabolic reprogramming would result in more efficient energy expenditure 
(Gerdes et al. 2005; Condon 2006; Ramage et al. 2009). A number of studies 
probing the importance of TA systems in E. coli have provided support for this 
hypothesis. Two TA systems in strains of extraintestinal pathogenic E. coli 
(yefM-yoeB and ybaJ-hha) have been associated with promoting colonization of 
the host bladder, while the pasTI TA system was found to be essential for survival 
within the host kidneys. Low-level expression of the PasT toxin in such strains 
significantly increased survival in response to nitrosative and oxidative stresses as 
well as during nutrient limitation (Norton & Mulvey 2012). RNA cleaving toxins 
such as SymE in E. coli have been proposed to be activated in response to the 
cellular stress response, playing a role in recycling damaged mRNAs that have 
been produced as a result (Kawano 2012).  
Taken together, the observations made in E. coli along with recent research on 
M. tb (Arcus et al. 2005; Ramage et al. 2009; McKenzie 2011) have led to the 
hypothesis that the numerous TA proteins encoded within the M. tb genome are 
involved in the transitions between active and persistent/dormant phases of M. tb 
growth. The working model is that under adverse conditions, specific proteases 
are activated within the M. tb cell that break-down the antitoxin at a greater rate 
than the toxin, allowing the toxin to be released and exhibit its toxic effect to 
curtail bacterial replication. Cellular processes may manipulate the balance of 
toxin to antitoxin produced in order to fine-tune the onset and duration of the 
persistent state until more favourable conditions for growth are encountered 
(Rotem et al. 2010). 
1.2.6 Distribution of Toxin-Antitoxin Systems in Mycobacteria 
TA systems are ubiquitous in the genomes of free-living prokaryotes, notably so 
in many bacteria with pathogenic properties (Gerdes et al. 2005).  The M. tb 
genome has been found to encode 88 putative TA loci (Ramage et al. 2009; 
Frampton et al. 2012; Min et al. 2012) and many interpret this massive expansion 
as an indication of their involvement in TB pathogenesis (Ramage et al. 2009).  
Of the identified TA systems encoded in the M. tb genome, 37% have been 
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mapped to regions noted as sites of horizontal gene transfer (HGT), suggesting 
that the mycobacteria may have originally acquired these TA genes from other 
species (Arcus et al. 2011). The majority of M. tb TA systems are found to be 
conserved only in mycobacteria with pathogenic properties, indicating that 
attaining these systems was an important step in evolution of M. tb (Ramage et al. 
2009). Why M. tb has so many TA systems and the exact physiological role that 
they play in the cell is unclear. Expression profiling of M. tb TA systems under a 
number of environmental conditions, revealed four that were selectively 
upregulated during either hypoxic stress (Rv2009-2010 and Rv1955-1956) or 
phagocytosis into macrophages (Rv1560-1561 and Rv0549c-0550c) (Ramage et 
al. 2009). Interestingly, different TA systems were seen to be upregulated in 
response to different stressers, suggesting that specific subsets of TA systems are 
triggered in response to certain environmental changes as opposed to 
global/genome-wide TA system activation. Together these results hint at TA 
systems’ involvement in M. tb cellular processes for overcoming stresses which 
are likely encountered in vivo. 
1.3 The VapBC Toxin-Antitoxin Family 
The vapBC (virulence associated proteins B and C) operons make up the largest 
of the nine identified TA families, however little is known about their 
physiological role. The association of many vapBC operons with repetitive 
elements, transposases and virulence factors implies a contribution to virulence 
(Arcus et al. 2005; Ramage et al. 2009). With the increasing technical feasibility 
and affordability of whole genome sequencing, a range of organisms encoding 
vapBC TA systems at varying abundance is being revealed. Noteworthy 
organisms displaying a large number include Microcystis aeruginosa (34 loci) 
Pyrococcus kodakaraensis (28 loci) and Sulfolobus tokodaii (24 loci) (Arcus et al. 
2011). Among the mycobacteria, the expansion of vapBC systems is restricted to 
mammalian pathogenic species such as M. tb where at least 47 vapBC loci have 
been identified (Ramage et al. 2009; Ahidjo et al. 2011). In contrast, 
non-pathogenic Mycobacterium smegmatis and the pathogen 
Mycobacterium leprae reportedly encode one and none vapBC loci respectively. 
A mechanism of HGT among the gene pool may explain observations of 
homologous TA elements occurring between phylogenetically distant organisms, 
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while showing little conservation between isolates belonging to the same bacterial 
species (Arcus et al. 2005; Van Melderen & Saavedra De Bast 2009).  
The VapBC TA family is characterised by the toxic component (VapC) belonging 
to the PilT N-terminal domain (PIN domain) family of proteins, while the 
anti-toxin component (VapB) falls into the protein family of transcription factors.  
1.3.1 PIN-domain Proteins 
The PIN-domains constitute an extensive protein family, with members identified 
in all three domains of life. Despite there being poor sequence conservation across 
the family, the 11 PIN-domain structures in the Protein Data Bank exhibit high 
conservation in three-dimensional structure (Arcus et al. 2011). PIN-domains 
possess a triad of strictly conserved acidic residues along with a fourth less well 
conserved acidic residue (Figure 1.3).  
 
Figure 1.3 The Hidden Markov Model which defines the PIN-domain family of proteins. The 
height of a letter represents the proportion of information it provides with respect to its position in 
the PIN-domain family. Column widths indicate the importance of this position in defining the 
family. Dark and light pink columns represent sequence regions containing insertions. Taken from 
PFam (Finn et al. 2010) using HMM Logo (Schuster-Bockler et al. 2004).  
 
An additional feature of PIN-domain proteins is the positioning of a polar residue 
(Asn, Ser or Thr) directly following the first conserved Asp residue (Arcus et al. 
2011). The conserved tertiary structure positions the quartet of conserved residues 
(three asparagines (D) and one glutamine (E)) and the polar residue in close 
spatial proximity within a negatively charged pocket constituting the active site 
(Figure 1.4). Positioned here, these residues play an important role in sequestering 
Mg
2+
 ions that are required for catalytic activity (Arcus et al. 2011). 
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Figure 1.4 Structure of the PIN-domain. A, A cartoon schematic of the PIN-domain coloured 
blue to red from N- to C-terminus. B, The same structure as A, indicating the four conserved 
acidic residues, the conserved polar residue and a black Mg
2+ 
ion. Figure taken from Arcus et al 
(2011). 
The Pfam database currently lists 6253 annotated PIN-domain protein sequences 
occurring in 1341 species (Finn et al. 2010). The number of PIN-domain 
sequences mapped to the M. tb genome is notably higher than that found in any 
other studied organism. The PIN-domain motif is thought to be associated with 
ribonuclease function (Clissold & Ponting 2000; Ramage 2010). Accordingly, in 
mycobacteria, PIN-domain proteins exhibit their toxicity through endogenous 
ribonuclease activity, cleaving ssRNA in a sequence-specific and 
Mg
2+
/Mn
2+
-dependent manner (Robson et al. 2009). 
1.3.2 Ribonuclease Activity of VapC Proteins 
1.3.2.1 Proposed Catalytic Mechanism of VapC 
The definitive catalytic mechanism of PIN domain proteins is currently unknown, 
however recently, two mechanisms for catalysis of ssRNA cleavage by VapC 
PIN-domain proteins were proposed. The data support a reaction proceeding via a 
one metal, or two metal catalysis mechanism (Figure 1.5). Crystal structures of 
VapCPAE0151 from Pyrobaculum aerophilum reveal the first metal to be 
coordinated by the second and third conserved aspartate residues, and this metal is 
implicated in the activation of the water nucleophile. This cleavage mechanism is 
believed to leave ssRNA products with a 5’-terminal monophosphate group, as is 
indicated by matrix-assisted laser desorption ionization time of flight mass 
spectrometric (MALDI TOF MS) analysis of VapC RNase assay cleavage 
products (McKenzie 2011; Duyvestyn 2012).  
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Figure 1.5 Proposed catalytic mechanism of PIN-domains. A, One-metal catalysis mechanism. 
B, Two-metal catalysis mechanism. Conserved acidic residues of the active sites are shown in 
cyan, the nucleophile in blue, the RNA substrate in black and the metal ion as a labelled black 
circle. Arrows represent electron movement. Figure taken from Duyvestyn (2012). 
 
1.3.2.2 Screening for VapC Sequence-Specificity using Pentaprobes 
It is theorised that the four conserved acidic residues in the PIN-domain active site 
of VapC enzymes interact with substrate ssRNA in a manner that allows specific 
bases to be recognised (Duyvestyn 2012).  A sensitive and robust method for the 
determination of RNase sequence-specificity of a number of VapC proteins has 
recently been developed (McKenzie et al. 2012b). This method utilizes RNA 
Pentaprobes, and smaller RNA oligos of parent Pentaprobes, as substrates to 
probe the specificity of VapC. Together, twelve Pentaprobe RNA sequences 
encode every combination of five bases. Post-assay, VapC RNase reactions are 
subjected to MALDI TOF MS analysis in order to detect the masses of substrate 
cleavage products. MALDI TOF MS analysis is particularly suited to RNA 
molecules as they are less prone to the loss of bases during the ionization process 
which occurs with DNA (Nordhoff et al. 1993). MALDI TOF MS data can then 
be used to infer VapC cut sites in the substrate RNA sequence. An outline of the 
process from VapC purification to cut site determination is detailed in Figure 1.6.  
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Figure 1.6 Schematic 
diagram of VapC 
purification and 
sequence specificity 
analysis. VapC toxicity is 
neutralised through 
co-expression with its 
cognate antitoxin VapB. 
VapB is removed through 
a trypsin mediated 
proteolytic degradation 
and the remaining VapC is 
purified by anion 
exchange 
chromatography. RNase 
sequence-specificity and 
activity is screened using 
Pentaprobe RNA and 
short Pentaprobe 
oligonucleotide RNA 
(ticks or crosses indicate 
cleavage or no cleavage 
respectively). Oligo RNA 
cleaved is examined by 
MALDI TOF MS and 
in-house software is used 
to determine VapC cut 
sites. Figure adapted from 
McKenzie et al (2012b). 
 
1.3.2.3 The Impact of Secondary Structure on RNase-Specificity 
It has recently been proposed that recognition of secondary structural motifs in the 
RNA substrate is an important contributor to the specificity of VapC-mediated 
mRNA degradation (McKenzie et al. 2012a; McKenzie et al. 2012b). Using the 
Pentaprobe system as described above, it was seen that VapCMS1284 from 
M. smegmatis cleaved full Pentaprobe RNA far more efficiently than it cleaved its 
corresponding shorter oligonucleotides. This was attributed to differences in 
secondary structure at or around the VapC recognition sites in the shorter RNA 
fragments (McKenzie 2011; McKenzie et al. 2012a). Microarray identification of 
in vivo VapCMS1284 RNA targets and their subsequent testing in RNase assays in 
vitro revealed that the three target transcripts experimentally characterised to be 
efficiently cut appeared to share the same basic predicted secondary structure: a 
stable hairpin immediately downstream of the target cut sequence. A sequence 
alignment and consensus secondary structure was created based on these three 
substrates (Figure 1.7). 
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Figure 1.7 Secondary structure characterisation of VapC targets. The predicted RNA 
secondary structures for the three experimentally validated VapCMS1284 targets found in the 
MSMEG_2124 5′ untranslated region (UTR), MSMEG_2121 mRNA, and the artificial Pentaprobe 
932 sequence along with a consensus model of predicted VapCMS1284 targets. Figure adapted from 
McKenzie, et al. (2012a). 
Further investigation found that substrates containing the predicted optimal 
consensus structure were cleaved more efficiently than those with other secondary 
structures. It is currently theorised that the optimal VapC recognition motif is 
likely to be a combination of the correct target sequence along with a certain 
secondary structure (McKenzie et al. 2012a).  
1.3.3 Characterised Autoregulation in vapBC Toxin-Antitoxin Systems 
Transcriptional autoregulation of vapBC operons through binding of the VapBC 
protein complex to the vapBC promoter DNA has been noted in a number of 
systems from disparate taxa. 
1.3.3.1 The fitAB System of Neisseria gonorrhoeae 
The fitAB (fast intracellular trafficking) systems consist of a VapB antitoxin 
(FitA), and a VapC toxin (FitB). FitAB-mediated transcriptional autoregulation of 
the fitAB operon in the Neisseria gonorrhoeae genome has been investigated.  In 
this system, four FitA antitoxins and four FitB toxins form a tetramer of 
heterodimers that binds to the fitAB promoter dsDNA. The N-terminus of the FitA 
antitoxin contains a ribbon-helix-helix (RHH) domain that was found through 
DNAse I footprint assays to bind and protect a 62 bp region within the promoter. 
This region includes an 8 bp IR, 
5’
TGCTATCA-N14-TGATAGCA
3’
, and covers 
the putative -10 promoter sequence for the operon (Wilbur et al. 2005). Figure 1.8 
provides a structural representation of FitA and FitB bound to promoter DNA and 
indicates the positioning of the IR within this region.  
Chapter One: Introduction 
 
 
17 
 
 
Figure 1.8 Structure of the FitAB-IR36 complex. A, a ribbon diagram of FitA (magenta) and 
FitB (cyan) bound to a 36 bp region of the fitAB promoter DNA. B, a rotated view of A, depicting 
two FitA β-sheets binding to the same DNA helix face. C. Sequence of the 36 bp promoter DNA 
region with the 8 bp IR emphasised in yellow. Figure taken from Mattison et al. (2006). 
On evaluation of structural data for crystals of FitAB bound to a 36 bp region of 
the fitAB promoter it was seen that specific interactions between antitoxin residues 
and DNA bases were only being made at six of the eight nucleotide positions in 
each IR half, with interactions at the remaining two nucleotides being made 
non-specifically between amino acid residues and the DNA phosphate backbone 
(Mattison et al. 2006). This observation suggests that the antitoxin of VapBC 
systems may potentially recognise and bind to both perfect and near-perfect 
palindromic sequences in the cognate promoter. The following model has been 
proposed for how the FitAB-promoter interaction contributes to the pathogenic 
physiology of N. gonorrhoeae (Mattison et al. 2006): when in an extracellular 
environment, FitAB is bound to promoter DNA, repressing transcription of the 
fitAB operon. Upon epithelial cell invasion, FitAB releases the DNA, allowing 
fitAB operon expression and slowing N. gonorrhoeae replication. 
1.3.3.2 The vapBC2 System of Rickettsia felis 
Investigation of the vapBC2 system from Rickettsia felis revealed that a VapBC2 
octomer binds a 27 bp region of dsDNA in its own promoter. Within this region, a 
near-perfect palindrome with half-sequences of 
5’
TA(A/G)TATATA(C/T)TAA
3’
 
was suggested as being essential for VapBC2 binding (Mate et al. 2011). As in the 
A B
C
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case of FitAB bound to DNA, the VapBC2 DNA binding complex consists of four 
toxins and four antitoxins forming a tetramer of heterodimers, arranged circularly 
via alternative antitoxin-antitoxin and toxin-toxin dimerisation interfaces (Figure 
1.9).  
 
Figure 1.9 The VapBC2-DNA complex. VapB2 antitoxins are depicted in shades of blue, VapC2 
toxins in shades of yellow and orange. Toxin and antitoxin dimers are labelled in relation to the 
colour of their counterparts. Monomers are labelled A – H. Figure adapted from Maté et al. (2011). 
The antitoxins interact with the concave face of the curved DNA, where one 
VapB2 homodimer is seen to directly recognize one region within the near-perfect 
palindrome, while a second region is recognised by the other VapB2 homodimer. 
In contrast to the FitAB system, the DNA-binding domain of the VapB2 antitoxin 
does not display a RHH domain, rather VapB2 homodimers form a 
swapped-hairpin β–barrel fold as is observed for MazE (Mate et al. 2011). 
1.3.3.3 The ntPR System of Sinorhizobium meliloti 
The ntrPR operon of Sinorhizobium meliloti encodes a protein pair that forms a 
TA module belonging to the VapBC family. Transcription of this operon is found 
to be negatively autoregulated by binding of the NtrPR complex to a 141 bp 
region of the ntrPR promoter through DNA-binding domains at the N-terminal of 
NtrP. DNase I footprint experiments demonstrated that within the promoter, a 
10 bp direct repeat sequence (
5’
GGCATATACA-N4-GGCATATACA
3’
) was the 
specific binding site of NtrP. Electrophoretic mobility shift assay (EMSA) testing 
of DNA oligonucleotides containing either half of the direct repeat revealed that 
one half is sufficient to sustain VapBC binding. The direct-repeat overlaps the 
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annotated transcriptional start-site, suggesting VapBC repression through steric 
inhibition of RNA-polymerase (Bodogai et al. 2006). 
1.3.3.4 The vapBC-1 System of Nontypeable Haemophilus influenza 
Expression of the vapBC-1 TA operon in this organism is similarly seen to be 
repressed by the VapBC complex. Unlike previously described systems, vapBC-1 
is unique in that both the VapBC-1 complex and VapC-1 alone are observed to 
exhibit DNA binding activity to the promoter dsDNA, recognizing a perfect IR 
(
5’
GTATATACT-N12-AGTATATAC
3’
). Altering nucleotide sequence in one half 
of the IR substantially diminishes binding of VapBC-1, while alteration in both 
halves completely abolishes VapBC-1-promoter DNA interaction. The binding 
requirement for both halves of the IR indicates recognition by a dimer. 
Surprisingly, VapB-1 alone displays no DNA interaction with the promoter region 
even at high concentrations; therefore its proposed role is in the direction of 
VapC-1 to the promoter binding site (Cline et al. 2012). 
1.4 The vapBC Toxin-Antitoxin Systems in Mycobacteria 
1.4.1 The vapBC System of Mycobacterium smegmatis 
M. smegmatis, a non-pathogenic relative of M. tb, has been used as a model 
system for studying VapBC proteins as it only possesses a single vapBC operon. 
This, and its close relatedness to M. tb, makes M. smegmatis an ideal system for 
gathering results that may be extrapolated to M. tb, leading to evidence as to the 
corresponding function for homologous TA elements in the M. tb genome. The 
MSMEG_1283/4 operon of M. smegmatis encoding the vapBC system is found to 
be constitutively expressed at low levels through transcription as a leaderless 
mRNA throughout the growth cycle (McKenzie 2011).  
1.4.1.1 VapC Toxicity 
A number of studies have used the overexpression of the toxin, often in a 
heterologous host, to demonstrate toxicity of the toxin module. In such an 
approach, Robson et al (2009) investigated toxicity of the M. smegmatis 
chromosomally encoded VapCMS1284 protein when conditionally expressed under 
the control of a tetracycline-inducible promoter. The effect of VapCMS1284 
overexpression was monitored in both an M. smegmatis mc
2
155 wild-type strain 
and an M. smegmatis mc
2
155∆vapBC knockout strain. The effect of 
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vector-derived VapCMS1284 overexpression was seen to be more marked in the 
knockout M. smegmatis strain than in the wild-type. M. smegmatis mc
2
155 
expressing VapCMS1284 exhibited a 10-fold reduction in colony forming units 
(CFU)/ml compared with strains expressing either the empty vector or VapBC 
complex, while the knockout strain exhibited a 100-fold difference when 
VapCMS1284 expression was induced. These observations suggest an ability of both 
endogenous VapBMS1283 in the wild-type strain and co-expressed vector-derived 
VapBMS1283, to offset the toxic effect of induced vector-derived VapCMS1284. 
Strains expressing VapCMS1284 only formed barely-visible, pinpoint-sized 
colonies. A VapC-induced alteration in cell morphology was also noted, as 
electron microscopy revealed that the length of single cells was slightly increased 
in VapCMS1284-expressing strains compared to the lengths seen in strains 
expression VapBCMS1283/4 or the empty vector (Robson 2010).  
Further investigations supported a mechanism of VapCMS1284-mediated growth 
inhibition and toxicity in M. smegmatis through inhibition of translation rather 
than transcription or DNA replication, a result consistent with the RNase activity 
of VapC enzymes (Robson et al. 2009). Observed toxicity in growth experiments 
was attributable to the presence and effects of the VapC protein rather than the 
mRNA transcript through identification of VapCMS1284 protein in vivo via Western 
blot using polyclonal antibodies raised against purified VapCMS1284. The 
VapCMS1284 translational inhibition was classed as bacteriostatic, as removal of 
tetracycline reversed growth inhibition. Observation of this in the knockout strain 
indicated that VapBMS1283 was not involved in this reversal process. An analogous 
phenotype of toxin-mediated reversible growth arrest in absence of the antitoxin 
has been observed for the M. tb relBE TA system when it is overexpressed in 
M. smegmatis strains (Korch et al. 2009). These findings allude to the presence of 
currently uncharacterised intracellular mechanisms for degradation of the toxin 
(Robson et al. 2009).  
1.4.1.2 VapC RNase-Specificity 
The toxic activity of VapCMS1284 was found to be mediated by inhibition of 
translation through an endoribonuclease mechanism targeting AUA(U/A) 
sequences on ssRNA in vitro (McKenzie 2011). VapCMS1284 has been 
demonstrated to both cleave and bind to RNA, where binding was indicated by a 
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smearing of the RNA in assay lanes on urea denaturing gels where VapCMS1284 
was present (McKenzie et al. 2012a).  Microarray analysis of the transcriptome in 
response to VapCMS1284 overexpression revealed that downregulated transcripts 
and their upstream regions were rich in the AUA(U/A) VapCMS1284 recognition 
sequence. Among the downregulated transcripts were those with annotated roles 
in carbon metabolism and transport (Robson 2010). These transcripts play a 
fundamental role in the utilization of glycerol during aerobic respiration. Through 
regulating the mRNA involved in this process, VapCMS1284 may be playing a role 
in balancing anabolic and catabolic processes within the cell.  
1.4.1.3 Intracellular Roles of VapB and the VapBC Complex 
In concordance with the classical TA system interactions model, an 
autoregulatory role has been observed for the VapBCMS1283/4 complex of the 
MSMEG_1283/4 operon. Three-fold higher expression levels were observed for a 
promoter-vapB-lacZ fusion construct in a ΔvapBC deletion strain than in the 
wild-type strain, indicating that the MSMEG_1283/4 operon is subject to 
autoregulation, and that either one or both TA proteins are required in this system 
for repression (Robson et al. 2009). 
Supporting this, EMSAs revealed that the purified VapBCMS1283/4 complex 
specifically binds a 126 bp region of MSMEG_1283/4 promoter DNA. Within this 
region, both halves of a 6 bp perfect IR (
5’
TATAGA–N13-TCTAT
3’
) are essential 
for VapBC binding. The IR overlaps both -35 and -10 promoter elements (Robson 
et al. 2009).  
In addition to comprising a component of the repressor complex in autoregulation, 
VapBMS1283 is suggested as being a factor required for translation of VapCMS1284 
mRNA transcript. A lack of intracellular copies of VapCMS1284 protein in 
M. smegmatis mc
2
155 ∆vapB deletion strains has been noted, despite the 
occurrence of elevated MSMEG_1284 transcript levels (Robson 2010). This 
highlights the importance of RNA processing and translational coupling in proper 
VapC expression from the M. smegmatis MS1283/4 operon. 
1.4.2 The vapBC Systems of Mycobacterium tuberculosis 
After extensive investigation of the M. tb chromosomally encoded TA systems, it 
was found that of the 88 putative systems, at least 47 belong to the VapBC family 
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(Ramage et al. 2009; Ahidjo et al. 2011). This represents the highest number of 
vapBC systems seen among intracellular pathogens, yet despite this, their roles in 
M. tb physiology are unclear and the evolutionary processes that have led to this 
great expansion of vapBC elements in the M. tb genome remain enigmatic.  Many 
of the vapBC operons in the M. tb genome are found to be linked to repetitive 
elements, transposases and virulence factors, suggesting their possible origin via 
HGT. While originating from mobile elements, it may be the case that through the 
course of evolution these systems have adopted important functional roles within 
the cell (Arcus et al. 2005). 
There are conflicting reports of the occurrence of ‘cross-talk’ between M. tb TA 
system components of separate operons. In a study conducted by Zhu et al (2010), 
several non-cognate TA interactions were observed in M. tb, both within and 
between different TA families (e.g. MazF toxins and VapB antitoxins). If such a 
phenomenon is enlisted, this could add an additional layer of sophistication to the 
TA network and in turn to the potential metabolic regulatory control that the 
organism can exhibit. In contrast to these findings, examinations of M. tb vapBC 
systems by Ahidjo et al (2011) and Ramage et al (2009) found M. tb VapB 
antitoxins to be specific to their cognately encoded VapC toxins, whereby the 
cognate VapB was the only antitoxin able to rescue VapC-induced growth 
inhibition (Ramage et al. 2009).  
As previously mentioned, a functional role for certain M. tb VapBC homologues 
(Rv2009-Rv-2010, Rv1955-1956, Rv1560-1561 and Rv0549-Rv0550) in the stress 
response has been suggested given the observation of their increased activation 
under hypoxic conditions and macrophage infection (Ramage et al. 2009). 
Structures have been solved for three VapBC TA complexes from M. tb (Miallau 
et al. 2009; Min et al. 2012) which illustrate a tight binding between VapB and 
VapC as a tetramer of VapBC heterodimers, similar to the structures observed for 
the FitAB complex from N. gonorrhoeae (Mattison et al. 2006; Arcus et al. 2011) 
and the VapBC2 complex from R. felis (Mate et al. 2011). 
1.4.2.1 VapC Toxicity 
The physiological role of M. tb vapBC TA systems has been probed through 
observing the toxicity of VapC proteins on M. smegmatis and/or M. tb cell 
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cultures. A toxicity survey of ten M. tb VapC toxins has been conducted by 
Ahidjo et al (2011). In this work, putative toxin or putative TA pairs were 
conditionally expressed under the control of a tetracycline-inducible promoter and 
effects on M. smegmatis and M. tb growth were observed. The screen identified 
four VapC toxins (Rv0549c, Rv0595c, Rv2549c and Rv2829c) which displayed 
such toxicity. Toxicity of Rv3320c was also revealed when this VapC was 
constitutively expressed (Ahidjo et al. 2011). The effects of M. tb VapC 
expression on growth of E. coli, M. smegmatis and/or M. tb has also been reported 
by other groups (Gupta 2009; Ramage et al. 2009). While there is some 
concordance among results, for many VapCs there are conflicting reports of 
toxicity. This is thought to be due to differences in expression vectors, growth 
conditions, strains used or translation initiation signals. Reported lack of toxicity 
for certain M. tb VapC proteins has been suggested to be due to one or more of 
these factors leading to reduced protein expression and, in turn, insufficient VapC 
levels required for any evident effect. This has led to an incorrect classification as 
‘non-toxic’.  Indeed, it was found that Rv2549c growth inhibition was only 
observed once the induced protein level exceeded a certain threshold (Ahidjo et al. 
2011). As such, it is likely that the current number of VapC proteins described as 
‘toxic’ is an under-representation. 
1.4.2.2 The Rv0065a/c and Rv0617a/c vapBC Systems 
The Rv0065a/c and Rv0617a/c operons of M. tb encode functional TA systems 
belonging to the VapBC family. VapCRv0065 and VapCRv0617 are Mg
2+
-dependent, 
sequence-selective ribonucleases whose activity is selectively and completely 
inhibited by their cognate antitoxin (Ahidjo et al. 2011). VapCRv0065 shares 26% 
amino acid identity and 50% amino acid similarity with the toxic M. tb 
VapCRv0549c protein, and VapCRv0617 shares  38% sequence identity and 55% 
sequence similarity with the toxic M. tb VapCRv3320c protein (Ahidjo et al. 2011). 
VapCRv0065 and VapCRv0617 proteins have been observed to target ssRNA rather 
than dsRNA, ssDNA or dsDNA (Ahidjo et al. 2011; McKenzie et al. 2012a). 
While it has been noted that VapC proteins of the Shigella flexneri 2a virulence 
plasmid pMYSH6000 and Salmonella enteric serovar Typhimurium LT2 vapBC 
operon are tRNases, cleaving initiator tRNA
fMet
 between the anticodon stem and 
loop (Winther & Gerdes 2011), there has been no evidence of such an activity for 
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mycobacterial VapC proteins VapCMS1284, VapCRv0065 or VapCRv0617  (McKenzie et 
al. 2012a). 
A general method for the overexpression and purification of TB VapC proteins 
has been developed, and the Pentaprobe system (Section 1.3.2.2) applied to 
determine their RNase sequence-specificity (McKenzie et al. 2012b). H37Ra 
genomic DNA was used as template for the cloning of these operons into 
expression vectors as the Rv0065a/c and Rv0617a/c operons display 100% 
sequence conservation between H37Ra and H37Rv strains. A combination of 
RNase assays against the twelve Pentaprobes sequences and their shorter oligos 
and subsequent MALDI TOF MS analysis of cleavage products led to the 
conclusion that VapCRv0065 and VapCRv0617 have the same sequence-specificity, 
targeting GC-rich 4-mers in the mRNA. Table 1.2 provides a summary of the 
RNase properties determined for VapCRv0065 and VapCRv0617 along with those for 
VapCPAE0151 from P. aerophilum. 
Table 1.2 Sequence-specificity of three characterised VapC proteins 
VapC 
ORF 
Organism Pentaprobes 
cut 
932 oligos
*
 
cut 
Sequence-specificity 
Rv0065 M. tb 922 1-7 (G/C)G(G/C)(G/C/A) 
  923   
  924   
  925   
  926   
  927   
  932   
Rv0617 M. tb 922 1-7 (G/C)G(G/C)(G/C/A) 
  923   
  924   
  925   
  926   
  927   
  932   
PAE0151 P. aerophilum 922 3-6 GG(U/G)G 
  923   
  924   
  925   
  927   
  932   
*
A schematic diagram of the 932 Pentaprobe and oligonucleotides is included in Appendix C5. 
Table adapted from McKenzie et al (2012b) 
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VapCRv0065 and VapCRv0617 produce near identical banding patterns and fragment 
masses when assay products for the same substrate are run on urea denaturing gels 
or analysed by MALDI TOF mass spectrometry respectively (McKenzie et al. 
2012b). It has been noted that there is a level of redundancy in their RNAse 
specificity, whereby VapCRv0065  and VapCRv0617 may cleave a range of other 
sequences albeit with less efficiency and at a slower rate (McKenzie et al. 2012b). 
The apparent lack of individuality in RNase specificity between the M. tb VapC 
proteins, along with their GC-rich targeting within the GC-rich M. tb genome (GC 
content of 66%), is confounding, suggesting a potentially wide range of RNA 
transcripts in the organism containing the target sequence. (McKenzie et al. 
2012a). This specificity contrasts that which was previously determined for 
VapCMS1284 of M. smegmatis, and unlike VapCMS1284,VapCRv0065 and VapCRv0617  
exhibit no binding activity against ss or dsRNA (Ahidjo et al. 2011). 
In concordance with conclusions drawn from the M. smegmatis vapBC system, it 
has been proposed that in addition to recognition of a primary sequence, 
VapCRv0065 and VapCRv0617 require an additional layer of target recognition 
residing in the mRNA secondary structure (McKenzie et al. 2012b). Whether 
these two VapC target the same or unique RNA secondary structural motifs 
remains to be determined. 
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1.5 Research Objectives 
The abundance of vapBC operons in the M. tb genome has led us to focus on the 
biological roles of the proteins that they encode. Elucidating such roles for the 
array of approximately 47 vapBC TA systems encoded in the M. tb genome 
presents a challenging task. As preliminary work on the RNase specificity of 
VapC proteins encoded from the Rv0065a/c and Rv0617a/c vapBC operons had 
been conducted, these two systems were chosen to be investigated further for this 
thesis research.  
The aim of this thesis was to determine the phenotypic effect of these two vapBC 
systems and investigate their underlying biochemistry. The main objectives to 
fulfil this aim were: 
1) To determine the in vivo phenotypic effect of VapCRv0065 and VapCRv0617 
conditional expression in M. smegmatis strains. 
2) To investigate the specificity and activity of the VapCRv0065 and 
VapCRv0617 RNases. 
3) To investigate the DNA-binding activity and thus autoregulatory role of 
the VapBC complex in the Rv0065a/c and Rv0617a/c TA systems.
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2 Chapter Two: Materials & Methods 
Tables of bacterial strains, plasmids, buffers and media used in this study can be 
found in Appendix A. Sequencing results can be found in Appendix B. Protein and 
RNA information can be found in Appendix C. 
 
2.1 General Materials and Methods 
2.1.1 DNA Manipulations 
2.1.1.1 Mycobacterium tuberculosis Genomic DNA 
M. tb H37Ra strain genomic DNA was obtained from the Proteins & Microbes 
Lab, University of Waikato. 
2.1.1.2 Escherichia coli Plasmid DNA Extraction 
E. coli plasmid DNA was extracted from 3 ml of an overnight LB culture using 
the QIAprep Spin Miniprep Kit (Qiagen, Netherlands) according to the 
manufacturer’s instructions. A 30 µl elution buffer volume was used. 
2.1.1.3 Agarose Gel Electrophoresis 
Separation of DNA fragments was achieved via agarose gel electrophoresis. DNA 
fragments >1000 bp were run on 0.8 % (w/v) gels, fragments 200-400 bp on 1.5 % 
(w/v) gels, and fragments <200 bp on 2% (w/v) gels. A 1 Kb Plus DNA Ladder 
(Invitrogen, USA) was included as a standard of band sizes. Gels were prepared 
containing 1x SYBERSafe
TM
 DNA gel stain (Invitrogen, USA). Samples were 
mixed with 2.5 µl 5 x DNA Loading Dye prior to their loading onto the gel. All 
gels were run in 1x TAE buffer (40 mM Tris-acetate, 2 mM EDTA) at 100 V for 
45 – 60 minutes. Gels were visualised on a blue light box (Invitrogen, USA) and 
images were captured by a camera. 
2.1.1.4 DNA Extraction from an Agarose Gel 
A scalpel blade was used to excise the desired band from the agarose gel. DNA 
was extracted from the gel using a QIAquick Gel Extraction Kit (Qiagen, 
Netherlands) according to manufacturer’s instructions. A 30 µl elution buffer 
volume was used. 
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2.1.1.5 DNA Purification from Solution 
A QIAquick PCR Product Purification Kit (Qiagen, Netherlands) was used to 
purify DNA from 25 µl polymerase chain reaction (PCR) samples according to 
the manufacturer’s instructions. A 30 µl elution buffer volume was used. 
2.1.1.6 DNA Quantification 
DNA was quantified using a Nanodrop 2000 spectrophotometer (Nanodrop 
Technologies, USA) at a measurement wavelength of 260 nm. The purity of DNA 
samples was assessed by calculating 260/280 and 260/230 ratios, which indicate 
protein and carbohydrate contamination respectively.  
2.1.1.7 Restriction Enzyme Digest 
Restriction enzyme digests were performed as per the manufacturer’s instructions. 
Buffers were chosen as recommended by the manufacturer. A double digest was 
performed if a buffer compatible with both restriction enzymes was available. 
Reactions included ≤30 µl of DNA, 2 µl of enzyme (Invitrogen (USA) or Roche 
Applied Science (Switzerland)), appropriate 1x buffer and MilliQ H2O up to 
100 µl. Incubations were performed at 37 ⁰C for three hours. 
2.1.1.8 DNA Ligation 
Ligation reactions were carried out as per the manufacturer’s recommendations 
using 1 U of T4 DNA Ligase (Invitrogen, USA), 1x Ligase Buffer (Invitrogen, 
USA), a ratio of 1:3 vector:insert and MilliQ H2O up to a total volume of 20 µl. 
Reactions were incubated for four hours at room temperature or at 16 ⁰C 
overnight. 
2.1.1.9 Annealing of DNA Oligonucleotides 
Single-stranded complementary DNA oligonucleotides were designed and 
analysed using Geneious Pro (Version 5.02) (BioMatters Ltd, NZ). 
Oligonucleotides were ordered through Invitrogen (USA) and made up to a final 
concentration of 100 µM in 1x TE buffer. Equal molar ratios of forward and 
reverse oligonucleotides were added to 10 µl Binding Buffer (50 mM Tris-HCl 
pH 8.0, 1 mM EDTA, 150 mM NaCl). Samples were heated at 95 ⁰C for 5 
minutes and cooled to room temperature over 45 minutes. The single-stranded 
oligonucleotides and annealed product were run alongside each other on a 2 % 
agarose gel (Section 2.1.1.3) to assess the success of the annealing reaction. 
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2.1.1.10 Two Halves Mutagenesis 
The two halves mutagenesis technique was used to mutate bases in perfect IR 
halves of a 130 bp region of the Rv0617a/c promoter to adenines (A). This 
method, outlined in Figure 2.1, involves introduction of the mutation into 
overlapping halves of the target region of DNA using PCR and mutagenic primers 
designed using the QuikChange Primer Design software 
(www.genomics.agilent.com). Joining of the halves through PCR is then possible 
due to the shared, mutated sequence region present at one end of each overlapping 
half. The result is a full length region of DNA containing the desired mutation.      
 
                                  
Figure 2.1 Schematic diagram of two halves mutagenesis. The desired mutation in the DNA 
region and mutagenic primers are shown in red. 
2.1.1.11 Preparation of Electrocompetent Escherichia coli 
A glycerol stock of the appropriate E. coli strain was streaked onto an LB agar 
plate and incubated overnight at 37 ⁰C. A single colony was used to inoculate 
10 ml of LB medium which was then incubated overnight at 37 ⁰C, shaking at 
200 rpm. The overnight culture was used to inoculate 1 L of LB media. The 1 L 
culture was incubated at 37 ⁰C, 200 rpm until an OD600 of 0.5-0.7 was reached. 
The culture was chilled on ice for 45 minutes before being centrifuged at 4000 g 
for 15 minutes at 4 ⁰C. The cell pellet was resuspended in an equal volume of 
chilled 10 % (v/v) glycerol and centrifuged at 4000 g for 15 minutes at 4 ⁰C. The 
supernatant was discarded, the pellet resuspended in 500 ml of chilled 10 % (v/v) 
glycerol, and the cells were centrifuged at 4000 g for 15 minutes at 4 ⁰C. The 
supernatant was discarded and the pellet was resuspended in 20 ml of chilled 
10 % (v/v) glycerol. The entire volume was transferred to a pre-chilled 50 ml 
2. PCR to join halves
1. PCR to create each half of the DNA region
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Falcon tube and centrifuged at 4000g for 15 minutes at 4 ⁰C. The supernatant was 
tipped off and the pellet was resuspended in 2 or 3 ml of chilled 10 % (v/v) 
glycerol, depending on whether the OD600 of the 1 L culture was 0.5 or 0.7 
respectively. Aliquots (40 µl) of cells suspension were dispensed into 1.5 ml 
microfuge tubes, flash frozen in liquid nitrogen and stored at -80 ⁰C. 
2.1.1.12 Electroporation of Escherichia coli 
The following protocol was used for transformation of both DH5α and TOP10 
electrocompetent E. coli strains. Plasmid DNA or ligation reaction (1 µl) was 
added to a 1.5 ml microfuge tube containing 40 µl of electrocompetent E. coli 
cells thawed on ice. The total volume was transferred to a pre-chilled 0.2 cm 
electroporation cuvette (BioRad Laboratories, USA) on ice. The cuvette was 
tapped to settle the solution and the sample was electroporated with a Bio-Rad 
Gene Pulser
TM
 (Bio-Rad Laboratories, USA) at 2.5 kV, 25 µF capacitance and 
200 Ω resistance. For recovery, 1 ml of SOC medium was immediately added to 
the electroporated cells, and the entire volume was transferred from the cuvette 
into a 1.5 ml microfuge tube. Recovering cells were incubated for 1 hour at 37 ⁰C, 
200 rpm. Aliquots of 50 and 100 µl were plated onto LB agar plates supplemented 
with the appropriate antibiotic. Colonies from these plates were used to seed 5 ml 
LB broth cultures containing the appropriate antibiotic. These cultures were 
incubated at 37 ⁰C, 200 rpm overnight, allowing plasmid DNA isolation the 
following day according to the method outlined in Section 2.1.1.2. 
2.1.1.13 Preparation of Electrocompetent Mycobacterium smegmatis 
A glycerol stock of the appropriate M. smegmatis strain was streaked onto an LB 
agar plate supplemented with 0.05 % Tween-80 (LBT) and incubated overnight at 
37 ⁰C. A single colony was used to inoculate 5 ml of LBT media which was then 
incubated overnight at 37 ⁰C, shaking at 200 rpm, until an OD600 of ~0.7 was 
reached. A 1 ml volume of the overnight culture was used to inoculate 100 ml of 
7H9/ADC + 0.05 % Tween-80 media. The 100 ml culture was incubated at 37 ⁰C, 
200 rpm until an OD600 of 0.5-0.7 was reached. The culture was chilled on ice for 
90 minutes before being centrifuged at 4000 g for 20 minutes at 4 ⁰C. The cell 
pellet was resuspended in 100 ml of chilled 10 % (v/v) glycerol and centrifuged 
again at 4000 g for 20 minutes at 4 ⁰C. The majority of supernatant was discarded, 
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leaving a small amount for resuspension of the pellet. The volume was transferred 
to a pre-chilled 50 ml Falcon tube and centrifuged at 4000 g for 20 minutes at 
4 ⁰C. The supernatant was tipped off and the pellet was resuspended in 0.2 ml 
chilled 10 % (v/v) glycerol. Aliquots (40 µl) of cells suspension were dispensed 
into 1.5 ml microfuge tubes, flash frozen in liquid nitrogen and stored at -80 ⁰C. 
2.1.1.14 Electroporation of Mycobacterium smegmatis 
The following protocol was used for transformation of the M.  smegmatis strains 
mc
2
4517, mc
2
155 and mc
2155ΔvapBC. Plasmid DNA or ligation reaction (1 µl) 
was added to a 1.5 ml microfuge tube containing 40 µl of electrocompetent M. 
smegmatis cells thawed on ice. Chilled glycerol (260 µl of 10% (v/v)) was added 
and the total volume (300 µl) was transferred to a 0.2 cm electroporation cuvette 
(BioRad Laboratories, USA) chilled on ice. The cuvette was tapped to settle the 
solution and electroporated with a Bio-Rad Gene Pulser
TM
 (BioRad Laboratories, 
USA) at 2.5 kV, 25 µF capacitance and 1000 Ω resistance. For recovery, 1 ml of 
7H9/ADC media was immediately added to the electroporated cells and the entire 
volume was transferred from the cuvette into a 15 ml Falcon tube. Cells were 
incubated for 3 hours at 37 ⁰C, 200 rpm. Aliquots of 10, 50 and 150 µl were plated 
onto 7H10/ADC + 0.05% (v/v) Tween-80 agar plates supplemented with the 
appropriate antibiotic. 
2.1.2 RNA Manipulation 
2.1.2.1 Total RNA Extraction from Mycobacterium smegmatis 
Method developed by Ali Ruthe, Proteins & Microbes Lab, University of  
Waikato. 
A glycerol stock of wild-type M. smegmatis mc
2
155 was streaked on a low salt 
LBT agar plate in the absence of antibiotics.  The plate was incubated in a plastic 
container at 37 ⁰C for three to four days. A saturated paper towel was placed in 
the container to prevent plate desiccation. One colony was selected to inoculate 
10 ml of LBT medium and the culture was incubated for approximately three days 
at 37 ⁰C.  The 10 ml of culture was immediately added to 40 ml of 5 M GITC pH 
7.0. Cells were pelleted by centrifugation (4600 g for 15 minutes at 4 ⁰C) and 
supernatant was discarded. Fresh 5 M GITC (0.5 ml) was used to resuspend the 
cell pellet, after which the entire volume was transferred to a 2 ml tube containing 
0.3 g of 0.1 mm and 2.5 mm zirconia beads. A Fastprep FP120 bead beater 
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(Thermosavant, USA) was used to mix the beads for 20, 25, 30 and 35 second 
time periods, with one minute cooling intervals in between. Following this, brief 
centrifugation removed foam. One tenth of the volume (50 µl) of 2 M sodium 
acetate pH 4.0 was added and the solution was gently mixed.  An equal volume 
(500 µl) of water-saturated phenol was added, the solution was mixed vigorously, 
and the tube was left to rotate for 10 minutes. 1-bromo, 3-chloro propanate 
(100 µl) was added, followed by agitation of the solution for one minute and 
incubation on ice for five minutes. The solution was centrifuged and the top 
aqueous phase removed. Steps from the addition of 2 M sodium acetate pH 4.0 
were then repeated, with the volumes adjusted accordingly. After the final 
centrifugation step, the top layer was removed, added to an equal volume of 
isopropanol, and chilled on ice for 30 minutes to precipitate the RNA. The sample 
was centrifuged (13000 g, 4 ⁰C, 30 minutes), 1 ml of 70 % ethanol was added, 
centrifuged (13000g, 4 ⁰C, 15 minutes), the supernatant was discarded, 1 ml of 
100 % ethanol was added, centrifuged (13000g, 4 ⁰C, 15 minutes) and the 
supernatant was discarded. A 25 µl volume of 10 mM Tris-HCl pH 7.0, 0.5 mM 
MnCl2 was used to resuspend the pellet. DNA was degraded through the addition 
of 1 µl DNase (Promega, USA) per µg RNA, followed by incubation for 30 
minutes at 37 ⁰C, 600 rpm.  DNase activity was quenched through the addition of 
1.1 µl EGTA stop solution per 1 µl of DNase used, followed by heat treatment for 
10 minutes at 65 ⁰C. The concentration of RNA was determined using the 
Nanodrop 2000 spectrophotometer (Section 2.1.2.4) and RNA was stored at -
80 ⁰C.  
2.1.2.2 RNA Precipitation 
RNA samples were precipitated to eliminate salts and contaminants by addition of 
2 M NaOAc pH 4 (10 % the volume of RNA) followed by 2.5 x the volume of 
100 % ethanol. The RNA was left to precipitate at -20 °C for 30 - 60 minutes. 
Samples were centrifuged at 13000 rpm for 30 minutes at 4 °C and the 
supernatant was discarded. The pellet was washed with 1 ml chilled 70 % ethanol, 
centrifuged at 13000 rpm for 10 minutes at 4 °C, washed with 1 ml 100 % chilled 
ethanol and centrifuged once more at 13000 rpm for 10 minutes at 4 °C to 
re-pellet the RNA. The supernatant was discarded and the tube was left at room 
temperature for 5 minutes to allow the pellet to air-dry. The pellet was 
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resuspended in 25 µl of water or Tris/MnCl2. For long term storage the pellet was 
resuspended in 50 µl ethanol and frozen at -80 °C. Concentration of RNA was 
determined using the Nanodrop 2000 spectrophotometer (Section 2.1.2.4). 
2.1.2.3 Purification of 16S and 23S rRNA from Total RNA 
Aliquots (20 µl) of isolated total RNA (Section 2.1.2.1) were loaded on a 1% TAE 
agarose gel containing Sybersafe along with 2 µl of 5 x DNA Loading Dye. The 
gel was run in 1x TAE buffer at 100 V for 1 hour.  Bands were visualised on a 
blue light box and 16S and 23S bands (at 2.5kb and 1.5kb respectively) were 
excised using a sterile scalpel. Thick walled non-autoclaved microfuge tubes (0.6 
ml) were pierced at the bottom using a flamed needle and a small sterile glass 
bead was placed in the tubes to block the hole. Two to three excised gel bands 
were added per tube, and tubes were frozen at -80 °C for 30 minutes. The 0.6 ml 
tubes were placed into larger 1.5 ml non-autoclaved microfuge tubes. Tubes were 
centrifuged at 13000 rpm for 6 minutes at 4 °C to elute nucleic acids from the gel 
bands. The volume of liquid eluted from gel bands into the larger microfuge tube 
was measured and RNA was then precipitated from this (Section 2.1.2.2). 
2.1.2.4 RNA Quantification 
RNA concentration was measured using a Nanodrop 2000 spectrophotometer 
(Nanodrop Technologies, USA). Absorbance was measured at 260 nm and the 
260/280 ratio was used to indicate sample purity. 
2.1.3 Polymerase Chain Reaction 
2.1.3.1 Primers 
Primers were designed and analysed using Geneious Pro (Version 5.02) 
(BioMatters Ltd, NZ). This program was used to check melting temperatures and 
possible secondary structures such as primer dimers or hairpins. Primers were 
ordered through Integrated DNA Technologies (IDT, USA) and made up to a final 
concentration of 100 µM in 1x TE buffer. Primers were stored at - 20 ⁰C. For use 
in ligation cloning, primers were designed to have a restriction site flanked by 
four bases. 
2.1.3.2 PCR for Amplification of Genomic DNA and Plasmid Inserts 
For amplifying genomic DNA or plasmid inserts, primers were used at 10 pmol 
per reaction. For each set of primers, a temperature gradient PCR was initially 
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conducted to determine the optimum primer annealing temperature. Reactions 
were carried out in a 25 µl volume. Single reactions included either 10 – 100 ng of 
genomic DNA from the M. tb H37Ra strain, or 1 ng of plasmid DNA. One unit of 
DNA polymerase was added per reaction. In all cases, annealing time was 
dependent on amplicon length (1 kb = 1 minute). The components of reactions 
and the PCR cycling regimes applied were in accordance with the polymerase 
enzyme used, as outlined in the following sections. 
2.1.3.3 Platinum Pfx PCR 
PCR samples set up with Platinum Pfx DNA polymerase (Invitrogen) contained 
1x Pfx Amplification Buffer, 1 mM MgSO4, 1 U Platinum Pfx DNA polymerase, 
0.3 mM deoxynucleotide mix (dATP, cCTP, dTTP & dGTP), 0.2 µM of each 
primer and 10 to 100 ng template DNA. 
PCR Cycling Conditions:  94 ⁰C    2:00 
    94 ⁰C    0:15 
    Tm        0:30       x 29 
    68 ⁰C    0:30 
    68 ⁰C    7:00 
2.1.3.4 Taq PCR 
PCR samples set up with Taq DNA polymerase (Roche) contained 1x Taq PCR 
buffer, 1.5 mM MgCl2, 2.5 U Taq DNA polymerase, 0.2 mM deoxynucleotide 
mix (dATP, cCTP, dTTP & dGTP), 0.2 µM of each primer and 10 to 100 ng 
template DNA. 
PCR Cycling Conditions:  94 ⁰C    2:00 
    94 ⁰C    0:15 
    Tm       0: 30      x 29 
    72 ⁰C    0:30 
    72 ⁰C    7:00 
2.1.3.5 iProof PCR 
PCR samples set up with iProof
TM
 DNA polymerase (Bio-Rad) contained 1x 
iProof GC Buffer, 1 mM MgCl2, 0.5 U iProof DNA polymerase, 0.2 mM 
deoxynucleotide mix (dATP, cCTP, dTTP & dGTP), 0.2 µM each primer and 10 
to 100 ng template DNA.  
PCR Cycling Conditions:  98 ⁰C    0:30 
    98 ⁰C    0:10 
    Tm        0: 30      x 25 
    72 ⁰C    0:15 
    72 ⁰C    7:00 
min:sec 
min:sec 
min:sec 
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2.1.3.6 Touchdown PCR 
The touchdown PCR protocol was used with iProof
TM
 DNA polymerase.  
PCR Cycling Conditions:   
98 ⁰C    0:30 
    98 ⁰C    0:10 
    70 ⁰C    0:30         x 9 
    -1 ⁰C per cycle 
72 ⁰C    0:15 
    98 ⁰C    0:10 
60 ⁰C    0:30         x 20 
    72 ⁰C    0:15 
    Go to step 6, 20x 
72 ⁰C     7:00 
2.1.3.7 Colony PCR 
Colony PCR was used to screen for the presence of an insert in a particular 
plasmid. A single colony was picked off a plate and resuspended in 10 µl of 
0.2 mM ampicillin in a 1.5 ml microfuge tube by pipetting up and down multiple 
times. One µl of this solution was used as the template in a 25 µl PCR with Taq 
polymerase (Section 2.1.3.4) 
2.2 Methods relating to Mycobacterium smegmatis Growth 
Experiments 
2.2.1 Construction of Tetracycline Inducible Constructs 
For tetracycline inducible expression of VapC and VapBC proteins, the 667 bp 
Rv0065a/c operon, the 437 bp Rv0065Cc gene, the 662 bp Rv0617a/c operon and 
the 438 bp Rv0617c gene were amplified from H37Ra M. tb genomic DNA 
(Proteins & Microbes lab, University of Waikato) using the primers listed in 
Table 2.1 and Platinum Pfx polymerase (Section 2.1.3.3). Primers introduced a 
synthetic ribosome-binding consensus site (GGAGG) at the 5’-end of PCR 
products and flanking BamHI and SpeI restriction enzyme sites. PCR products 
were digested (Section 2.1.1.7) and ligated (Section 2.1.1.8) into BamHI/SpeI sites 
of the pMind vector (Proteins & Microbes lab, University of Waikato), placing 
them under control of the transcriptional regulator tetR and the intervening 
operator region tetO. Plasmids were transformed into TOP10 electrocompetent E. 
coli (Section 2.1.1.12). Colony PCR (Section 2.1.3.7) along with plasmid 
purification (Section 2.1.1.2) and sequencing based on the Applied Biosystems 
min:sec 
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3130xl Genetic Analyser (WDSF, University of Waikato) confirmed the presence 
of each insert in the correct orientation to the tetRO promoter region.  
2.2.2 Conditional VapC and VapBC Protein Expression 
Plasmids were electroporated into M. smegmatis mc
2
155
 
(wild-type) and 
M. smegmatis ΔvapBC strains (Section 2.1.1.14). In the ΔvapBC strain, the 
chromosomally encoded MSMEG_1283/4 vapBC operon had been replaced with 
the kanamycin resistance cassette aphA-3 through allelic exchange mutagenesis 
(Robson 2010). 
M. smegmatis strains harbouring plasmids 0617vapBC_pMind, 0617vapC_pMind 
and pMind were grown in LBT medium for 38 hours to an OD600 between 0.2 and 
0.4. An aliquot of each LBT starter culture (100 µl) was used to seed a second 
starter culture in Hartman’s-de Bont minimal medium (HdB) supplemented with 
0.2 % (v/v) glycerol, 50 mM MES and 0.05 % (v/v) Tween-80. Cultures were 
grown for 21 hours and then diluted to an OD600 of 0.0025 in 200 ml HdB medium 
in a 500 ml flask. OD600 values were monitored until they reached 0.1 – 0.15 
(19 hours), at which point protein expression was induced by addition of 20 ng/ml 
tetracycline (Tc). This concentration was previously reported as sufficient for 
protein expression while remaining sub-inhibitory (Blokpoel et al. 2005; Robson 
2010). Samples of culture were taken every six hours for the next 102 hours in 
order to monitor cell growth (OD600 values) and viability (colony forming unit 
(CFU) values). Cell viability was examined through serially diluting samples 
100-fold from 10
-2
 to 10
-6 
in 1x phosphate buffered saline (PBS) (0.02 M 
phosphate (0.0038 M NaH2PO4, 0.15 M NaCl, pH 7.4)). Three 5 µl aliquots of 
each dilution were spotted onto plates containing both hygromycin B and 
tetracycline, and hygromycin B only plates. 
All media were supplemented with 50 µg/ml hygromcyin B for plasmid 
maintenance and media for ΔvapBC strains were additionally supplemented with 
50 µg /ml kanamycin. 
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Table 2.1 Primers used for cloning into pMind vector 
Primer Primer Sequence RE + RBS
* 
RE 
F 0065vapC_pMind AAATTTGGATCCGGAGGAATAATGGTGG
ATGAATGTGTA 
BamHI 
 0065vapBC_ 
pMind 
AAATTTGGATCCGGAGGAATAATGGCTA
CCATTCAAGT 
BamHI 
 0617vapC_pMind AAATTTGGATCCGGAGGAATAATGGTGA
CGGTGCTGCT 
BamHI 
 0617vapBC_pMind AAATTTGGATCCGGAGGAATAATGGTGC
GCACTACCATC 
BamHI 
R 0065vapC_pMind AAATTTACTAGTTCATTGGTGGTCGTTGG
AATGAGTACC 
SpeI 
 0065vapB_ pMind AAATTTACTAGTTCATTGGTGGTCGTTGG
AATGAGTACC 
SpeI 
 0617vapC_pMind AAATTTACTAGTTCACCGAACGAGTTTGA
TTTCGCACG 
SpeI 
 0617vapBC_pMind AAATTTACTAGTTCACCGAACGAGTTTGA
TTTCGCACG 
SpeI 
*
RE, restriction enzyme site; RBS, ribosome binding site 
2.3 Methods Relating to Protein Expression and Purification 
2.3.1 Small Scale Protein Expression in Mycobacterium smegmatis 
Small scale protein expression trials were used to screen for VapB and VapC 
protein expression after transforming pYUB28b plasmids containing the 
Rv0065a/c and Rv0617a/c operons into electrocompetent M. smegmatis mc
2
4517 
cells. 
2.3.1.1 Small Scale Protein Expression 
Transformed cells were streaked onto antibiotic selective plates (low salt LBT 
plates supplemented with kanamycin (50 µg/ml) and hygromycin (50 µg/ml)). 
Plates were incubated in a plastic container at 37 ⁰C for 3 – 4 days. A saturated 
paper towel was placed in the container to prevent plate desiccation. A single 
transformed colony was used to inoculate 10 ml of PA-0.5G/Tween-80 medium. 
The culture was incubated for 48 hours at 37 ⁰C, 200 rpm. A 100µl aliquot of the 
PA-0.5G/Tween-80 seeder culture was used to inoculate 10 ml of 
ZYP-5052/Tween-80 medium (1:100 dilution) and this culture was incubated at 
37 ⁰C for 96 hours, 200 rpm. Cells were pelleted by centrifugation at 4500 g for 
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20 minutes at 4 ⁰C. The supernatant was discarded, and cell pellets were 
resuspended in l ml of lysis buffer (50 mM sodium phosphate buffer pH 7.4, 
200 mM NaCl, 20 mM imidazole). A whole cell sample was run on a sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel for 
analysis, consisting of 5 µl of resuspended cell pellet, 10 µl of lysis buffer and 5 
µl of 4 x SDS loading buffer. The resuspended cells were lysed on ice using a 
Misonic Sonicator (Qsonica, USA). Sonication involved 3 x 15 second, and 2 x 12 
second bursts at setting 3.5. Cell lysate was centrifuged for 20 minutes at 13000 g, 
4 ⁰C to pellet the insoluble fraction. The supernatant was decanted into a separate 
microfuge tube. The pellet was resuspended in 200 µl of lysis buffer. Soluble and 
insoluble fraction samples were taken to be run on an SDS-PAGE gel for analysis, 
consisting of 15 µl of either fraction added to 5 µl of 4 x SDS loading buffer. 
2.3.1.2 His-tag Binding Tests 
The soluble fraction of cell lysate was subjected to His-tag binding tests. A 50 µl 
aliquot of Ni Sepharose (GE Healthcare, UK) was added to a 1.5 ml microfuge 
tube. This was washed with 1 ml of lysis buffer and centrifuged at 2000 g for 
30 seconds to pellet the Ni sepharose. The supernatant was discarded, and 200 µl 
of the soluble fraction of cell lysate was added. The lysate/Ni sepharose mixture 
was incubated for 15 minutes at room temperature whilst shaking at 1000 rpm. 
Centrifugation at 2000 g for 30 seconds was conducted to pellet the Ni sepharose. 
A 10 µl sample of the supernatant was added to 5 µl of 4 x SDS loading buffer for 
analysis on an SDS-PAGE gel. The remaining supernatant was discarded and the 
Ni sepharose was once again washed by addition of 1 ml lysis buffer followed by 
centrifugation at 2000 g for 30 seconds. The washing process was repeated two 
times, after which 25 µl of 4 x SDS loading buffer was added to the Ni sepharose 
for analysis by SDS-PAGE. SDS-PAGE gels were run and stained as outlined in 
Sections 2.3.5.4 and 2.3.5.5 in order to detect the presence of VapB and VapC 
protein in samples. 
 
2.3.2 Large Scale Protein Expression in Mycobacterium smegmatis 
2.3.2.1 Streaking Plates 
Glycerol stocks of mc
2
4517 strains containing the pYUB28b plasmid containing 
either the Rv0065a/c or Rv0617a/c operons were streaked onto antibiotic selective 
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plates (low salt LBT plates supplemented with kanamycin (50 µg/ml) and 
hygromycin (50 µg /ml)). Plates were incubated in a plastic container at 37 ⁰C for 
3 – 4 days. A saturated paper towel was placed in the container to prevent plate 
desiccation. 
2.3.2.2 Seeder Cultures 
Expression of VapBC protein was achieved using auto-induction medium 
supplemented with Tween-80 (0.05 %), kanamycin (50 µg /ml) and hygromycin 
(50 µg/ml). A sterile loop was used to pick one colony of the desired 
M. smegmatis strain. The colony was then used to inoculate 10 ml of 
PA-0.5G/Tween-80 medium, which was incubated at 37 ⁰C, 200 rpm for 48 hours 
and positioned horizontally to achieve maximum aeration.  
2.3.2.3 Expression Cultures 
A 10 ml seeder culture was used to inoculate 1 L of ZYP-5052/Tween-80 medium 
supplemented with kanamycin (50 µg/ml) and hygromycin (50 µg/ml). The 
culture was grown in a baffled flask at 37 ⁰C, 200 rpm for 96 hours.  
2.3.2.4 Glycerol Stocks 
For long term storage of bacterial cultures, glycerol stocks were prepared by 
combining 0.5 ml of 50% (v/v) glycerol and 0.5 ml of fresh liquid bacterial 
culture. Stocks were stored at -80 ⁰C. 
2.3.2.5 Harvesting Cells from Expression Cultures 
Cells from large scale expression cultures were pelleted by centrifugation at 
4600 rpm, 4 ⁰C for 20 minutes. The supernatant was discarded and pellets were 
stored at -80 ⁰C.  
2.3.3 Purification of the VapBC complex  
2.3.3.1 Fast Performance Liquid Chromatography (FPLC) 
An ÄKTA Basic
TM 
or ÄKTA Prime
TM 
FPLC system (GE Healthcare, UK) was 
used to perform fast performance liquid chromatography. UV absorbance was 
monitored at a wavelength of 280 nm in order to detect the elution of proteins. 
2.3.3.2 Purification of His-tagged Proteins through IMAC 
Immobilised metal affinity chromatography (IMAC) was used to purify proteins 
which had been expressed with an N-terminal His-tag. The IMAC column used 
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was a 5 ml HiTrap
TM 
Chelating HP column (GE Healthcare, UK). Prior to use, the 
column was primed by washing through 5 ml of 100 mM NiCl2, followed by 
20 ml of water and 20 ml of the lysis buffer to be used during the run. 
Expression culture cell pellets were resuspended in 30 ml lysis buffer and an 
EDTA-free protease inhibitor tablet (Roche, Applied Science, Switzerland) was 
added. The cells were sonicated on ice using a Misonix Sonicator (Qsonica, 
U.S.A) at setting 7.5 in 30 second bursts until cell lysis occurred (approximately 
3-5 minutes total sonication time). Insoluble material was pelleted by 
centrifugation at 13000 rpm for 20 minutes at 4 ⁰C. Supernatant was filtered 
through 1.2 and 0.45 µM Minisart filters (Sartorius AG, Germany). The filtered 
supernatant was loaded dropwise onto a 5 ml HiTrap
TM
 Chelating HP column (GE 
Healthcare, UK). The column was attached to an FPLC system and 20 ml of lysis 
buffer was run through at a rate of 1 ml/min to elute unbound proteins. To elute 
bound proteins, a 75 ml gradient of 0-50 % elution buffer (lysis buffer + 1M 
imidazole) was run at a rate of 1 ml/min while collecting 2 ml fractions. Fractions 
that corresponded to the UV peak were analysed on an SDS-PAGE gel (Section 
2.3.5.4). After protein purification was complete, the column was washed with 
20 ml of water and stored in ethanol. Between purifications of different proteins, 
the column was washed with 10 ml 100 mM EDTA pH 8.0 to strip Ni
2+ 
ions and 
then re-primed with 5 ml of 100 mM NiCl2. 
2.3.3.3 Size Exclusion Chromatography of the VapBC Complex 
To further purify protein, size exclusion chromatography (SEC) was performed 
using a HiLoad
TM
 16/60 Superdex
TM
 column (GE Healthcare, UK). VapBC 
protein fractions from the IMAC purification were pooled and concentrated down 
to 5 ml (Section 2.3.5.2). The column was pre-equilibrated in SEC Buffer (50 mM 
sodium phosphate, pH 7.0, 200 mM NaCl) overnight. The protein solution was 
loaded onto the equilibrated size exclusion column through a 0.2 µM filter (Pall, 
USA). Fractions were analysed on an SDS-PAGE gel (Section 2.3.5.4). 
2.3.3.4 Dialysis of the VapBC Complex 
Dialysis was conducted to reduce the salt content of the protein sample to a level 
suitable for anion-exchange chromatography. SEC fractions spanning the protein 
peak were pooled into 6-8 kDa molecular weight cut off Spectra Por
®
 dialysis 
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tubing (Spectrum Laboratories, UDA) cut to the appropriate length based on the 
volume of liquid to dialyse (tubing held 3.3 ml/cm). Dialysis was conducted in a 
1 L beaker containing 800 ml of dialysis buffer (50 mM sodium phosphate, pH 
7.0, 100 mM NaCl) with gentle stirring at 4 ⁰C. After 2 – 3 hours incubation the 
dialysis buffer was replaced with 800 ml of fresh buffer. Dialysis was continued 
overnight at 4 ⁰C with gentle stirring.  
2.3.4 Tryptic Digest of the VapBC Complex 
A ratio of 0.1 mg trypsin : 0.7 mg VapBC protein was used to preferentially 
degrade the more labile VapB protein. Digests were incubated for 1 hour at room 
temperature, and stopped by addition of an equal amount of trypsin inhibitor 
(Sigma Aldrich, USA) to the amount trypsin that was initially added. Samples 
were then incubated at room temperature for 15 minutes with shaking (500 rpm). 
2.3.5 Purification of VapC 
2.3.5.1 Anion Exchange Chromatography 
Anion exchange chromatography was performed using a 5 ml HiTrap
TM
 Q Anion 
Exchange column (GE Healthcare, UK). The column was washed with 20 ml of 
water and pre-equilibrated with 40 ml of dialysis buffer. Samples were filtered 
through a 0.2 µM Minisart filer (Sartorius AG, Germany) before being loaded 
onto the column. The column was attached to an ÄKTA Basic
TM 
or ÄKTA 
Prime
TM 
FPLC system. A 50 ml gradient of 0-100% anion elution buffer (50 mM 
sodium phosphate buffer pH 7.4, 1 M NaCl) was used to elute bound proteins. 
Fractions were analysed on an SDS-PAGE gel (Section 2.3.5.4). 
2.3.5.2 Concentration of Protein 
Protein samples were concentrated using 20 ml or 2 ml Vivaspin concentrators 
(Sartorius AG, Germany) with 5 kDa molecular weight cut-offs. Concentrators 
were spun at 3600 g, 4 ⁰C until the desired concentration or volume was achieved. 
2.3.5.3 Measurement of Protein Concentration 
The concentration of protein samples was measured using a Nanodrop 2000 
spectrophotometer (Thermo Scientific, USA). This measures absorbance of the 
sample at 280 nm and calculates protein concentration using the Beer-Lambert 
equation, A = ε c l, where A is the absorbance at 280 nm, ε is the theoretical molar 
extinction coefficient (M
-1
cm
-1
), c is the concentration (M) and l is the path length 
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in cm. The online tool ProtParam was used to calculate theoretical molar 
extinction coefficients for proteins/protein complexes and these values were used 
in the following formula to calculate the actual concentration values: 
Nanodrop protein concentration value 
      Molar extinction coefficient 
2.3.5.4 SDS-Polyacrylamide Gel Electrophoresis 
SDS-PAGE gels were prepared in a SE275 Hoeffer gel casting apparatus 
(Hoeffer
®
 Inc, USA). Gels consisted of a pH 8.8 16.5% acrylamide resolving gel 
layer beneath a pH 6.8 5% acrylamide stacking gel layer. Acrylamide was added 
from a 30% acrylamide/bis stock solution 37.5:1 (BioRad Laboratories, USA). 
Protein samples were prepared for analysis by mixing with 4 x SDS loading 
buffer at a 3:1 ratio. Samples were heated at 95 ⁰C for 5 minutes before being 
loaded onto gels. In order to estimate protein band sizes, samples were run 
alongside a Precision Plus Protein™ Unstained Standard protein ladder (Biorad 
Laboratories, USA). Gels were run in 1 x SDS-PAGE running buffer at 70 V 
through the stacking layer and voltage was increased to 150 V once the resolving 
layer was reached. 
2.3.5.5 Coomasie Blue Stain for SDS-PAGE 
The quick coomassie blue staining method was used to stain SDS-PAGE gels 
(Wong et al. 2000). The gel was placed in a microwaveable container, submerged 
in Fairbanks stain A, microwaved for 30 seconds then cooled to room temperature 
for approximately 20 minutes with gentle shaking. The stain was then tipped off, 
the gel was rinsed with water and the above process was repeated using Fairbanks 
stains B, C and D. 
2.4 Methods relating to RNase Assays and their Analysis 
2.4.1 932 Pentaprobe RNA Fragments 
2.4.1.1 Design of 932 Pentaprobe Fragments 
The 932 Pentaprobe was used as a scaffold from which to design overlapping 
RNA fragments of 18-100 bp in length. Fragments were labelled based on their 
position along the 932 Pentaprobe. The two smallest RNA fragments (33 bp and 
18 bp) were ordered through Integrated DNA Technologies (USA) and had the 
following sequences: 
=  True protein concentration 
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932 94-126: 
5’
GGGGUGAUAUAAUAUGAUGCCGGGCGGGGGCCG
3 
932 109-126: 
5’
GAUGCCGGGCGGGGGCCG
3’
 
The remaining fragments were generated through PCR amplification using 932 
Pentaprobe DNA as template, followed by in vitro transcription, as outlined 
below. 
2.4.1.2 PCR Amplification of 932 Pentaprobe Fragments 
932 Pentaprobe RNA and DNA was acquired from Jo McKenzie (Proteins and 
Microbes lab, University of Waikato). The 932 fragment DNA was amplified 
from 932 Pentaprobe DNA through PCR with Taq or Platinum Pfx polymerase 
(Sections 2.1.3.3 and 2.1.3.4). An additional round of PCR was conducted to add 
a T7 promoter sequence onto the 5’ end of each DNA fragment. Primers used for 
each round of PCR are detailed in Table 2.2. 
Table 2.2 Primers used for amplification of Pentaprobe 932 fragments 
Primer Primer Sequence 
F 932 90-170 CACTGGGGTGATATAATATGATGCCG 
 932 90-170 T7 ACGCTAATACGACTCACTATAGGCACTGGGGTGAT 
 932 70-150 TCCAACCTCACACCACATTACACTGGGGTG 
 932 70-150 T7 TAATACGACTCACTATAGGGAGATCCAACCTCACACC 
 932 50-150 GTGCTGGAATTCTGCAGATCTCCA 
 932 50-150 T7 TAATACGACTCACTATAGGGAGAGTGCTGGAATTCTG 
R 932 90-170 TGCCTAATCCCACCTAGCGTATCG 
 932 70-150 TCGGGTCATGTAGTGCTACGTTACGGCCC 
 932 50-150 GTAACGTAGCACTACATGACCCGAT 
 
2.4.1.3 In Vitro Transcription of 932 Pentaprobe Fragments 
The T7 MEGAscript
®
 kit (Ambion, USA) was used for transcription of PCR 
products to RNA. Reactions consisted of 1 µg PCR product template, 2 µl of each 
rNTP (75 mM stock), 2 µl T7 polymerase enzyme mix, 2 µl 10 x enzyme buffer 
and diethyl pyruvate carbonate (DEPC)-treated water to a final volume of 20 µl. 
Reactions were incubated at 37 ⁰C for 2 hours. TURBO DNase (1 µl) was added 
and reactions were incubated at 37 ⁰C for 15 min at 600 rpm. RNA was purified 
by precipitation as outlined in Section 2.1.2.2.  
Chapter Two: Materials & Methods 
 
 
44 
 
2.4.2 RNA Secondary Structure Predictions 
RNA secondary structures for this thesis were predicted using RNAfold (Hofacker 
et al. 1994). This program predicts secondary structure through three kinds of 
dynamic programming algorithms: the minimum free energy (MFE) algorithm, 
which produces a single optimal structure (Zuker & Stiegler 1981), the partition 
function algorithm, which calculates base pairing probabilities based on 
thermodynamic principles (McCaskill 1990) and the suboptimal folding 
algorithm, which computes every suboptimal structure that is within a given 
energy range of the optimal energy (Wutchy et al. 1999). 
2.4.3 General VapC Ribonuclease Assay Method 
VapC ribonuclease assays were conducted against a range of RNA substrates over 
a 60 minute incubation time course. Assays were used to determine whether or not 
cleavage was occurring and, if so, where these cut sites were located on the 
substrate RNA. Prior to beginning assay work, the workspace and pipets to be 
used were cleaned with RNase Away
®
 (Sigma-Aldrich, USA) to reduce the risk of 
RNase contamination. Individual assay reactions were set up for each time point 
to additionally reduce the possibility of RNase contamination. Assays were 
prepared on ice in 0.2 ml microfuge tubes and all incubations occurred at 37 ⁰ C. 
Reactions to be analysed by urea denaturing gels were stopped by the addition of 
10 µl 2x formamide loading buffer and heated at 70 ⁰C for 5 minutes. Reactions to 
be analysed by mass spectrometry were heat inactivated at 95 ⁰C for 5 minutes, 
after which salt and ethanol were used to precipitate the RNA (Section 2.4.6.1). 
2.4.3.1 Pyrobaculum aerophilum VapC Ribonuclease Assay 
Time Course Assay Reactions 
Reactions for each time point consisted of the following: 1 µg purified RNA, 1 µg 
purified VapC protein, 6 µl Assay Buffer (20 mM Tris-HCl pH 9.2, 20 mM NaCl, 
10 mM MgCl2) and 2 µl of nuclease free H2O. Assays were incubated for 5, 15, 
30 and 60 minute periods.  
RNA Only Negative Controls 
RNA only negative control reactions were set up as above but excluding the VapC 
protein. One control was stopped immediately at 0 hr incubation while the other 
was left to incubate for the duration of the assay. 
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EDTA Control 
A reaction was set up as per the time course samples however 40 mM EDTA was 
added to inhibit RNase activity. The reaction was incubated for the duration of the 
assay. 
VapBC Negative Control 
An assay reaction was set up as per the time course samples however the VapC 
was substituted for 1 µg of VapBC protein complex. 
2.4.3.2 Mycobacterium tuberculosis VapC Ribonuclease Assay 
Time Course Assay Reactions 
Reactions for each time point consisted of the following: 1 µg purified RNA, 1 µg 
purified VapC protein, 6 µl Assay Buffer (20 mM sodium phosphate buffer pH 
7.4, 20 mM NaCl, 10 mM MgCl2) and 2 µl of nuclease free H2O. Assays to be 
analysed by MALDI TOF-MS were carried out in an assay buffer consisting of 
20 mM ammonium phosphate pH 7.4, 20 mM NaCl and 10 mM MgCl2. Reactions 
were incubated for 5, 15, 30 and 60 minute periods.  
Negative Controls 
Negative controls for M. smegmatis VapC ribonuclease assays were the same as 
those for P. aerophilum assays except for the assay buffer which instead was that 
listed above (20 mM phosphate buffer pH 7.4, 20 mM NaCl, 10 mM MgCl2). 
2.4.4 Urea Denaturing Polyacrylamide Gel Electrophoresis RNA Analysis 
(Urea Denaturing-PAGE)  
Urea denaturing-PAGE gels were prepared in a SE275 Hoeffer gel casting 
apparatus (Hoeffer
®
 Inc, USA). Gels consisted of a resolving layer that varied 
from 5-20% acrylamide. The amount of acrylamide used was dependent on the 
size of the RNA samples being analysed: RNA molecules <150 bases were run on 
20% gels, molecules 150-300 bases were run on 10% gels and molecules >1000 
bases were run on 5% gels. Gels consisted of 6 M urea, 0.05% APS (w/v) and 
0.05% TEMED (v/v). Acrylamide was added from a 30% acrylamide/bis stock 
solution 37.5:1 (BioRad Laboratories, USA).  
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The gels were pre-run in 1x TBE buffer at 70 V for 20 minutes after which wells 
were flushed with 1 x TBE. Samples were loaded and the gel was run at 150 V 
until the xylene cyanol dye front neared the bottom of the gel. 
2.4.5 Visualisation of RNA 
SYBR
TM
 Green II RNA Stain (Invitrogen, USA) was used to visualise RNA that 
had been run on polyacrylamide or agarose gels. Gels were incubated in the stain 
for 40 minutes with agitation and then visualised under UV light or on a blue light 
box (Invitrogen, USA). A low range ssRNA ladder (New England Biolabs, USA) 
was run alongside samples in order to determine the sizes of bands. 
2.4.6 MALDI TOF Mass Spectrometry of RNA Oligonucleotides 
2.4.6.1 Sample Purification and Preparation 
RNA samples were purified through ammonium acetate and ethanol precipitation 
as this desalting technique was proven to result in maximum sample recovery 
(McKenzie et al. 2012b). To the RNA sample was added 5 M ammonium acetate 
(to a final concentration of 2 M) and three times the volume of ethanol as RNA 
sample. Precipitation steps that followed were as outlined in Section 2.1.2.2.  The 
MALDI TOF MS matrix was prepared fresh daily. The matrix consisted of 10 µl 
2.5 M diammonium citrate, 5 mg 3-hydroxypicolinic acid (3-HPA), 125 µl 
acetonitrile (ACN) and 365 µl of DEPC-treated water. The solution was vortexed 
well, and centrifuged at 13000 g for 5 minutes. Aliquots of matrix solution (1 µl) 
were spotted onto an Anchorchip™ target plate (Bruker Daltonics, USA) and left 
to air-dry. Oligonucleotide calibration standard (Bruker Daltonics, USA) (1 µl), or 
sample (1 µl) was overlayed on the dried matrix solution spots and left to air-dry. 
2.4.6.2 MALDI TOF Set Up and Spectra Analysis 
Samples were analysed on an Autoflex™ II MALDI TOF MS (Bruker Daltonics, 
USA) in linear mode. The laser power was typically set at 60 % however values 
varied depending on the ionisation requirements of the samples. The mass range 
selector was set to ‘low-range’, gain to 2500 V, acceleration voltage to 20 kV and 
at a pulsed ion extraction of 150 ns. A mass range of 2-12 kDa was collected. 
Spectra were firstly collected for the oligonucleotide calibration standard (Bruker 
Daltonics, USA) and these were used to calibrate the spectrometer through an 
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automatic polynomial correction. FlexAnalysis™ software (Bruker Daltonics, 
USA) was used to identify and label peaks of the spectra. 
2.4.7 Developed Protocol for Identification of In Vivo VapC Targets 
2.4.7.1 VapCPAE0151 Ribonuclease Assay 
An RNase assay with VapCPAE0151was conducted against the 924 Pentaprobe 
RNA (Proteins & Microbes Lab, University of Waikato) as outlined in Section 
2.4.3.1. Reactions were run on a 10% urea denaturing gel to judge ribonuclease 
activity (Section 2.4.4). The assay was repeated using an increased amount of 924 
Pentaprobe and VapC (4 µg of each) and an incubation period of 30 minutes. 
RNA from reactions was precipitated as outlined in Section 2.1.2.2. RNA from 
the precipitated VapCPAE0151 assay reactions (4 µg) along with 4 µg of purified 
Pentaprobe 924 RNA (control) was heated at 65 ⁰ C for 5 minutes for denaturation 
before being placed on ice.  
2.4.7.2 Poly(A)-tailing of RNA 
Poly(A)-tailing of RNA samples was achieved through use of an 
mRNA-ONLY™ Prokaryotic mRNA Isolation Kit with Poly(A) Tailing 
(Epicentre, USA). Whilst on ice, the following was added to sterile 0.2 ml tubes: 
2 µl Poly(A) Polymerase 10x Reaction Buffer, 2 µl 10 mM ATP, 0.5 µl 
Riboguard RNase Inhibitor, 4 µg  RNA, 1 µl (4 units) Poly(A) polymerase and 
DEPC H2O up to 20 µl. Tubes were incubated for 20 – 30 minutes at 37 ⁰C after 
which the tailing reaction was immediately stopped by storage of samples at 
-20 ⁰C. RNA was precipitated as outlined in Section 2.1.2.2 using 10 µl of 
RNase-free H2O for resuspension.  
2.4.7.3 Ligation of Acceptor Oligo 
T4 RNA Ligase (New England Biolabs, UK), a ligase documented by the 
manufacturer to have specific activity toward RNA fragments with a 
5’mono-phosphate as opposed to 5’-triphosphate, was used to ligate a synthesised 
RNA ‘Acceptor Oligo’ to samples with such a 5’-moiety (those cleaved by 
VapC).  The RNA Acceptor Oligo designed for this protocol had the sequence 
5’-GAGGAUCCCUGCAGGAAA-3’. This sequence was based on that of the 
RNA tag used in the ExactSTART™ Full-Length cDNA Library Cloning Kit 
(Epicentre, USA), which employs the same principle of using T4 RNA Ligase to 
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selectively tag the 5’mono-phosphate of RNA with a known RNA sequence. The 
RNA Acceptor Oligo sequence includes recognition sites for both BamHI 
(GGATCC) and PstI (CTGCAG).  Ligation reactions consisted of the following: 
10 µl of poly(A)-tailed RNA, 5 µl of Acceptor Oligo RNA at 10pmol/ul, 4 µl of 
10x T4 RNA Ligase Buffer, 1 µl of T4 RNA Ligase, 4 µl of 10 mM ATP and 
16 µl of 50% PEG8000. Incubation was at 37 ⁰C for 30 minutes, followed 
immediately by 1
st
 strand cDNA synthesis. 
2.4.7.4 cDNA synthesis 
The following reagents were added to the ligation reactions for 1
st
 strand cDNA 
synthesis: 2 µl 100 µM oligo d(T)+PstI fwd primer (Table 2.3), 4 µl 100 mM 
dNTPs and 6 µl DEPC H2O. Samples were heated at 65 ⁰C for 5 minutes, 
incubated for at least 1 minute on ice and centrifuged briefly. Superscript III RT 
(4v), 16 µl 5x FS Buffer and 4 µl 0.1 M DTT were added, the mixture was gently 
mixed, incubated at 50 ⁰C for 50 minutes, and then inactivated by heating at 70 ⁰C 
for 15 minutes. Reactions were nanodropped to assess the yield of 1
st
 strand 
cDNA. 2
nd
 strand cDNA was produced through Platinum Pfx PCR cycling 
(Section 2.1.3.3) using primers cDNA_PCR Fwd and cDNA_PCR Rev (Table 
2.3). A low primer annealing temperature of 56 ⁰C was chosen to promote primer 
annealing. Table 2.3 provides details of primers used for this protocol. 
Table 2.3 Primers used in VapC target identification protocol 
Primer Primer Sequence
* 
F oligo d(T)+PstI CTGGCACTGCAGTTTTTTTTTTTTTTTA 
 cDNA_PCR GAGGATCCCTGCAGGAAA 
R cDNA_PCR GACCGTGACGTCAAAAAAAAAA 
*
Restriction enzyme sites (PstI and BamHI) recognition sites are underlined 
2.5 Methods relating to VapBC DNA Binding Experiments 
Purified VapBC protein complex was used in EMSAs in order to examine its 
ability to bind to its cognate vapBC promoter region. EMSA experiments were 
performed using a DIG gel shift kit, 2
nd
 Generation (Roche, USA). VapBC 
binding activity was tested against DNA fragments that were 3’-end labelled with 
the immunohistochemical marker digoxigenin-11-ddUTP. All primers used are 
listed in Table 2.4. 
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2.5.1 Amplification of Rv0065a/c and Rv0617a/c Promoter DNA 
Primers Rv0617promoterF and Rv0617promoterR were designed using Geneious 
Pro (Version 5.02) (BioMatters Ltd, NZ) to amplify a region 130 bp upstream of 
the GTG translational start site of the Rv0617a/c operon. Primers 
Rv0065promoterF and Rv0065promoterR were used to amplify a region 101 bp 
upstream of the ATG translational start site of the Rv0065a/c operon. Primers 
Rv0065promoter dstrF and Rv0065promoter dstrR were used to amplify a 150 bp 
region spanning 38 bp upstream and 112 bp downstram of the ATG translational 
start site of the Rv0065a/c operon. Genomic H37Ra DNA (Proteins & Microbes 
lab, University of Waikato) was used as the template for amplifications. A 
temperature gradient PCR found the optimum primer annealing temperature for 
all primers to be 63.5 ⁰C; this temperature was used in all subsequent PCRs using 
the Platinum Pfx enzyme (Section 2.1.3.3). Platinum Pfx was chosen as the 
polymerase due to its higher fidelity, 26 x higher than that of the Taq enzyme. 
Reactions were run on 2% agarose gels and the correct sized bands excised and 
purified using a QIAGEN gel extraction kit (Section 2.1.1.3 and Section 2.1.1.4).  
2.5.2 Amplification of the mazEF Promoter 
To assess the specificity of VapBC binding to the promoter of the operon from 
which it was encoded, a non-specific competition control was required in EMSA 
assays. Non-specific competitor DNA consisted of a non-target region of DNA 
from elsewhere in the M. tb genome. The promoter of an operon encoding 
proteins from the MazEF TA family, Rv1494/5, was chosen for this. Rv1494 is a 
303 bp gene annotated at coordinates 1686269-1686571 on the M. tb H37Ra 
chromosome. Based on this, a region 600 bp upstream of coordinate 1686269 was 
amplified from H37Ra genomic DNA (Proteins & Microbes lab, University of 
Waikato) using primers Rv1494promoterF and Rv1494promoterR. The DNA was 
then purified from solution (Section 2.1.1.5). 
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Table 2.4 Primers used for investigation of VapBC-promoter binding activity 
Primer Primer Sequence 
F Rv0065promoter CTGGCCGATCTGCGCGCGGT 
 Rv0065promoter dstr GTGGATAAGCCGGCATTCTTAGCCG 
 Rv0617 Bind2 GCCACCCAACACGGCTCAAAA 
 Rv0617 Bind3 GCCGGCTCGTCTGCCAAAAGG 
 Rv0617promoter CCGCCACCCAACACGGCTCGT 
 Rv1494promoter CGAGATCTCCGAAGCGCTGGAGAAG 
R Rv0065promoter AGCGGAGTTCACCGGCTAAGAATGCCG 
 Rv0065promoter dstr TCGATGAGCTTGGTGCGCATATACG 
 Rv0617 Bind2 GAGCCGGCCGAGACAGCTTTT 
 Rv0617 Bind3 CTGATCATGCTGGCCTTTTGG 
 Rv0617promoter GCCTCATCCTAACATCGCTGCATCGTGATGC 
 Rv1494promoter CGCGGGCCTCTCGCTAATCCAGCGTG 
Primers in this table include those used for amplification of promoter regions (promoters of 
Rv0065a/c, Rv0617a/c and Rv1494/5 operons) and two-halves mutagenesis. 
 
2.5.3 Creation of Perfect IR Mutations 
Two halves mutagenesis (Section 2.1.1.10) was used to create versions of the 130 
bp Rv0617a/c promoter region where either the 5’-half, the 3’-half, or both halves 
of the 6 bp perfect IR were mutated to contain adenine (A) at the four central base 
positions. This method utilised mutagenic primers along with primers 
complementary to the 5’ and 3’-ends of the Rv0617a/c 130bp promoter region. 
‘Bind 2’ represents a version of the 130 bp promoter region where the upstream 
perfect IR half was mutated, while ‘Bind 3’ represents the same for the 
downstream perfect IR half.  Primer pairs Rv0617 Bind2F and Rv0617 
promoterR, and Rv0617 promoterF and Rv0617 Bind2R were used in iProof 
PCRs according to the manufacturer’s instructions (Section 2.1.3.5) to create each 
half of the Bind2 strand. Halves were joined in a Platinum Pfx PCR (Section 
2.1.3.3) using primers Rv0617promoterF and Rv0617promoterR. The same 
process was used to create Bind 3, however the touchdown PCR protocol (Section 
2.1.3.6) was instead used for creation of the two halves. Bind 4, where both halves 
of the perfect IR were mutated, was created in the same manner as Bind 3 using 
Rv0617 Bind3 primers, and the Bind 2 sequence as the template. 
2.5.4 Design of Promoter Oligonucleotides 
The 130 bp Rv0617a/c promoter region was divided into five overlapping oligos 
of 40 or 50 bases in length for use in EMSAs in order to narrow down candidate 
near-perfect inverted repeats (NPIRs) to which VapBCRv0617 bound. The design 
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was such that both halves of each candidate IR were included in at least one of the 
oligos. Table 2.5 outlines the properties of these five promoter oligos. Oligos were 
ordered from Integrated DNA Technologies (IDT, USA) as sense and antisense 
ssDNA (Table 2.6). These strands were annealed as outlined in Section 2.1.1.9. 
Table 2.5 Properties of designed Rv0617a/c promoter oligonucleotides 
Oligo Length (bp) Covers both halves of: Covers one half of: 
1 40 IRA, IRB1 IRB2 
2 40 IRB2 IRA, IRB1, IRC, IRD 
3 40 IRC, IRE IRD, IRF, IRG 
4 50 IRD, IRE, IRF, IRG IRB2, IRH 
5 50 IRH, IRI, IRJ IRD, IRF 
 
2.5.5 Electrophoretic Mobility Shift Assays (EMSAs) 
2.5.5.1 Labelling Target DNA 
Double-stranded DNA (100 ng) and sterile MilliQ water were added to a 
microfuge tube to a final volume of 10 µl. Reactions were set up on ice, and to the 
oligonucleotide was added 4 µl 5 x Labelling Buffer (Roche), 4 µl  25 mM CoCl2 
solution, 1 µl 1 mM DIG-ddUTP solution (Roche) and 1 µl 400 U/µl terminal 
transferase (Roche). Reactions were mixed and spun briefly, then incubated at 
37 ⁰C for 15 minutes. Reactions were stopped by addition of 2 µl of 0.2 M EDTA 
pH 8.0 and returned to ice. Sterile MilliQ water (3 µl) was added to bring the final 
reaction volume to 25 µl and concentration to 4 ng/ul (0.155 pmol/µl) of labelled 
DNA. The DIG-labelled DNA was diluted to 0.4 ng/ul (4.80 fmol) with TEN 
Buffer (10 mM Tris, 1 mM EDTA, 0.1 M NaCl, pH 8.0) for use in EMSAs. 
2.5.5.2 Preparation of VapBC for EMSA 
VapBC molarity calculations were based on the tetrameric VapBC complex sizes 
of 98.04 kDa (98040 g/mol) and 94.8 kDa (94800 g/mol) for VapBCRv0065a/c and 
VapBCRv0617a/c respectively. These values were calculated in ProtParam 
(au.expasy.org/tools/protparam.html). Purified VapBC protein was diluted to the 
correct molarity for binding assays in 50 mM potassium phosphate buffer pH 7.3 
containing 200 mM NaCl and 0.05 mg/ml bovine serum albumin (BSA). 
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Table 2.6 Primers used in creation of Rv0617a/c promoter oligos. 
ssDNA Oligo ssDNA Oligo sequence 
F Oligo 1 CCGCCACCCAACACGGCTCGTGCGCTGTCTCGGCCGGC
TC 
 Oligo 2 CTCGTGCGCTGTCTCGGCCGGCTCGTCTGCCGCACGGC
CA 
 Oligo 3 GCTCGTCTGCCGCACGGCCAGCATGATCAGTCCCGTTG
GA 
 Oligo 4 CACGGCCAGCATGATCAGTCCCGTTGGAATACCGGTGA
GCGTCGGCGCGC 
 Oligo 5 GGTGAGCGTCGGCGCGCGCATCACGATGCAGCGATGT
TAGGATGAGGCGGTG 
 Oligo 5 mut1  GGAAAAAATCGGCGCGCGCATCACGATGCAGCGATGT
TAGGATGAGGCGG 
 Oligo 5 mut2 GGTGAGCGTCGGCGCGAAAAAAACGATGCAGCGATGT
TAGGATGAGGCGG 
 Oligo 5 mut3 GGTGAGCGTCGGCGCGCGCATCACGATGCAGCGATGT
TAGGAAAAAAAAG 
 Oligo5 mut4 GGTGAGCGTCGGCGCGCGCATCACGATGCAAAAAAAT
TAGGATGAGGCGG 
R Oligo 1 GAGCCGGCCGAGACAGCGCACGAGCCGTGTTGGGTGG
CGG 
 Oligo 2 TGGCCGTGCGGCAGACGAGCCGGCCGAGACAGCGCAC
GAG 
 Oligo 3 TCCAACGGGACTGATCATGCTGGCCGTGCGGCAGACG
AGC 
 Oligo 4 GCGCGCCGACGCTCACCGGTATTCCAACGGGACTGATC
ATGCTGGCCGTG 
 Oligo 5 CCGCCTCATCCTAACATCGCTGCATCGTGATGCGCGCG
CCGACGCTCACC 
 Oligo 5 mut1  CCGCCTCATCCTAACATCGCTGCATCGTGATGCGCGCG
CCGATTTTTTCC 
 Oligo 5 mut2 CCGCCTCATCCTAACATCGCTGCATCGTTTTTTTCGCGC
CGACGCTCACC 
 Oligo 5 mut3 CTTTTTTTTCCTAACATCGCTGCATCGTGATGCGCGCGC
CGACGCTCACC 
 Oligo 5 mut4 CCGCCTCATCCTAATTTTTTTGCATCGTGATGCGCGCGC
CGACGCTCACC 
 
2.5.5.3 EMSA Reactions 
EMSA reactions were set up on ice to a final volume of 6.5 µl. Into each reaction 
was added the appropriate volume of purified VapBC protein, 0.4 ng DIG labelled 
DNA, 2 µl 5 x Binding Buffer (Roche), 0.5 µl 1 mg/ml poly dI-dC (Roche) and 
MilliQ water. Binding reactions were incubated for 20 minutes at room 
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temperature. Reactions were placed back on ice and 2.5 µl of loading buffer with 
bromophenol blue (Roche) was added. 
2.5.5.4 EMSA Controls 
Specific competition 
A reaction was set up as outlined in Section 2.5.5.3 with the addition of 125 x 
excess (50 ng) of un-labelled target DNA (Rv0617a/c promoter for VapBCRv0617a/c 
assays, and Rv0065a/c promoter for VapBCRv0065a/c assays). 
Non-specific competition 
A reaction was set up as outlined in Section 2.5.5.3 with the addition of 125 x 
excess (50 ng) of un-labelled non-target DNA (600 bp region of the M. tb mazEF 
promoter). 
2.5.5.5 Native TBE Polyacrylamide Gel Electrophoresis 
Tris-borate-EDTA (TBE) native acrylamide gels (6%) were prepared the day 
before use to ensure complete polymerisation. Gels were pre-run in 1 x TBE 
Buffer at 60 V for 20 minutes. Samples were loaded onto the gel and run at 150 V 
until the dye-front had migrated approximately two-thirds of the way down the 
gel. 
2.5.5.6 Contact-Blotting and Crosslinking of Oligonucleotides 
One plate was removed from the 6% TBE gel. A dry Hybond-N
+
 membrane (GE 
Healthcare, USA) trimmed to size was placed onto the gel, followed by three 
layers of dry Whatman 3 MM blotting paper, a glass plate, and a load of 100 g. 
Transfer was complete after 30 minutes. The membrane was transferred DNA side 
up onto a sheet of Whatman 3 MM blotting paper soaked in 2 x SSC (300 mM 
NaCl, 30 mM Na3C6H5O7, pH 7.0) and placed onto a sheet of tinfoil. Crosslinking 
was achieved using a Bio-Link BLX-254 BRL UV Crosslinker Irradiation System 
(Life Technologies, USA) which irradiated the membrane with 120 mJ at UV 254 
nm for 20 seconds. The membrane was either used immediately, or stored 
air-dried between two sheets of Whatman 3 MM blotting paper at 4 ⁰C. 
2.5.5.7 Chemiluminescent Detection 
All incubations were performed at 15 – 25 ⁰C with agitation in a small plastic 
container. The membrane was washed for 2 minutes in 40 ml washing buffer 
(0.1 M maleic acid, 0.15 M NaCl, pH 7.5, 0.3 % (v/v) Tween-20), and then 
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incubated for 30 minutes in 40 ml 1x blocking solution which was prepared by 
diluting a 10x blocking solution stock (Roche) in maleic acid buffer (0.1 M 
Maleic acid, 0.15 M NaCl, pH 7.5). An antibody solution was prepared by 
centrifuging Anti-Digoxigenin-AP (Roche) for 5 min at 10,000 rpm, and diluting 
the antibody 1 : 10,000 (75 mU/ml) in 1 x blocking solution. The membrane was 
incubated in the antibody solution for 30 minutes. Two 15 minute wash steps were 
conducted in 40 ml washing buffer, followed by equilibration for 2-5 minutes in 
40 ml detection buffer (0.1 M Tris-HCl, 0.1 M NaCl, pH 9.5). The membrane was 
placed between two plastic sheets and incubated with 1 ml of CSPD solution 
(Roche) (diluted 1:100 in detection buffer) for 5 minutes at room temperature. 
The membrane was sealed in the plastic and incubated at 37 ⁰C for 10 minutes to 
enhance the luminescence reaction. The membrane was exposed to film 
(Amersham Hyperfilm
TM
 MP) for 20 – 25 minutes. In a dark room, films were 
developed for at least 2 minutes in Kodak Developer and replenisher (Sigma 
Aldrich) and fixed for at least 30 seconds in Kodak Fixer and replenisher (Sigma 
Aldrich). Films were visualised on a light box and photographed. 
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3 Chapter Three: Results 
3.1 The Effects of Conditional Expression of VapCRv0617 on 
Mycobacterium smegmatis Growth and Morphology 
Studies conducted on a number of the 47 vapBC TA systems encoded within the 
M. tb genome have revealed that some, but not all of the M. tb VapC proteins 
have a growth inhibitory effect when overexpressed in mycobacterial species 
(Gupta 2009; Ramage et al. 2009; Ahidjo et al. 2011). To determine whether or 
not the VapCRv0617 protein from M. tb displays toxicity, observations were made 
of its effect on the growth and viability of M. smegmatis cells when conditionally 
overexpressed. In addition, the toxicity was classified as either bacteriostatic or 
bactericidal depending on whether or not M. smegmatis growth could be rescued 
when expression of the VapC protein was halted. Ideally experiments would be 
conducted in the native organism M. tb; however due to hazard restrictions the 
non-pathogenic relative M. smegmatis was chosen as an appropriate model. 
3.1.1 The Effect of VapCRv0617 on Cell Growth and Viability 
For conditional expression experiments, four inducible constructs were created 
using pMind vectors, containing either an entire vapBC operon or a single vapC 
gene under the control of a tetracycline inducible promoter (Section 2.2.1). 
Constructs were designated 0065vapBC_pMind, 0065vapC_pMind, 
0617vapBC_pMind and 0617vapC_pMind. All constructs were designed to 
encode a synthetic ribosomal binding site (RBS) at the 5’ end in order to ensure 
translation in vivo. The whole-operon constructs were included in the experiment 
as a means to confirm that any toxicity observed was a result of the VapC protein 
alone and not of the VapBC complex. These constructs also served as controls to 
ensure that any growth inhibition was not an artefact of the general 
overexpression of a protein. Each construct was transformed into two 
electrocompetent strains of M. smegmatis; mc
2
155 (wild-type strain) and 
mc
2
155ΔvapBC (deletion strain where the single vapBC operon of M. smegmatis 
was deleted from the chromosome) (Section 2.1.1.14). The deletion strain was 
prepared by Jennifer Robson (University of Otago).  
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M. smegmatis mc
2
155 wild-type and ΔvapBC deletion strains containing 
0617vapBC_pMind, 0617vapC_pMind and an empty pMind vector were grown 
up for large-scale conditional expression studies as outlined in Section 2.2.2. After 
19 hours of incubation, the 200 ml cultures grown in HdB medium reached  OD600 
values between 0.1 - 0.15 and thus were simultaneously induced with tetracycline 
(20 ng/ml). Blokpoel et al (2005) previously reported that greatest expression 
using the pMind vector occurred 24 hrs after 20 ng/ml tetracycline induction. 
Optical density at 600 nm was therefore monitored 6 hourly over the following 
121 hours, and 11 measurements of viability (plating of cells for CFU 
determinations) were taken over a 96 h period post-induction.   
Analysis of changes in the OD600 readings over the 121 hour period (Figure 3.1) 
indicated that both M. smegmatis deletion strains and wild-type strains entered the 
stationary phase after an incubation time of approximately 37 hours. Deletion 
strains expressing VapBCRv0617a/c and the empty vector reached an OD600 
maximum of ~3 and maintained OD600 readings within the range of 2.57 - 3.04 
through the remainder of the 121 hr sampling period. The deletion strain 
expressing VapCRv0617 exhibited slight inhibition of growth, where a reduced 
OD600 maximum of ~2.3 was reached after 37 hours. The OD600 of the 
toxin-expressing deletion strain fell to a final reading of ~1.4 over the sampling 
period. 
VapCRv0617-mediated growth inhibition was similar in the deletion strain and the 
wild-type strain expressing the VapCRv0617 toxin. The wild-type strain expressing 
VapCRv0617 reached a maximum OD600 of 2.2 after 49 hrs incubation. This was in 
comparison to the OD600 maximum of ~3 that was reached at the 37 hour 
incubation point in the wild-type strains expressing VapBCRv0617a/c or empty 
vector. Final OD600 readings at 96 hours post-induction were 3.03, 2.85 and 1.48 
for wild-type strains expressing empty vector, VapBCRv0617a/c and VapCRv0617 
respectively, while these values were 2.8, 2.65 and 1.4 for deletions strains 
expressing empty pMind vector, VapBCRv0617a/c andVapCRv0617 respectively. 
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Figure 3.1. The effect of VapCRv0617 overexpression on the growth of M. smegmatis mc
2
155 
and ΔvapBC strains. OD600 was monitored for M. smegmatis mc
2
155 (A) and ΔvapBC (B) strains 
harbouring plasmids 0617vapBC_pMind (expressing VapBC; open squares), 0617vapC_pMind 
(expressing VapC; solid triangles) or pMind (expressing empty vector; solid circles). Protein 
expression was induced during early exponential growth (OD600 of 0.1-0.2) by the addition of 20 
ng/ml tetracycline (indicated by black arrow). Results shown indicate the mean ± from one 
independent experiment representative of three biological replicates. 
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In order to further investigate the effect of VapCRv0617 on cell viability and to 
determine whether this effect was of a bacteriostatic or bactericidal nature, 
samples of the culture were taken at 11 time points after tetracycline induction (6 
hourly for 48 hours, followed by 24 hourly for 48 hours) and plated onto LBT 
agar plates containing both hygromycin (50 µg/ml) and tetracycline (20 ng/ml), or 
hygromycin (50 µg/ml) alone (Section 2.2.2). All plates for the M. smegmatis 
deletion strain were additionally supplemented with kanamycin at 50 µg/ml The 
inclusion of tetracycline in the plates served to maintain overexpression of the 
pMind construct (VapBCRv0617a/c, VapCRv0617 or empty vector). At each time 
point, a 1 ml sample of culture was taken and three 5 µl serial dilutions of this 
were spotted onto the plate. Plates were incubated for 3 days at 37 ⁰C, after which 
colonies were counted for determination of CFUs and any differences in 
morphology between strains were noted. An example of colony growth for a 
dilution series of two wild-type M. smegmatis mc
2
155 cultures carrying an empty 
pMind vector 24 hours after tetracycline induction is shown in Figure 3.2.  
 
Figure 3.2 Colonies resulting from 5 µl spots of culture dilution series of 10
-2
, 10
-4 
and 10
-6 
after three days incubation at 37 ⁰C. Dilutions for two replicates of the M. smegmatis 
mc
2
155-pMind strain are pictured, starting both clockwise and anticlockwise downward from the 
top two segments. 
The degree of VapCRv0617 toxicity became more apparent when comparing 
measurements of CFUs for both wild-type and deletion strains expressing the 
VapCRv0617 toxin, VapBC complex or empty vector (Figure 3.3). Again, the 
relative effects of VapCRv0617, VapBCRv0617a/c or empty vector expression between 
the wild-type and deletion strain were similar. By 96 hours post-induction, the 
wild-type strain expressing VapCRv0617 exhibited an 87-fold reduction in cell 
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viability compared to that of the strain expressing the empty vector, and an 
86-fold reduction compared to the strain expressing the VapBCRv0617a/c complex 
(Figure 3.3A). Similarly, induction of VapC expression in deletion strains led to 
86-fold and 82-fold reductions in cell viability when compared to deletion strains 
expressing empty vector and VapBCRv0617 respectively (Figure 3.3B). 
 
Figure 3.3 The effect of VapCRv0617 overexpression on the viability of M. smegmatis mc
2
155 
and ΔvapBC strains. The effect of conditionally expressing VapCRv0617, VapBCRv0617a/c or empty 
pMind vector on cell viability was examined in M. smegmatis mc
2
155 (A) and a ΔvapBC deletion 
strain (B). Strains expressing empty vector are denoted by solid circles, strains expressing 
VapCRv0617 by solid squares and strains expressing VapBCRv0617a/c by open squares. CFU viability 
measurements were taken in the 96 h period following induction of expression with 20 ng/ml 
tetracycline. Graphs shown are from data acquired from one independent experiment 
representative of three biological replicates. Results shown indicate the mean ± SD of three 
technical replicates of each of three biological replicates. 
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3.1.2 The Effect of VapCRv0617  on Cell Morphology 
At all sampling time points, both M. smegmatis mc
2
155 and M. smegmatis 
ΔvapBC strains expressing either VapBCRv0617a/c or the empty pMind vector 
exhibited normal colony growth on the agar plates in both the presence and 
absence of tetracycline. In contrast, when grown on tetracycline-supplemented 
plates, both the wild-type and deletion strains expressing VapCRv0617 formed 
fewer colonies, many of which were smaller than average (Figure 3.4). Colony 
growth was normal when VapCRv0617 expressing strains were grown on agar plates 
in absence of tetracycline, indicating the inhibitory effect was of a bacteriostatic 
nature. 
  
Figure 3.4 The effect of conditional expression of VapBC, VapC, and empty pMind vector on 
the growth of M. smegmatis mc
2
155 and ΔvapBC strains. A mosaic of agar plates showing 
colony growth of the M. smegmatis mc
2
155 strain (A) and the ΔvapBC deletion strain (B) 
containing pMind, 0617vapBC_pMind or 0617vapC_pMind in the presence (+Tc) and absence 
(-Tc) of tetracycline. Plates represent cultures 48 hours post-induction. Each segment includes 
three technical replicates of M. smegmatis culture growth at 48 hours post-induction diluted 
10,000-fold. 
A
B
mc2155
ΔvapBC
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3.2 Protein Expression and Purification 
For activity assays, the non-toxic VapBCRv0065a/c and VapBCRv0617a/c protein 
complexes and toxic VapCRv0065 and VapCRv0617 proteins of M. tb were 
successfully expressed and purified as outlined in this section. 
3.2.1 Protein Expression in Mycobacterium smegmatis 
Expression and purification of the toxic VapC proteins alone has previously 
represented a significant hurdle in their biochemical characterisation (Mattison et 
al. 2006; Ramage et al. 2009). The expression protocol followed in this thesis for 
M. tb VapBC and VapC purification was based on that developed for expression 
of the M. smegmatis protein VapCMS1284.  
Expression of VapCMS1284 was initially attempted in M. smegmatis; however the 
toxicity of this protein posed a problem. In an attempt to escape the toxicity, 
plasmids containing this construct were driven to mutation, resulting in a 
nonsensical stop-codon upstream of the true vapC stop codon. Subsequent 
expression attempts of VapCMS1284 as both a His-tagged fusion protein and as a 
maltose-binding protein (MBP) fusion protein were unsuccessful, resulting in 
insolubility and the formation of large soluble VapC aggregates respectively. The 
large soluble VapC aggregates appeared to protect the MBP from being 
proteolytically degraded which hampered downstream purification. In order to 
overcome these issues, an alternate approach was taken that involved initial 
expression and purification of the entire VapBCMS1283/4 complex. Given its lack of 
toxicity, the complex is more amenable to overexpression in vivo (Robson et al. 
2009). Expression of the VapBC complex in E. coli was ruled out after it was 
determined that the E. coli transcriptional machinery does not recognise the 
overlap in bases occurring between the vapB and vapC genes in the vapBC 
operon, resulting solely in expression of insoluble VapB (Summers 2007; 
McKenzie 2011). Expression of the VapBC complex in M. smegmatis was much 
more successful. Greater success in this organism may be due to its larger degree 
of similarity to M. tb, meaning it has the correct mycobacterial molecular systems 
in place required for the production of M. tb proteins.  
The VapBCRv0065a/c, VapBCRv0617a/c, VapCRv0065 and VapCRv0617 proteins were 
expressed in this manner, and IMAC and size exclusion chromatography were 
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carried out to purify either VapBC complex. Functional VapC protein could 
subsequently be acquired through a limited trypsin digest to remove the labile 
VapB antitoxin which is reported as being more readily affected by proteolytic 
degradation (Gerdes et al. 2005). Anion exchange chromatography was then 
required to separate the VapC toxin from the trypsin and degraded VapB. 
3.2.2 Cloning of Rv0065a/c and Rv0617a/c Operons into pYUB28b 
E. coli-mycobacterial shuttle plasmids, pYUB28b, containing either the 
Rv0065a/c TA operon or the Rv0617a/c TA operon (amplified from H37Ra strain 
genomic DNA) were obtained from the Proteins & Microbes Lab, University of 
Waikato. The pYUB28b plasmid places the introduced construct under the control 
of a T7 promoter and enables purification with the addition of a C-terminal 
His-tag. Plasmids were initially transformed into electrocompetent E. coli TOP10 
cells (Sections 2.1.1.11 and 2.1.1.12) due to the ease of plasmid purification from 
this strain. Purified plasmids were sequenced to confirm the presence and 
accuracy of the insert sequence before being transformed into the M. smegmatis 
expression strain mc
2
4517 (Sections 2.1.1.13 and 2.1.1.14).  
3.2.3 Small Scale Protein Expression Trials 
Following transformation, expression of VapB and VapC protein from the 
pYUB38b vector was confirmed through small scale protein expression trials 
(Section 2.3.1). For both Rv0065a/c and Rv0617a/c protein expression, trials 
revealed the presence of VapB and VapC protein in the Ni sepharose fraction, 
indicating that both proteins were successfully being expressed and that the VapC 
protein possessed the C-terminal His-tag. VapB and VapC proteins were absent in 
the insoluble fraction and in wash fractions (data not shown). 
3.2.4 IMAC Purification of VapBC 
Large scale expression cultures were grown up from glycerol stocks as outlined in 
Section 2.3.2. Cell pellets of these cultures were lysed by sonication, centrifuged, 
and the supernatant was filtered through 1.2 and 0.45 µM filters. The Rv0065a/c 
and Rv0617a/c constructs within the pYUB28b plasmid had been designed so as 
to add a C-terminal His-tag. This tag enabled isolation of the VapBC complex 
through IMAC purification with a HiTrap
TM 
Chelating HP column (GE 
Healthcare, UK), (Section 2.3.3.2.) The chromatogram and corresponding 
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SDS-PAGE gel in Figure 3.5 depict the purification, column load and column 
flow-through fractions of a VapBCRv0065a/c sample. Non-specific proteins bound 
loosely to the column are eluted off early in the void peak. VapBCRv0065a/c elutes 
later in the gradient at approximately ~310 – 405 mM imidazole. Figure 3.6 
depicts the chromatogram and corresponding SDS-PAGE gel for a VapBCRv0617a/c 
IMAC purification. Here, VapBCRv0617a/c elutes off the column at approximately 
375 – 460 mM imidazole. Peak A in both spectra represents the void peak and 
contains only non-target proteins. The peaks labelled B and C in both spectra 
represent points of VapBC elution. 
 
Figure 3.5 VapBCRv0065a/c IMAC purification and corresponding 16.5% SDS-PAGE gel. The 
chromatogram depicts the UV absorbance and elution profile of VapBCRv0065a/c. Lanes in the 
SDS-PAGE gel denote insoluble protein (Pellet), column flow through (FT) and soluble protein 
(supernatant, S/N). Fractions and their corresponding elution position on the spectrum are labelled 
A-C. Positions of VapB and VapC proteins are indicated on the gel. 
In both gels the pellet, supernatant and flow through display an array of protein 
species, with enrichment seen for the VapC and VapB bands. Both SDS-PAGE 
gels for IMAC purifications displayed VapB and VapC protein bands in the later 
eluted fractions along with a band at approximately 25 kDa. This band may 
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represent the toxin dimer which, due to the strength of the interactions involved, 
had not been denatured by the reducing agent or the heat treatment prior to 
loading the gel, or by the denaturing reagents in the gel itself. 
 
        
Figure 3.6 VapBCRv0617a/c IMAC purification and corresponding 16.5% SDS-PAGE gel. The 
chromatogram depicts the UV absorbance and elution profile of VapBCRv0617a/c. Lanes in the 
SDS-PAGE gel denote insoluble protein (Pellet), column flow through (FT) and soluble protein 
(supernatant, S/N). Fractions and their corresponding elution position on the spectrum are labelled 
A-C. Positions of VapB and VapC proteins are indicated on the gel. 
3.2.5 Size Exclusion Purification of VapBC 
Fractions containing the VapBC protein complex were pooled and concentrated to 
5 ml (Section 2.3.5.2) before being run through a HiLoad
TM
 16/60 Superdex
TM
 
size exclusion column (SEC) (GE Healthcare, UK) (Section 2.3.3.3). Figure 3.7 
and Figure 3.8 depict the chromatograms and corresponding SDS-PAGE gels for 
VapBCRv0065a/c and VapBCRv0617a/c size exclusion purifications respectively. It can 
be seen in both figures that fractions in the region of points B and C contained 
eluted VapBC protein complex. The presence of a weak higher molecular weight 
band on gels at ~25 kDa may again represent VapC dimers which had not been 
fully denatured. 
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Figure 3.7 VapBCRv0065a/c size exclusion column purification and corresponding 16.5% 
SDS-PAGE gel. The chromatographm depicts the UV absorbance and conductivity profile of 
VapBCRv0065a/c. The SDS-PAGE gel denotes fractions from elution positions A, B and C on the 
spectrum. Positions of VapB and VapC proteins are indicated on the gel. 
Calibration of the S200 16/60 size exclusion column was carried out by Marisa 
Till (Proteins & Microbes lab, University of Waikato). This allowed calculation of 
Kav (gel phase distribution coefficient) values, and subsequent construction of a 
calibration curve. The equation from the calibration curve was Kav = -0.159 (MW) 
+ 2.1739 which is rearranged to form the equation MW = e
((Kav-2.1739)/-0.159)
.  Taking 
into account the calculated Kav values of VapBC complex peaks from the 
Rv0065a/c and Rv0617a/c SEC purifications (0.277 and 0.173 respectively), this 
led to calculated MWs of 151.71 kDa (VapBCRv0065a/c) and 292.86 kDa 
(VapBCRv0617a/c). These values were consistent with those observed in previous 
purifications (Jo McKenzie, unpublished results). While the observed MW value 
for VapBCRv0065a/c is similar to that seen for VapBCMS1282/4, which purifies as a 
tetramer of VapBC heterodimers bound to a 36 bp segment of DNA (152 kDa) 
(McKenzie 2011), the observed VapBCRv0617a/c MW value suggests purification of 
a larger complex. 
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    .  
Figure 3.8 VapBCRv0617a/c size exclusion column purification and corresponding 16.5% 
SDS-PAGE gel. The chromatogram depicts the UV absorbance and conductivity profile of 
VapBCRv0617a/c. The SDS-PAGE gel denotes fractions from elution positions A, B and C on the 
spectrum. Positions of VapB and VapC proteins are indicated on the gel. 
Fractions containing eluted VapBC protein were pooled and dialysed into a lower 
salt buffer overnight (Section 2.3.3.4). Dialysis was required to reduce the salt 
content of the sample, making it more amenable to subsequent anion exchange 
purification. The concentration of the VapBC sample was measured at 280 nm 
using the Nanodrop 2000 spectrophotometer (Nanodrop Technologies, USA) as 
outlined in Section 2.3.5.3, taking into account the molar extinction coefficient of 
the VapBC complex (0.649 for VapBCRv0065a/c and 0.534 for VapBCRv0617a/c) in 
order to obtain a more accurate concentration value.  
3.2.6 Isolation of VapC 
A common characteristic of TA systems is greater lability of the antitoxin 
compared with the toxin (McKenzie 2011). Instability indices of VapBRv0064 
(84.53), VapCRv0065 (43.18), VapBRv0616 (47.12) and VapCRv0617 (21.81) are in 
agreement with this, where larger numbers for both VapB indicate greater 
instability. Instability indices were calculated using ProtParam (Gasteiger et al. 
2005). Based on this property, a limited trypsin digest was used to selectively 
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degrade VapB whilst leaving functionally active VapC.  One hour incubation at 
room temperature using a ratio of 0.1 mg trypsin: 0.7 mg protein was found to 
result in optimal degradation of VapB, after which the reaction was stopped by 
addition of trypsin inhibitor (Section 2.3.4). For functional studies, the VapC 
protein must be purified away from the degraded VapB, trypsin and the inhibitor. 
Anion exchange chromatography was suitable for achieving this due to the 
differing isoelectric points of trypsin (10.5) and VapC (6.34 and 6.5 for 
VapCRv0065 and VapCRv0617 respectively) (values calculated using ProtParam  
(Gasteiger et al. 2005)). Trypsin digested protein sample was loaded onto a 
HiTrap
TM
 Q anion exchange column (GE Healthcare, UK) through a 0.2 µM 
filter, and anion exchange chromatography was performed to purify the VapC 
toxin (Section 2.3.5.1). Inactivated trypsin in the sample was eluted off the anion 
exchange column early on while the VapC toxin had a longer retention time on 
the column, eluting off at ~200-300 mM NaCl. Figure 3.9 and Figure 3.10 depict 
the chromatograms and corresponding SDS-PAGE gels for VapCRv0065 and 
VapCRv0617 anion exchange purifications respectively.  
 
Figure 3.9 Anion exchange purification of a trypsin digest of VapBCRv0065a/c and 
corresponding 16.5% SDS-PAGE gel. Trypsin is eluted off the column early on (A) while 
VapCRv0065 exhibits a greater retention time, remaining bound until early in the NaCl gradient (B & 
C). 
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Both gels depict presence of VapC bands and an absence of the previously noted 
VapB bands. The two smaller sized bands on the gel in Figure 3.9 differing in size 
to VapB and instead may represent small amounts of VapC degraded during the 
trypsin digest. The VapCRv0065 and VapCRv0617 bands ran at a slightly smaller size 
than seen in previous purification gels, attributable to cleavage of the ~1.5 kDa 
His-tag during the trypsin incubation. Such trypsin-mediated His-tag cleavage was 
noted during purification of the VapCMS1284 protein (McKenzie 2011). 
 
Figure 3.10 Anion exchange purification of a trypsin digest of VapBCRv0617a/c and 
corresponding 16.5% SDS-PAGE gel. Trypsin is eluted off the column early on (A) while 
VapCRv0617 exhibits a greater retention time, remaining bound until early in the NaCl gradient (B & 
C). 
Following anion-purification, fractions containing eluted VapC protein were 
pooled and concentrated, taking into account the molar extinction coefficients of 
VapCRv0065 (0.824) and VapCRv0617 (0.816) (values calculated using ProtParam  
(Gasteiger et al. 2005)). 
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3.3 VapC Ribonuclease Activity  
3.3.1 The Importance of RNA Secondary Structure in VapC Ribonuclease 
Activity 
To date, the impact of RNA secondary structure on VapC ribonuclease activity 
has yet to be investigated thoroughly. To examine this, ribonuclease assays were 
conducted in vitro with VapCRv0065 and VapCRv0617 against a number of 
synthesised RNA substrates. These substrates possessed varying secondary 
structures while retaining GC-rich 4-mers; sites previously determined to be 
targeted for cleavage by either VapC (Section 1.4.2.2). In these assays, negative 
controls included either EDTA (as PIN-domain proteins are 
Mg
2+
/Mn
2+
-dependent ribonucleases), VapBC (as cognate VapB inactivates VapC 
activity through formation of a benign complex), or no VapC (to ensure an 
absence of contaminating ribonuclease activity).  
3.3.1.1 932 Pentaprobe RNA VapC Ribonuclease Activity Assays 
Preliminary experiments conducted against all twelve Pentaprobe RNA substrates 
showed that VapCRv0065 and VapCRv0617 exhibited the most activity against the 932 
Pentaprobe (Section 1.4.2.2). To further confirm this, VapCRv0065 and VapCRv0617 
were tested in RNase assays against single-stranded 932 Pentaprobe RNA 
acquired from Joanna McKenzie (Proteins & Microbes lab, University of 
Waikato). Results were in agreement with previous findings, as both VapC 
proteins displayed Mg
2+
-dependent, sequence-specific ribonuclease activity 
against the 932 Pentaprobe, shown by degradation products on the gel (Figure 
3.11). 
   
Figure 3.11 VapCRv0065 and VapCRv0617  ribonuclease assays against 932 Pentaprobe RNA. 
VapC displays sequence-specific RNase activity against the 932 Pentaprobe.  Labels refer to RNA 
only negative controls (0 hr, 1 hr), EDTA negative control (EDTA), assay time points (5, 15, 30, 
60 min) and activity of the VapBC0065a/c/VapBC0617a/c complex (VapBC). A low range ssRNA 
ladder is shown down the side of the 10% urea denaturing gel. 
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Although urea denaturing polyacrylamide gels were used in these experiments, 
the large amount of secondary structure in the 932 Pentaprobe was observed as 
multiple high molecular-weight bands at the top of the gel. RNA only 0 hr and 
1 hr samples showed no RNA degradation, proving that there were no 
contaminating RNases present in the assay buffer. No degradation in the EDTA 
control samples indicated an absence of metal-independent RNases, such as 
Ribonuclease A, in the protein preparation. If metal-independent RNases were 
present here, degradation of RNA would still be seen upon inhibition of VapC 
with EDTA. Comparing RNA degradation between the VapC samples to those 
with either VapBCRv0065a/c or VapBCRv0617a/c revealed that VapB inhibited 
ribonuclease activity of its cognate VapC. A shared specificity between these 
VapC ribonucleases was indicated by the near identical fragmentation patterns 
that the two enzymes produced. Under these assay conditions, VapCRv0065 and 
VapCRv0617 had comparable activity. In both assays, a signification proportion of 
the 932 Pentaprobe was degraded by the 5 minute incubation time point. With 
increasing incubation, the number of smaller sized degradation products 
increased. This suggests that an optimal recognition site was being targeted 
quickly, after which other sub-optimal sites were also recognised for cleavage 
over a longer time-scale.  
3.3.1.2 932 Pentaprobe RNA Fragments VapC Ribonuclease Activity Assays 
Due to the activity exhibited against this substrate, the 932 Pentaprobe was chosen 
as the scaffold from which to design shorter RNA fragments. To determine the 
role of secondary structure in the specificity of these VapC proteins, the 
overlapping RNA fragments were designed to have differing secondary structures, 
while all encompassing a 15 bp GC-rich region of the 932 Pentaprobe (Section 
2.4.1). The structures of 932 fragments were predicted by RNAfold (Vienna RNA 
webservers, TBI) (Section 2.4.2) and these are included in Appendix C4. A goal 
of this work was to create a short substrate which would include the minimal, 
optimal secondary structure required for cleavage. A schematic of the positioning 
of the designed fragments in relation to the longer 932 Pentaprobe is provided in 
Figure 3.12. 
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Figure 3.12 The 932 Pentaprobe and subset fragments. The 932 Pentaprobe RNA (1-247) 
consists of the Pentaprobe sequence flanked by regions of vector. Positioning of Pentaprobe 
fragments 90-170, 50-150, 70-150, 94-126 and 109-126 in relation to the full 932 Pentaprobe is 
shown. Numbers indicate nucleotide position along the 932 Pentaprobe RNA. Red boxes represent 
GC-rich regions of the RNA. Ticks/crosses indicate that both/neither VapC protein displayed 
activity against the fragment. The 15 bp GC-rich centre is located at position 112-126 on the 932 
Pentaprobe RNA. 
 
Each 932 RNA fragment was incubated in vitro with purified VapCRv0065 or 
VapCRv0617 at 37 ⁰C in assay buffer (Section 2.4.3.2). Negative controls included 
were as previously described. RNase activity against the fragments was analysed 
by running assays on 20 % urea denaturing gels (Section 2.4.4). Results for 
VapCRv0065 and VapCRv0617 assays are shown in Figure 3.13 and Figure 3.14 
respectively. 
VapCRv0065 and VapCRv0617 degraded four of the five 932 Pentaprobe fragments; 
90-170, 50-150, 70-150 and 94-126. In all assays conducted, RNA only 0 hr and 
1 hr samples exhibited no RNA degradation indicating that there were no 
contaminating RNases present in the assay buffer. It had been previously 
established that VapCRv0065 and VapCRv0617 efficiently cleave the 932 94-126 
fragment (denoted ‘Oligo 3’ in previous experiments (Section 1.4.2.2)), and these 
assays confirmed this. While the gels suggested that there was a degree 
degradation in the initial 932 94-126 RNA preparation (seen as smearing in all 
lanes), there was definite VapC-mediated RNase activity occurring against this 
substrate as indicated by the presence of degradation bands in the VapC 60 minute 
sample that were absent in the controls. 
 
 
94-126
50-150
109-126
70-150
90-170
1 24730 60 90 120 150 180
932 PentaprobeFlanking Vector Seq Flanking Vector Seq





Chapter Three: Results 
 
 
72 
 
 
 
VapCRv0065 and VapCRv0617 did not appear to bind the Pentaprobe fragment RNA 
molecules that they cleaved, as no smearing was seen that was specific to lanes in 
which VapC protein had been added. This is in contrast to observations made for 
VapCMS1284 from M. smegmatis (Section 1.4.1). Substrate fragmentation patterns 
were virtually identical when comparing VapCRv0065 and VapCRv0617 mediated 
cleavage. By analysing the sizes of major cleavage products and correlating these 
with the positioning of bases along the substrate strands, suggestions can be made 
as to what cut sites mediate production of the degradation products. The cleavage 
product bands of sizes ~6 bases smaller than the 932 70-150 and 932 90-170 
substrates are in agreement with cleavage at the GC-rich regions present at the 
termini of these substrates (refer back to Figure 3.12). Degradation bands running 
at ~60 and ~40 bases in the 932 50-150 assays may correlate to a single cleavage 
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Figure 3.13 VapCRv0065  ribonuclease assay 
against 932 Pentaprobe fragments. 
Numbers at bottom left corner of gels denote 
Pentaprobe fragments. Labels refer to RNA 
only negative controls (0 hr, 1 hr), EDTA 
negative control (EDTA), assay time points 
(5, 15, 30, 60 min) and activity of the 
VapBC0065a/c complex (VapBC). A low range 
ssRNA ladder is shown down the side of the 
20% urea denaturing gel. 
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event at this substrate’s GC-rich centre. Interestingly, there are only very weak 
degradation bands corresponding to a single cleavage event at the GC-rich centre 
for the 932 90-170 and 932 70-150 fragments. In these two fragments, the 
GC-rich region is predicted to reside in a stem region of the RNA. In contrast, this 
region forms a hairpin loop in the 932 50-150 fragment. This motif has previously 
been associated with VapC activity; it was suggested that a hairpin loop 
immediately downstream of the cut site is preferable for cleavage by VapCMS1284 
(Section 1.3.2.3). No activity was observed for either VapC against the small 932 
109-126 Pentaprobe RNA fragment. 
       
 
 
Collectively, results of the assays in Figure 3.13 and Figure 3.14 corroborate the 
previously drawn conclusion that VapCRv0065 and VapCRv0617 target the same 
recognition sequence of GC-rich 4-mer regions in ssRNA.  
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Figure 3.14 VapCRv0617 ribonuclease assay 
against 932 Pentaprobe fragments. 
Numbers at bottom left corner of gels 
denote pentaprobe fragment. Labels refer to 
RNA only negative controls (0 hr, 1 hr), 
EDTA negative control (EDTA), assay time 
points (5, 15, 30, 60 min) and activity of the 
VapBC0617a/c complex (VapBC). A low 
range ssRNA ladder is shown down the side 
of the 20% urea denaturing gel. 
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In order to strengthen evidence for the negative result seen against the 932 
109-126 fragment for either VapC protein, assays against this substrate were 
repeated and analysed by MALDI TOF MS (Figure 3.15). 
 
Figure 3.15 932 109-126 RNA, VapCRv0617 and VapCRv0065 MALDI TOF MS results. Labels 
refer to RNA only negative controls (RNA 0, 60 min), EDTA negative control (Rv0617 EDTA), 
VapCRv-617 assay time points (Rv0617 15, 30, 60 min) and VapCRv0065 assay time points (Rv0065 
30, 60 min). Data analysed by Bruker Data Analysis and baseline subtracted. 
 
The mass spectra showed no degradation of the 932 109-126 fragment in negative 
controls nor in reactions including VapCRv0617 or VapCRv0065. Signal intensity of 
the molecular ion peak was slightly reduced in the Rv0617 30 min assay time 
point sample; however is restored in the 60 min time point sample. This reduced 
intensity and absence of degradation product peaks suggests that initially there 
was less RNA added to this reaction tube. Multiple peaks in the Rv0617 30 min 
molecular ion peak may be due to the formation of RNA adducts (i.e. M
+
Na). The 
MFE predicted secondary structure of the 932 109-126 fragment was compared 
RNA
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with that of the 94-126 fragment using RNAfold prediction software (Figure 3.16) 
in an attempt to rationalize why one was cleaved preferentially over the other. 
 
Figure 3.16 MFE secondary structure predictions for the 932 94-126 and 109-126 RNA. A, 
Predicted secondary structure of the 932 94-126 fragment. B, Predicted secondary structure of the 
932 109-126 fragment. Predictions were made using RNAfold (Vienna RNA webservers, TBI). 
 
The 932 109-126 RNA is predicted to have a large terminal loop region that is 
absent in the 932 94-126 structure. Both structures retain the 15 bp GC-rich region 
in a hairpin loop portion; however the 932 109-126 fragment has lost the longer 
stem region extending down from this. This comparison, along with analysis of 
the structures and assay results of the longer 932 fragments, could suggest that the 
presence of both a GC-rich cut site in a hairpin loop and a long stem region 
proximal to this are required for efficient VapC cleavage.  
The free energy of the predicted secondary structure for each of the RNA 
substrates tested is given in Table 3.1. Out of the four longest substrates (932 
1-247, 932 90-179, 932 50-150 and 932 70-150), both VapC proteins displayed 
the least activity against 932 70-150. This RNA substrate has the most positive 
free energy value, and therefore the least predicted secondary structure of the four.  
Table 3.1 Minimum free energy values at 37 ⁰C for each RNA substrate as 
calculated by RNAfold WebServer 
RNA Substrate Free Energy kcal/mol (at 37 ⁰C) 
932 1-247 -88.8 
932 90-170 -17.7 
932 50-150 -22.4 
932 70-150 -14.9 
932 94-126 -9.5 
932 109-126 -4.9 
The more negative the free energy value, the larger the amount of secondary structure in the RNA 
molecule and the higher the likelihood that this structure will form. 
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While a definitive secondary structural motif required for VapC cleavage has not 
been reported, these results support the growing evidence of such a phenomenon. 
3.3.2 VapC Ribonuclease Activity Against In Vivo Substrates 
In M. smegmatis, research conducted by Robson (2010) resulted in a number of 
postulated in vivo targets of the singular VapC protein, including transcripts 
involved in sugar metabolism and transport (Section 1.4.1). To date, no target 
transcripts have been identified in vivo for M. tb proteins VapCRv0065 and 
VapCRv0617. Elucidation of in vivo targets will be instrumental in shedding further 
light on the biochemical role that the M. tb encoded VapC proteins play in the 
bacterium’s metabolism. 
The 16S and 23S rRNA constitute indispensible components of the prokaryotic 
ribosome and are essential for cell viability. The 16S and 23S rRNA bands can be 
easily identified when total RNA is separated on a 1% agarose gel, running at 
sizes of approximately 1.5 kb and 2.9 kb respectively. Due to extensive research 
into the ribosome and its many components, the secondary structure of both 16S 
and 23S rRNA is well documented. As such, identification of cut sites along these 
rRNA molecules may elucidate secondary structure pre-requisites for VapC 
cleavage. These factors led to the investigation of whether the 16S and 23S rRNA 
were targets for VapCRv0065 and VapCRv0617 –mediated ribonuclease activity. 
A number of approaches were considered for isolation of rRNA. These included 
i) isolation of ribosomes from M. smegmatis culture using strong anion-exchange 
chromatography (Trauner et al. 2011) followed by total RNA extraction of the 
ribosomes; ii) an in vitro approach via PCR amplification of rRNA genes directly 
from M. tb H37Ra genomic DNA followed by in vitro transcription and 
purification (this approach would have the disadvantage in that the resulting 
synthesised transcripts would be lacking in post-transcriptional modifications that 
potentially take place in vivo to produce the mature rRNA molecules) and iii) 
isolation of total RNA followed by specific separation of rRNA from the total 
RNA pool. This last approach seemed the most feasible. A suggested method for 
determining the location of cut sites along the rRNA involved use of post-assay 
reverse transcription followed by real-time PCR analysis with primers situated at 
intervals along the 16S rRNA transcript. This was deemed undesirable as primers 
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used in the reverse transcription step would be subject to bias, which could skew 
results. Instead, assays against the rRNA were run on low percentage urea 
denaturing gels in an attempt to gain high resolution between the resulting 
fragmentation pattern bands. 
3.3.2.1 Mycobacterial Total RNA Ribonuclease Activity Assays 
Initial experiments aimed to roughly gauge the activity of VapCRv0065 and 
VapCRv0617 against mycobacterial rRNA. Due to the unavailability of M. tb total 
RNA, the activity of VapC against total RNA from both M. smegmatis mc
2
155 
and Mycobacterium bovis was tested. 
Preliminary assays investigating the ribonuclease potential of the VapC proteins 
indicated that VapCRv0065 and VapCRv0617 cleave M. smegmatis total RNA 
(McKenzie, unpublished results). These assays were repeated, specifically 
focusing on activity against the 16S and 23S rRNA bands. M. smegmatis total 
RNA was isolated from cultures using the GITC/phenol-chloroform extraction 
protocol as outlined in Section 2.1.2.1. RNase assays against each VapC protein 
were set up as described in Section 2.4.3.2 which included 15, 30 and 60 min time 
points. Controls included 0 hr and 1 hr RNA only samples, an EDTA control and 
a VapBC control (VapBCRv0065a/c or VapBCRv0617a/c). Assays were run on 1% TAE 
agarose gels for analysis (Section 2.1.1.3) (Figure 3.17).  
 
Figure 3.17 Ribonuclease activity of VapCRv0065 and VapCRv0617 from M. tb using 
M. smegmatis total RNA as a substrate. VapC proteins display Mg
2+
-dependent activity as 
addition of EDTA abolishes activity. RNA degradation in the presence of both VapC is seen over a 
period of 15 – 60 minutes. Negative controls are shown by 0 hr and 1 hr RNA only samples along 
with EDTA controls. A 1Kb
+
 molecular weight marker shows molecular masses of dsDNA. 
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VapCRv0065 and VapCRv0617 displayed Mg
+
-dependent ribonuclease activity against 
the M. smegmatis total RNA, as inclusion of EDTA in the assay buffer abolished 
ribonuclease activity. The disappearance of 23S and 16S rRNA bands and 
accumulation of smaller RNA fragments with increasing VapC incubation 
suggests both VapC proteins were active against the rRNA. Comparing this assay 
to that conducted with the 932 Pentaprobe RNA, it can be seen that VapCRv0065 
and VapCRv0617 cleaved the rRNA in this total RNA sample at a much faster rate. 
M. bovis total RNA was acquired from the Proteins & Microbes lab, University of 
Waikato. Due to the limited amount, only 15 and 30 minute time points were 
selected for assays. These assays revealed activity for both VapCRv0065 and 
VapCRv0617 against the M. bovis 16S and 23S rRNA (Figure 3.18) (assay with 
VapCRv0065 not shown).  
                     
Figure 3.18 Ribonuclease activity of VapCRv0617 from M. tb using M. bovis total RNA as a 
substrate. VapCRv0617 displays Mg
2+
-dependent activity as addition of EDTA abolishes activity. 
RNA degradation in the presence of VapCRv0617 is seen over a period of 15 – 30 minutes. Negative 
controls are shown by 0 hr and 1 hr RNA only samples along with EDTA controls. A 1Kb
+
 
molecular weight marker shows molecular masses of dsDNA. 
3.3.2.2 Mycobacterium smegmatis rRNA Ribonuclease Activity Assays 
In order to further investigate VapC–mediated cleavage of the rRNA, 16S and 
23S rRNA was purified from M. smegmatis total RNA as outlined in Section 
2.1.2.3. Ideally the native M. tb rRNA would be purified; however due to 
unavailability and technical restrictions M. smegmatis was chosen as a model. 
Genomic sequences for M. smegmatis mc
2
155 and M. tb H37Rv 16S rRNA genes 
were identified as having a nucleotide conservation score as 95% on the National 
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Centre for Biotechnology Information (NCBI) website. Figure 3.19 depicts a total 
RNA preparation run on a 1% TAE agarose gel (Section 2.1.1.3).  
 
Figure 3.19 Isolation of total RNA from M. smegmatis. Lanes 1-7 represent RNA samples that 
were isolated using a GITC/phenol-chloroform protocol for RNA extraction. Bands for 23S, 16S 
and 5S rRNA are indicated. Samples are run alongside a 1Kb
+
 ladder (Invitrogen) for size 
estimation. 
It was consistently noted that two bands were present at the 23S rRNA region. 
These two bands may reflect differing secondary structure in the 23S rRNA 
molecule. Purified 16S and 23S rRNA was used in RNase assays with VapCRv0065 
and VapCRv0617 and the resulting fragmentation patterns were observed in an 
attempt to gauge their specificities against these substrates. 
VapCRv0065 and VapCRv0617 ribonuclease assays against the purified 16S rRNA 
were conducted as outlined in Section 2.4.3.2. Controls included 0 hr and 1hr 
RNA only samples, an EDTA control and a cognate VapBC control. Figure 3.20 
depicts these assay samples run on 5 % urea denaturing gels prepared as outlined 
in Section 2.4.4. 
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Figure 3.20 Ribonuclease activity of VapCRv0065 and VapCRv0617 from M. tb against isolated 
M. smegmatis 16S rRNA. Labels refer to RNA only negative controls (0 hr, 1 hr), EDTA negative 
control (EDTA), assay time points (5, 15, 30, 60 min) and activity of the VapBCRv0065a/c or 
VapBCRv0617a/c complex (VapBC). A low range ssRNA ladder is shown down the side of the 5% 
urea denaturing gel. 
As indicated by the presence of degradation products in lanes including either 
VapC protein, VapCRv0065 and VapCRv0617 both displayed Mg
2+
-dependent 
ribonuclease activity against isolated and purified 16S rRNA from M. smegmatis. 
VapBC TA complexes displayed no ribonuclease activity (Figure 3.20). 
Ribonuclease activity of VapCRv0065 and VapCRv0617 against isolated and purified 
23S rRNA was tested following the same protocol as for the 16S rRNA assays. 
Controls in each assay included 0 hr and 1 hr RNA only samples, an EDTA 
control and a cognate VapBC control. Figure 3.21 depicts assays against both 
VapC proteins run on 5% urea denaturing gels prepared as outlined in Section 
2.4.4. 
 
Figure 3.21 Ribonuclease Activity of VapCRv0065 and VapCRv0617 from M. tb against isolated 
M. smegmatis 23S rRNA. Labels refer to RNA only negative controls (0 hr, 1 hr), EDTA negative 
control (EDTA), assay time points (5, 15, 30, 60 min) and activity of the VapBCRv0065a/c or 
VapBCRv0617a/c complex (VapBC). A low range ssRNA ladder is shown down the side of the 5% 
urea denaturing gel. 
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As indicated by the presence of degradation products in lanes including either 
VapC protein, VapCRv0065 and VapCRv0617 both displayed Mg
2+
-dependent 
ribonuclease activity against isolated and purified 23S rRNA from M. smegmatis. 
VapBC TA complexes displayed no ribonuclease activity. 
Both VapCRv0065 and VapCRv0617 appear to have greater activity against the 23S 
rRNA, since the majority of the full-length substrate was degraded after 
15 minutes incubation, whereas against the 16S rRNA an equivalent degree of 
degradation required 60 minutes. Unfortunately in both the 16S and 23S rRNA 
assays, no clear fragmentation pattern could be discerned. This hindered the 
comparison of RNase specificity of either VapC for these substrates, and 
prevented approximation of the location of cut sites along the rRNA based on the 
sizes of fragments produced.  The ratio of protein to RNA in subsequent RNase 
assays was decreased in an attempt to see VapC acting only upon primary cut 
sites, thus simplifying the degradation pattern. These assays still displayed a 
multitude of differently sized fragments appearing as a smear on the gel (data not 
shown). 
3.3.3 Proposed Protocol for the Identification of In Vivo VapC Targets 
Identification of the in vivo targets of the M. tb proteins VapCRv0065 and 
VapCRv0617 will shed light on their physiological roles and potential importance in 
M. tb virulence. A protocol was developed to specifically identify mRNA targets 
of VapC through selective RNA tagging, reverse transcription and subsequent 
PCR amplification. Bacterial mRNA within the cell is believed to natively occur 
with a 5’-triphosphate group on the first transcribed nucleotide (Schoenberg 
2007). The developed protocol takes advantage of the singular 5’-monophosphate 
left on the 3’ cleavage product by VapC (McKenzie 2011; Duyvestyn 2012) and 
uses this modification to selectively tag cleaved mRNAs with an RNA oligo of 
known sequence. Non-specific 3’ polyA-tailing allows the tagged mRNA 
molecules to be reverse transcribed into cDNA using primers complementary to 
the RNA oligo tag and the polyA-tail. A round of PCR on the cDNA strand 
amplifies these tagged molecules to a quantity sufficient for cloning and 
subsequent sequencing. A flowchart of this process is detailed in Figure 3.22. 
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Figure 3.22 Proposed protocol for identification of in vivo M. tb VapC mRNA targets. 
 
3.3.3.1 Development of Protocol with VapCPAE0151 and the 924 Pentaprobe 
The E.coli VapCPAE0151 protein was used in the development of this protocol. This 
protein was chosen over mycobacterial VapC species as it was readily available in 
a purified form, and preliminary VapCPAE0151 RNase assays assessed on urea 
denaturing gels revealed distinct fragmentation patterns against a number of the 
Pentaprobe RNA substrates (McKenzie et al. 2012b). An assay that produced a 
small number of cleavage products was desired as this would simplify their 
subsequent labelling and identification. IMAC nickel-purified VapCPAE0151 was 
acquired from the Proteins & Microbes lab, University of Waikato. In order to test 
the protocol, the 924 Pentaprobe was chosen as a substrate. When RNase assays 
against this substrate were run on a urea denaturing gel (Sections 2.4.3.1 and 
2.4.4), VapCPAE0151 cleaved the Pentaprobe into three major degradation products 
of approximately 120 bases, 80 bases and 65 bases (Figure 3.23). The principles 
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of this protocol dictate that these three products would specifically be labelled and 
amplified. 
 
 
 
Figure 3.23 Ribonuclease 
activity of VapCPAE0151 from 
Pyrobaculum aerophilum against 
the 924 Pentaprobe. Ladder = 
low range ssRNA marker. Lanes 
from left to right represent two 
RNA negative controls, assay 
time points at which samples were 
taken, an EDTA control and a 
VapBC control. Figure adapted 
from (McKenzie et al. 2012b). 
 
The protocol was followed through and stages were completed as outlined in 
Section 2.4.7.  After cDNA synthesis, rather than following on to cloning and 
sequencing, the cDNA was instead run on a 2% TAE agarose gel in order to 
quickly and roughly determine whether bands corresponding to the three primary 
924 degradation products had been selectively tagged and amplified. The protocol 
was independently followed through three times. Figure 3.24 depicts a gel 
representative of all results observed.  
 
 
 
Figure 3.24 2% TAE agarose gel 
of PCR amplified and tagged 
RNase assay 
products/Pentaprobe 924 RNA. 
The resulting 2% gel after 
following the proposed protocol 
for identification of VapC target 
transcripts. ‘Assay product’ lanes 
indicate samples where RNA 
originated from VapCPAE0151-924 
assay products. ‘924’ lanes 
indicate samples where RNA 
originated from purified 924 
Pentaprobe. A negative control 
where template was excluded 
from the PCR mixture is run in 
right-most lane. A 1Kb
+
 molecular 
weight marker shows molecular 
masses of dsDNA. 
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No bands corresponding to either the full length 924 Pentaprobe, or 
VapC-produced degradation fragments of the 924 Pentaprobe, were present on 
gels. The gels displayed a significant amount of unknown high molecular mass 
nucleic acid material which remained near the wells. Due to difficulties 
encountered in pinpointing problematic step(s) in the protocol, it was decided at 
this point that no further work was to be done to remedy the problems 
encountered.  The protocol shows promise for the development of a tool which 
could selectively identify VapC targets from a sample of mixed mRNA, and 
further optimisation will be required to achieve this. 
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3.4 VapBC Transcriptional Autoregulation through DNA 
Binding 
TA systems, including those belonging to the VapBC family, are well 
documented to have an autoregulatory function whereby the TA complex binds 
back to the promoter DNA to sterically repress transcription (Section 1.2.4). The 
following experiments examined the binding abilities of VapBCRv0065a/c and 
VapBCRv0617a/c against promoter DNA of their corresponding operons, which 
would suggest autoregulatory roles for these complexes in their TA system 
functioning. If promoter-VapBC binding was observed, it was then determined 
what sequence motif in the promoter region was required for binding. As 
previously discussed, studies characterising a number vapBC systems have 
reported IR sequences in the promoter whose presence is essential for maintaining 
the VapBC-DNA interaction. 
3.4.1 Identification of Promoter Regions 
The Rv0065 and Rv0617 genes, encoding VapCRv0065 and VapCRv0617 respectively, 
have previously been found to be leaderless (McKenzie, unpublished work) 
indicating that their transcriptional start points (TSPs) coincide with the start point 
of their translation. The genomic coordinates and nucleotide sequence of both 
Rv0065a/c and Rv0617a/c operons were identified using the website 
http://cmr.jcvi.org and searching within the Mycobacterium tuberculosis H37Ra 
genome. The Rv0617a/c operon was identified as starting at position 710780 on 
the chromosome and therefore the region 710650-710780 (130 bp) was taken as 
the putative promoter. The Rv0065a/c operon started at position 71587, and the 
region 71486-71587 (101 bp) was taken as the putative promoter. Both putative 
promoter regions contained a 6 bp perfect IR. The regions were analysed for 
distinguishing promoter features. 
A characteristic element of prokaryotic promoters is the hexameric sequence 
located around the region -10 nucleotides upstream of the TSP, referred to as the 
Pribnow box. Mycobacterial Pribnow boxes are known to be disparate to those 
characteristic of E. coli (Bashyam et al. 1996). A study by Bashyam et al (1996) 
surveyed the characteristics of Pribnow box-like sequences in mycobacterial 
promoters and identified conserved nucleotides at positions in the -10 hexameric 
sequences of M. tb samples; 80% T, 90% A, 60% Y, 40% g, 60% A and 100% T, 
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where the letter Y represents a pyrimadine base and capital letters indicate bases 
exhibiting conservation of 50% or more (Bashyam et al. 1996). The most 
important bases in the hexameric sequence were denoted as being at the first, 
second and sixth positions. These positions are functionally more important than 
in E.coli and are highly conserved among mycobacterial promoter sequences 
(Bashyam et al. 1996). The remaining positions in mycobacteria are thought to 
have high vulnerability to GC intrusions due to the higher GC content of 
mycobacterial DNA (Bashyam et al. 1996).  
Within the 130 bp putative Rv0617a/c promoter region, nucleotides 
5’-GATGTT-3’ occurring at positions -16 to -11 relative to the TSP may be a -10 
recognition element. This sequence was annotated as a -10 element in the M. tb 
promoter T26 (Bashyam et al. 1996). Nucleotides TAGGAT at positions -12 to -7 
relative to the TSP may also be a putative -10 element as this sequence fulfils the 
requirements of a sigma factor A recognition site (the sigA consensus sequence is 
identified as 5’-TA(G/T)(A/G)AT-3’ (Gomez & Smith 2000; Zaunbrecher et al. 
2009)). The SigA protein has been identified as an expression modulator of genes 
contributing to virulence (Wu et al. 2004), a category that the vapBC genes fall 
into. No previously annotated -10 recognition elements were found in the 101 bp 
Rv0065a/c promoter region. The -35 regions in the Rv0617a/c and Rv0065a/c 
promoters bear no resemblance to the 5’-TTGACA-3’ motif seen in E. coli and 
several other bacteria (Bashyam et al. 1996). This is not surprising as a number of 
studies have reported that no single -35 sequence is conserved among 
mycobacterial promoters (Bashyam et al. 1996). Each promoter region was found 
to contain a 6 bp perfect IR. Figure 3.25 outlines hypothetical -10 and -35 
elements along with perfect IRs in the putative Rv0065a/c and Rv0617a/c 
promoter regions. Details regarding the preparation of putative promoter DNA 
used in EMSAs can be found in Section 2.5.1. 
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5’CCGCCACCCAACACGGCTCGTGCGCTGTCTCGGCCGGCTCGTCTG
CCGCACGGCCAGCATGATCAGTCCCGTTGGAATACCGGTGAGCGTC
GGCGCGCGCATCACGATGCAGCGATGTTAGGATGAGGCGGTG 3’
+1
sigAT26
-10-35
A
5’CTGGCCGATCTGCGCGCGGTGCTCGACCGGTTAGAGAAGGCCAT
CGATGCCGCCGAAACGCCCGGTGGATAAGCCGGCATTCTTAGCCG
GTGAACTCCGCTATG3’
+1-10
-35
B
 
 
Figure 3.25 Putative 
Rv0065a/c and Rv0617a/c 
promoter elements. 
Underlined nucleotides 
represent putative promoter 
elements. TSP is indicated 
(+1, bold). Perfect IR are 
indicated by divergent 
arrows. A, 130 bp 
Rv0617a/c promoter region. 
Reported M. tb T26 
promoter and sigA binding 
site are labelled. B, 104 bp 
Rv0065a/c promoter region.  
 
3.4.2 VapBCRv0065a/c EMSAs with Putative Rv0065a/c Promoter DNA  
The 101 bp sequence of putative Rv0065a/c promoter DNA was DIG-labelled and 
used in an EMSA with purified VapBCRv0065a/c protein as described in Section 
2.5.5. VapBC was used in EMSA assays in the range 0 nM - 470 nM. Labelled 
DNA (4 ng) was used in each reaction. No shift was observed at any VapBC 
concentration (Figure 3.26). 
 
Figure 3.26 VapBCRv0065a/c 
does not bind to a 101 bp 
region of the Rv0065a/c 
promoter. EMSA experiments 
were performed with a 101 bp 
DIG-labelled region of 
promoter DNA (0.4 ng) 
encompassing a perfect 6 bp IR. 
Concentrations of VapBC are 
shown above each lane 
 
It was theorised that the recognition site for VapBCRv0065a/c may be downstream of 
the TSP. The region of DNA being tested was altered to span 38 bp upstream and 
112 bp downstream of the TSP. The 112 bp region downstream of the TSP 
contained three additional perfect IR. The 150 bp region was amplified from M. tb 
H37Ra genomic DNA (Proteins & Microbes lab, University of Waikato), 
DIG-labelled and tested with VapBCRv0065a/c in EMSAs. No shift was observed in 
the VapBC concentration range of 0 nM to 450 nM (Figure 3.27). To ascertain 
whether the lack of VapBCRv0065a/c DNA-binding activity was due to the complex 
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co-purifying with nucleic acids, rendering it unable to bind additional DNA, 
VapBCRv0065a/c purified through IMAC nickel, size-exclusion and anion exchange 
chromatography was run on a 1% TAE agarose gel and stained with 
SYBERSafe
TM
 DNA gel stain (Invitrogen, USA). The gel showed no presence of 
VapBC-associated DNA (data not shown). 
 
Figure 3.27 VapBCRv0065a/c does 
not bind to a 150 bp region of 
the Rv0065a/c promoter.  A, 
PCR amplification of a 150 bp 
DNA fragment proximal to the 
Rv0065a/c TSP. B, EMSAs were 
performed with the 150 bp DNA 
region (0.4 ng) encompassing a 
perfect 6-bp IR sequence. 
Concentrations of VapBC (nM) 
are shown above each lane. 
 
3.4.3 Cross-talk between VapBC Complexes and Promoter DNA 
EMSAs were used to investigate whether the VapBCRv0065a/c complex would bind 
the Rv0617a/c promoter region, and vice versa with the VapBCRv0617a/c complex. 
VapBC protein was tested at a concentration of 400 nM, and in both cases, no 
DNA-binding activity was observed with VapBC against its non-cognate 
promoter region (data not shown). 
3.4.4 VapBCRv0617a/c EMSAs with Putative Rv0617a/c Promoter DNA 
The 130 bp putative Rv0617a/c promoter region DNA was DIG-labelled and used 
in EMSAs with purified VapBCRv0617a/c protein as described in Section 2.5.5. 
Assays included 4 ng of DNA and VapBC in the range 0 nM - 350 nM (Figure 
3.28). A full shift indicating DNA binding was observed at 150 nM VapBC. 
Introduction of 125 x excess non-labelled DNA to indicate specific competition 
(130 bp Rv0617a/c promoter, ‘specific’ lane on gel) out-competed binding of the 
labelled DNA, seen in the near abolishment of the shift. A non-labelled, 
non-specific competition control (mazEF promoter DNA) was included to assess 
the specificity of VapBCRv0617a/c binding toward the cognate promoter. The gene 
Rv1495 in the M. tb genome is identified as a MazF toxin homolog (Huang & He 
2010) and the Rv1494 gene a MazE antitoxin homolog. Therefore, a 600 bp 
region upstream of the Rv1494 start site was amplified (Section 2.5.2) and taken 
to be the mazEF promoter. Addition of 125x excess of mazEF promoter DNA 
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(‘non-specific’ lane on gel) did not have an effect on the shift, indicating no 
competition for binding with the labelled DNA. 
3.4.4.1 EMSAs with Perfect Inverted Repeat Mutants 
The 130 bp Rv0617a/c promoter region contains a 6 bp perfect IR (5’-CGTGCG-
N22-CGCACG-3’) with halves positioned at nucleotides -112 and -84 relative to 
the transcriptional and translational start site of the Rv0617a/c operon. To assess 
whether the perfect IR was required for the VapBC binding that was exhibited 
with this region, either half or both halves were mutated as outlined in Section 
2.5.3. Mutations consisted of changing the four central bases of an IR half to 
adenine. Adenine substitution was thought to cause the most disruption to 
protein-DNA interactions given the high GC content of the M. tb genome. DNA 
sequencing based on the Applied Biosystems 3130xl Genetic Analyser (WDSF, 
University of Waikato) confirmed that mutations had been achieved. Sequencing 
results are included in Appendix B1. 
 
Figure 3.28 VapBCRv0617a/c binds specifically to a 130 bp region of the Rv0617a/c promoter. 
EMSA experiments were performed with a DIG-labelled 130 bp promoter fragment (0.4 ng) 
encompassing a perfect 6-bp IR sequence. Concentrations of VapBC are shown above each lane. 
Non-specific and specific binding is proven in lanes 9 and 10 using 125-fold excess (50 ng) of 
unlabelled 130-bp promoter and 600-bp mazEF promoter DNA respectively. 
Mutations in either half or both halves of the perfect IR did not affect 
DNA-binding as, in either case, EMSAs displayed no difference in shift compared 
to that seen with the wild-type sequence (Figure 3.29). These results indicate that 
the perfect IR in the promoter region of the Rv0617a/c gene is not essential for the 
VapBCRv0617a/c-DNA interaction. 
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Figure 3.29 VapBCRv0617a/c does not bind to the perfect IR in the Rv0617a/c 130 bp promoter 
region. EMSAs with VapBCRv0617a/c  were run against native and mutated versions of the 130 bp 
promoter region. A, native 130 bp promoter region. B, upstream half of the perfect IR mutated. C, 
downstream half of the perfect IR mutated. D, both halves of the perfect IR mutated. Lanes 1-8 of 
each assay include VapBC at concentrations of 0, 50, 100, 150, 200, 150, 300 and 350 nM. Non-
specific and specific binding is proven in lanes 9 and 10 using 125-fold excess (50 ng) of 
unlabelled 130-bp promoter and 600-bp mazEF promoter DNA respectively. 
 
3.4.4.2 Identification of Near-Perfect Inverted Repeats within the Rv0617a/c 
Promoter 
An investigation of the importance of NPIRs was sparked after analysis of the 
crystal structure of the FitAB TA complex bound to DNA (Mattison et al. 2006). 
This structure revealed that specific protein residue – DNA base interactions were 
only occurring at 6 of the 8 nucleotide positions in each perfect IR half. At 
positions 4 and 5 interactions were occurring non-specifically between the protein 
residues and the phosphate backbone of the DNA (Section 1.3.3). Taking this into 
consideration, the 130 bp Rv0617a/c putative promoter region was examined for 
NPIRs that agreed with the following parameters; at least five bp in length; no 
more than two base mismatches between halves; a spacer of at least five bp 
between halves. This screen resulted in eleven NPIRs identified in the Rv0617a/c 
130 bp putative promoter region, any of which VapBCRv0617a/c could potentially be 
recognising and requiring for binding. The NPIRs were labelled A through J, 
based on their proximity to the 5’-end of the promoter sense strand. Table 3.2 
provides a summary of identified NPIRs. Their positioning along the 130 bp 
promoter region is indicated in Figure 3.30. 
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Table 3.2 Properties of NPIRs in the 130 bp Rv0617a/c putative promoter region 
IR Code 
(5’-3’) 
Genomic 
position from 
TSP
* 
Mismatches 
(bp) 
IR 
Length 
(bp) 
Spacer 
Length (bp) 
Full IR 
covered in 
Oligo
***
: 
A -98, -118 2 6 14 1 
B1
**
 -103, -114 1 5 6 1 
B2
**
 -77, -103 1 5 21 2 
C -60, -80 2 6 14 2 
D -36, -75 2 6 33 3 
E -56, -73 1 5 12 3, 4 
F -45, -64 3 8 11 4 
G -48, -58 1 5 5 4 
H -30, -42 1 6 6 5 
I -27, -1 1 7 19 5 
J -14, -26 1 6 6 5 
*
Genomic positions were measured by counting from TSP (GTG) to the 3’-most base of each IR 
half 
**
B1 and B2 share one half of their IR sequence 
*** 
Oligo design is outlined in Section 2.5.4 
 
 
 
  
9
2
   
Figure 3.30 Putative Rv0617a/c promoter region indicating NPIRs and designed oligo positioning. NPIR (divergent grey arrows) with a maximum of three 
mismatches, minimum length of 5 bp and minimum spacer length of 5 bp were identified in the Rv0617a/c  130 bp region of DNA directly preceding the TSP 
(indicated in orange).  NPIRs are labelled A – J. Five oligos (purple) were designed to span the promoter region such that both halves of each IR were included in 
at least one of the oligos. 
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3.4.4.3 EMSAs with Rv0617a/c Promoter Oligos and Oligo Mutants 
In order to narrow down the region in the promoter to which the VapBCRv0617a/c 
complex binds, and in turn to reduce the number of potential NPIR candidates 
required for binding, five short, overlapping 40 – 50 bp DNA oligos were 
designed to span the 130 bp Rv0617a/c putative promoter region (Section 2.5.4) 
(Figure 3.30). These five oligos were used in EMSAs with VaBCRv0065a/c at 
concentrations of 0 – 350 nM protein (Figure 3.31). A shift indicating 
VapBCRv0065a/c -DNA binding was only observed against oligo 5, which covers the 
region immediately upstream of the Rv0617a/c TSP.  
 
 
Figure 3.31 VapBCRv0617a/c binds specifically to the 50 bp region of DNA directly preceding 
the TSP. EMSA experiments were performed to test VapBCRv0617a/c binding against five oligos 
that span the 130 bp Rv0617a/c promoter region. Lanes 1 to 8 represent VapBC at varying 
concentrations (nM) of 5, 10, 100, 150, 200, 250, 300 and 350. Non-specific and specific binding 
are demonstrated in lanes 9 and 10 using 125 x excess (50 ng) of unlabelled 130 bp promoter and 
600 bp mazEF promoter DNA respectively. 
This narrowed down potential target NPIRs to those with both halves in oligo 5 
(NPIRs H, I and J). Variants of oligo 5 were created where regions of NPIRs H, I 
and J were mutated to ascertain which of the three was essential for binding 
(Section 2.5.4). Assays with DNA variants that had mutations in H and I NPIRs 
displayed unaffected shifts (Bind 2 and 4), whereas when either half of NPIR J 
was mutated (Bind 3 and 5) the shifts were significantly impaired (Figure 3.32).  
DNA 
VapBC-DNA complex 
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This led to the conclusion that NPIR J is the recognition sequence in the promoter 
required for VapBCRv0617a/c binding. 
         
Figure 3.32 Testing VapBCRv0617a/c binding against four oligo 5 variants. EMSA experiments 
were performed to test VapBCRv0617a/c binding against four mutated promoter region oligos where 
IR halves had been selectively mutated out. Bind 1 (native oligo 5), Bind 2 (5’ half of NPIR H 
mutated), Bind 3 (5’ halves of NPIRs H, I and J mutated), Bind 4 (3’ half of NPIR I mutated) and 
Bind 5 (3’ half of NPIR J mutated). 
EMSAs against Binds 1, 3 and 5 were repeated with a greater VapBCRv0617a/c 
concentration range to validate results (Figure 3.33). These assays corroborated 
the previous findings, as VapBCRv0617a/c binding activity against oligo 5 DNA was 
again impaired when either half of NPIR J was mutated. This was visualised as a 
complete abolishment of shift when the upstream NPIR half was mutated, and a 
near-complete abolishment when the downstream NPIR half was mutated.  
 
Figure 3.33 VapBCRv0617a/c requires NPIR J for binding to the Rv0617a/c promoter region. 
EMSA experiments were performed to test VapBCRv0617a/c binding against two mutated promoter 
region oligos where IR halves had been selectively mutated out. Bind 1 (native oligo 5), Bind 3 (5’ 
halves of NPIRs H, I and J mutated) and Bind 5 (3’ half of NPIR J mutated). 
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VapBC-binding competition assays were performed using VapBCRv0617a/c protein 
complex (500 nM) and unlabelled oligo 5 DNA fragments with a native sequence 
(Bind 1), non-target NPIR H mutated (Bind 2) or either half of target NPIR J 
mutated (Binds 3 and 5) at 25 x and 50 x that of the DIG-labelled Bind 1 (0.4 ng) 
(Figure 3.34). A lack of shift indicated that the unlabelled DNA provided in 
excess was bound by the VapBCRv0617a/c complex, and as such, ‘out-competed’ the 
DIG-labelled Bind 1 DNA. 
 
Figure 3.34 VapBCRv0617a/c gel shift competition experiments. Competition experiments were 
performed with VapBC complex (500 nM) and DIG-labelled Oligo 5 ‘Bind 1’ DNA. Increasing 
amounts of unlabelled competitor DNA were used at 25x and 50x that of DIG-labelled Bind 1. 
Concentration factors and varieties of competitor DNA used for each shift are shown above each 
lane. 
Lanes 3 and 4 indicate that 25 x and 50 x excess of the unlabelled, native Bind 1 
were sufficient to outcompete the DIG-labelled Bind 1 DNA, visualised as a 
complete loss of shift compared with that seen for Bind 1 in the absence of 
competition (Lane 2). A complete retardation of shift was also seen with addition 
of unlabelled Bind 2 (Lanes 5 and 6). This further confirms that the NPIR H is not 
required for VapBCRv0617a/c binding to this region. In contrast, excess levels of 
unlabelled Bind 3 and Bind 5 were unable to out-compete labelled Bind 1, 
indicating that VapBCRv0617a/c had lost affinity to these oligo 5 variants due to the 
mutations introduced into NPIR J.  
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4 Chapter Four: Discussion & Future Research 
4.1 Discussion 
4.1.1 General Background 
Since their discovery more than 20 years ago (Gerdes et al. 1986), a multitude of 
studies on TA systems have resulted in a number of postulated biological roles for 
these ubiquitous prokaryotic genes, including involvement in the stress response, 
long term dormancy and formation of MDT persister cells (Frampton et al. 2012). 
The vapBC TA systems are widely spread among prokaryotes and display 
dramatic expansions in a number of pathogenic organisms. Due to their relatively 
recent identification, the biological roles of vapBC systems remain mainly 
uncharacterised. Database mining efforts are constantly identifying new vapBC 
systems, and the count for those encoded in the M. tb genome has reached at least 
47 (Ramage et al. 2009; Arcus et al. 2011). To investigate the function of vapBC 
operons in M. tb, I have examined the biology and biochemistry of VapC 
ribonucleases and VapBC protein complexes of two of the 47 vapBC operons 
encoded on the M. tb chromosome. Characterisation of these proteins aimed to 
provide insight into their physiological roles within the M. tb cell and into how 
these roles may contribute to the virulence, persistence and drug resistance of this 
pathogen. 
In this section the results of this thesis are discussed, focusing on VapC toxicity, 
VapC RNase specificity, transcriptional autoregulation mediated by VapBC, and 
the wider implications that the functioning of these systems may have on the 
pathogenicity of M. tb. 
 
4.1.2 VapCRv0617 Overexpression is Toxic and Bacteriostatic to 
Mycobacterium smegmatis Strains 
In order to assess the toxicity of VapCRv0617, overexpression constructs were 
designed to conditionally express VapCRv0617, VapBCRv0617a/c  or empty vector in 
both M. smegmatis mc
2
155 wild-type and ΔvapBC deletion strains as a function of 
tetracycline inducer level. Similar experiments conducted for a number of M. tb 
VapC proteins have revealed a toxic role for the majority (Gupta 2009; Ramage et 
al. 2009; Ahidjo et al. 2011). In both the wild-type and deletion strains, 
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conditional expression of VapCRv0617 alone resulted in a substantial reduction in 
OD600 readings and bacterial CFUs over time. This is suggestive of induced cell 
stasis mediated by action of VapC. The inhibition of growth is presumably due to 
the effect of VapCRv0617 on the rate of translation and protein synthesis, given its 
ribonuclease activity and the fact that this effect was confirmed for the 
VapCMS1284 protein when expressed in M. smegmatis (McKenzie 2011). 
Co-expression of the cognate vapB on the operon with vapC, and in turn, 
production of the entire VapBCRv0617a/c protein complex, abrogated toxicity. This 
result is in agreement with the model of classical VapBC system interactions 
whereby toxicity of VapC can be tempered by expression of its cognate VapB 
(Arcus et al. 2011).  
A greater VapCRv0617-mediated inhibitory effect was seen in CFU observations as 
opposed to OD600 readings. This may be attributed to the fact that the absorbance 
readings are influenced by the presence of both dead and live cells. In a parallel 
study of the toxicity of VapCMS1284 in M. smegmatis (Robson 2010) it was 
observed that VapCMS1284 overexpression resulted in altered cell morphology, 
namely in the lengthening of cells. This, along with cellular swelling, which is a 
commonly encountered specific cell change associated with exposure to toxins 
(Koshy et al. 1996; Kumar et al. 2012), may have contributed to increase the 
OD600 readings in the VapCRv0617 growth experiment. 
Cultures expressing VapCRv0617 were seen to form fewer and slightly smaller 
colonies on tetracycline-supplemented agar plates; however normal growth 
resumed when these cultures were plated in the absence of tetracycline. This 
indicates that the toxic effect of VapCRv0617 is bacteriostatic rather than 
bactericidal, which is concordant with the mechanism of toxicity reported for a 
number of other toxins both inside (Pedersen et al. 2002; Gupta 2009; Robson et 
al. 2009; Ahidjo et al. 2011; Winther & Gerdes 2011; Cline et al. 2012) and 
outside (Pedersen et al. 2002) the VapBC family. The reversion back to normal 
growth upon removal of the tetracycline inducer also suggests an inactivation or 
break down of existing VapCRv0617 protein. The cellular factors leading to this 
instability of VapCRv0617 in the absence of tetracycline are not known. 
Stress-induced ATP-dependent serine proteases have been implicated in the 
degradation of the labile antitoxin in many TA systems (Yamaguchi & Inouye 
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2011; Yamaguchi et al. 2011). ClpXP has been theorised to play a role in 
influencing antitoxin stability in M. tb (Zhu et al. 2010) and ClpAP has been 
attributed to MazE antitoxin degradation  (Aizenman et al. 1996). M. tb encodes 
two ClpP homologs, which form a mixed complex with an annotated role in the 
degradation of abnormally produced proteins (Raju et al. 2012). It may be 
speculated that such proteases also play a role in VapC degradation in absence of 
VapB.  
It is important to note that the observed VapCRv0617 toxicity is only predicted to be 
due to the presence of VapCRv0617 protein. To confirm that toxicity is due to 
protein expression rather than to the effect of the vapC transcript, a western blot 
analysis for detection of VapCRv0617 would be required. In extrapolating the level 
of toxicity of VapCRv0617 seen in M. smegmatis strains to what would be expected 
in vivo in M. tb strains, it must be kept in mind that, on a proteomic level, 
genomic comparisons indicate that approximately 1218 of the 4034 (30.2 %) 
protein-coding genes of M. tb H37Ra do not have orthologues in M. smegmatis 
(Altaf et al. 2010). 
4.1.3 Mycobacterium tuberculosis and Mycobacterium smegmatis TA 
Elements Exhibit No Cross-talk 
The theory of cross-talk occurring between TA elements encoded on separate 
operons is highly contested. A recent investigation by Wang et al (2013) revealed 
that the toxin MsqR of the msqR/msqA TA system enriches toxin ghoT mRNA 
both in vitro and in vivo through degrading the antitoxin ghoS mRNA. Similarly, 
a study conducted by Zhu et al (2010), identified several non-cognate TA 
interactions in M. tb, both within and between different TA families (e.g. MazF 
toxins and VapB antitoxins).  In contrast to these findings, examinations of M. tb 
vapBC systems by Ahidjo et al (2011) and Ramage et al (2009) found M. tb VapB 
antitoxins to be specific to their cognate VapC toxins, whereby the cognate VapB 
was the only antitoxin able to rescue VapC-induced growth inhibition (Ramage et 
al. 2009). In this thesis research, VapCRv0617-mediated inhibitory effects were 
comparable between the M. smegmatis wild-type and deletion strains, a result 
which argues against functionally relevant cross-talk interactions occurring 
between toxin and antitoxin components of the vapBC systems in M. smegmatis 
and M. tb. If cross-talk were occurring, it would be expected that endogenous 
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VapBMS1283 produced from the wild-type M. smegmatis mc
2
155 strain may reduce 
VapCRv0617 activity, resulting in a lessened degree of growth-inhibition in the 
wild-type than in the knockout where no endogenous VapBMS1283 is produced. 
Since no such difference in growth-inhibition was observed, it can be concluded 
that there is no interaction between VapBMS1283 and VapCRv0617.  
Results from EMSAs revealed that VapBCRv0617a/c did not bind to a 600 bp 
promoter region upstream of the M. tb encoded mazEF TA system operon, nor did 
it bind to the fellow Rv0065a/c vapBC TA system promoter. This provides 
evidence against any degree of VapBC-mediated autoregulatory cross-talk 
occurring within the multiple vapBC systems or among different TA systems in 
M. tb. 
4.1.4 VapCRv0065 and VapCRv0617 are Ribonucleases Targeting a 
Combination of RNA Sequence and Structure 
It remains unclear how PIN-domain proteins achieve specificity in their 
ribonuclease activities. VapCRv0065 and VapCRv0617 RNase assays included in this 
thesis support the previously drawn conclusion that both these VapC proteins 
target GC-rich 4-mers in the RNA. Due to the high GC content of the M. tb 
genome, this points toward a role of VapCRv0065 and VapCRv0617 as global gene 
down-regulators of mRNA transcripts when conditions allow for VapC to be free 
from its cognate VapB inhibitor. Sequence specificity directing toxins to a broad 
range of targets within the cell is not uncommon in TA systems. For example, the 
MazF toxin from E. coli targets ACA sequences, which, due to its high prevalence 
across the genome, makes MazF an extremely potent toxin (Zhang et al. 2003). 
The shared recognition sequence for both VapCRv0065 and VapCRv0617 is similar to 
the case seen in P. aerophilum, where two VapC proteins separately encoded in 
the genome, VapCPAE0151 and VapCPAE2754, were found to target the same RNA 
sequence (GGUG) (McKenzie 2011). These P. aerophilum VapC proteins 
differed from each in terms of catalytic rate, as VapCPAE2754 displayed faster 
ribonuclease activity compared to VapCPAE0151 (McKenzie 2011). In contrast, 
VapCRv0065 and VapCRv0617 appeared to have equivalent ribonuclease activity. If 
these proteins do in fact have the same activity, it could be speculated that 
activation of a single one of these two M. tb TA systems could be employed for a 
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lower level of transcriptome regulation, while the additive effect of activation of 
both would result in more rapid alterations to the transcriptome when required. 
RNA recognition sequences for the remaining ~45 VapC proteins encoded in the 
M. tb genome are yet to be determined, and it will be interesting to see whether 
they too target GC-rich 4-mers in the RNA. 
A higher degree of specificity in the RNase activity of M. tb VapC proteins was 
suggested by results obtained from the VapCRv0617 conditional expression 
experiment conducted in M. smegmatis. The fact that VapCRv0617 displayed only 
slight toxicity suggested that a small subset of mRNA transcripts was being 
targeted for degradation. If the toxin was non-specifically degrading the majority 
of the transcriptome, or cleaving at every GC-rich 4-mer site of the mRNA, a 
much larger growth inhibitory effect would be expected. 
Accordingly, results of VapCRv0617 and VapCRv0065 RNase assays against the 932 
109-126 RNA fragment suggested that this additional activity determinant resides 
in the secondary structure of the RNA. If these VapC proteins solely recognised 
the GC-rich 4-mer cut sites, then the above fragment, given the activity observed 
against its slightly extended counterpart (932 94-126) and its significant GC 
content, would be predicted to be cleaved very efficiently. Instead, the complete 
loss of activity when the 932 94-126 fragment was truncated by just 12 bases 
while retaining all predicted cut sites is a strong indicator of the influence that 
secondary structure imparts on VapC RNase activity. As both VapCRv0065 and 
VapCRv0617 lacked activity against the 932 109-126 fragment, this suggests that 
they may exhibit specificity for the same RNA secondary structural element. The 
efficient cleavage by both VapC of substrates with a higher degree of secondary 
structure, (the 932 Pentaprobe and the longer 932 Pentaprobe fragments) further 
supports the theory that VapC requires the presence of a particular structural motif 
for RNase activity to be exhibited. The 932 fragments that were cleaved the most 
efficiently at their GC-rich centre had this sequence located in a hairpin loop 
which was flanked by a long stem region. This may be a motif required for 
efficient VapC cleavage, however it is also possible that the secondary structure 
motif recognised is positioned further from the cut site. 
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The optimal combination of sequence and secondary structural motifs associated 
with VapC RNase activity may be present in the rRNA component of 
M. smegmatis total RNA samples. The results of RNase assays with M. smegmatis 
total RNA revealed that the majority of rRNA in the sample was degraded within 
15 minutes of incubation with either VapC. In contrast, RNase mediated 
degradation of the 932 Pentaprobe RNA occurred over a longer timescale, perhaps 
due to such VapC recognition elements being less abundant or lacking. 
Narrowing down the site and identity of the secondary structural motif(s) required 
for VapC cleavage will be hampered by methods of structure determination. 
Current physical methods involved in RNA structure determination such as x-ray 
diffraction and NMR spectroscopy are time-consuming and costly, so methods 
involving the computational prediction of structure, such as use of the RNAfold 
software, are necessary (Mohsen et al. 2009). This approach, however, is 
hampered by its reliance on algorithmic predictions, meaning that results are 
associated with a degree of uncertainty. 
VapC-mediated cleavage at certain secondary structure elements in the mRNA 
may serve to feed redundant mRNA transcripts into more generalised cell RNA 
degradation pathways. While the general system for mRNA degradation in 
mycobacteria is not well characterised, it is known that secondary structural 
elements such as those at the 5’ and 3’ UTRs can increase stability of the mRNA 
and provide a barrier against degradation by nucleases (Steege 2000). Results 
indicated that both VapCRv0065 and VapCRv0617 are able to cleave in vitro 
synthesised RNA with a high degree of predicted secondary structure. Therefore, 
in vivo, when the correct secondary structural element is present, VapC-mediated 
cleavage may remove this barrier, increasing the susceptibility of mRNA 
transcripts to enter general RNA degradation pathways.  
An additional factor that may contribute to the specificity of VapC ribonuclease 
activity which has not yet been investigated is the potential influence of RNA 
modifications such as methylation. While not commonly associated with bacterial 
RNA, Yi & Pan (2011) suggest there is increasing evidence for RNA 
modifications playing a regulatory role in prokaryotic cells, especially during the 
stress response.  The methylated nucleotides m
6
A, m
1
A, Cm, m
5
C, Gm, m
1
G, m
7
G, 
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m
5
U and Um are common in both eukaryotes and prokaryotes (Motorin & Helm 
2011).  Bacterial rRNA methylation at several 2’-O sites along  rRNA is reported 
to confer resistance to certain antibiotics such as aminoglycosides, macrolides and 
lincosamides through altering the affinity of these drugs for the ribosome 
(Motorin & Helm 2011). The 2’-O-methylation of tRNAs was shown to prevent 
cleavage by ribotoxins (Yi & Pan 2011). VapC proteins such as VapCRv0617 and 
VapCRv0065 that appear to target the same primary RNA sequence and secondary 
structure may in fact be differentiated by the RNA modifications that either one 
recognises. 
The additional layers of VapC RNase specificity residing in the RNA secondary 
structure, and potentially in RNA modifications, would reduce the enormous 
number of target transcripts in the M. tb genome that would be cleaved based on 
sequence recognition alone. Different VapC proteins in the same organism may 
strategically target unique subsets of the transcriptome specific to different 
metabolic pathways. This would allow strict control over the genetic elements 
expressed at any one time, equipping the cell with a mechanism to ‘reprogram’ 
itself to quickly adapt to changing external factors and different stress conditions.  
4.1.5 VapCRv0065 and VapCRv0617 Display Ribonuclease Activity Against 16S 
and 23S rRNA Isolated from Mycobacterium smegmatis  
While both VapCRv0065 and VapCRv0617 enzymes displayed Mg
2+
-dependent 
ribonuclease activity against purified M. smegmatis 16S and 23S rRNA, the 
RNase action was to such an extent that discrete degradation product bands could 
not be identified. Instead, the array of degradation products appears as a smear on 
the gel. This indicates that the VapC enzymes cleave at a multitude of sites along 
the rRNA sequences. Due to the lack of definite degradation product bands, it was 
decided that this approach for determining secondary structure requirements of the 
VapC enzymes was not to be pursued further. If the results of this experiment are 
taken to indicate VapCRv0617 and VapCRv0065 activities against rRNA in vivo, it 
must be kept in mind that ribosomal proteins associated with the rRNA in vivo 
may play a role in protecting the rRNA from such ribonuclease factors. For 
example, the MazF toxin from E. coli is seen to target ACA sequences and 
effectively cleaves both 23S and 16S rRNA in vitro, yet displays no such activity 
in vivo (Zhang et al. 2003). 
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4.1.6 VapBCRv0617a/c Binds a NPIR in the Rv0617a/c Promoter  
Analysis of a 150 bp region upstream of the Rv0617a/c transcriptional start point 
revealed two possible -10 elements: one which shared sequence with a -10 
element annotated in another M. tb promoter (‘T26’) (Bashyam et al. 1996)  and 
another which shared the consensus sequence for mycobacterial sigma factor A 
binding site (Gomez & Smith 2000; Zaunbrecher et al. 2009). No -35 element that 
showed similarity to other mycobacterial or E. coli -35 elements was found in this 
region; however this is unsurprising given that there is very little sequence 
conservation of this element among mycobacteria (Bashyam et al. 1996). Within 
the 150 bp region, one perfect IR was identified along with eleven NPIRs. EMSA 
experiments revealed that VapBCRv0617a/c binds specifically to this 150 bp region 
of DNA. Mutations made to either half of the perfect IR in this region had no 
effect on gel shifts, implying that the perfect repeat was not essential for 
VapBCRv0617a/c binding. Further EMSA experiments identified a 6 bp NPIR 
overlapping the -10 region, ‘NPIR J’ as being essential for VapBCRv0617a/c 
binding, as complete or near-complete loss of shift was observed when either half 
was mutated. Loss of shift when either half-site alone is mutated suggests that 
VapBCRv0617a/c must bind both sites of the NPIR to achieve repression.  
While the majority of VapBC complexes characterised to date have displayed 
perfect IR recognition, the VapBC2 complex of Rickettsia felis similarly requires 
a near-perfect palindrome for binding (Mate et al. 2011). The fact that the NPIR 
that VapBCRv0617a/c bound overlaps the putative -10 recognition site is consistent 
with a mechanism of autoregulation whereby binding of the complex sterically 
excludes RNA polymerase from the DNA. It is possible that the VapBCRv0617a/c 
complex binds to the DNA in a similar manner to the VapBC complex (‘FitAB’) 
of N. gonorrhoeae; as a tetramer of heterodimers, where each VapB dimer binds 
to one half of the IR (Mattison et al. 2006). The two systems differ however in 
that the FitAB complex was shown to require only one half of the IR for binding. 
Analysis of the 101 bp region upstream of the Rv0065a/c transcriptional start 
point revealed no similarity in the -10 and -35 regions to those seen in other 
mycobacterial promoters. Despite the presence of a IR sequence, EMSA 
experiments indicated no DNA binding activity of VapBCRv0065a/c to this region, 
nor to a region extending downstream of the TSP. If VapBCRv0065a/c does exhibit 
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autoregulatory activity through binding to its cognate promoter, this binding site 
must be relatively far from the TSP. Is has been noted in the ccdAB (Afif et al. 
2001), phd/doc (Johnson et al. 1996) and parDE (Magnuson & Yarmonlinksy 
1998) TA systems that an altered toxin:antitoxin ratio can result in the formation 
of TA complexes with varied stoichiometry that no longer exhibit DNA-binding 
activity. An alternate explanation for the absence of VapBCRv0065a/c DNA-binding 
activity therefore may be that the ratio of toxin : antitoxin in the VapBCRv0065a/c 
samples was such that it caused destabilisation of the repressor-DNA complex. 
This mechanism of alleviating repression when the toxin ratio is high is suggested 
to be a common mechanism in TA systems, and may function to promote 
production of the antitoxin to prevent harmful toxin activation when it is not 
required (Afif et al. 2001). 
Conversely, the Rv0065a/c operon may not employ autoregulation through 
VapBC binding to the promoter region. Individualised transcriptional regulation 
mechanisms among the vapBC systems of M. tb may add an extra layer of 
complexity to the regulation of the vapBC TA system network, helping explain 
the persistence of such an expanded number of these operons in the genome. 
4.1.7 VapBC Systems’ Theorised Physiological Role in Mycobacterium 
tuberculosis 
A hallmark of M. tb infections is the bacteria’s ability to persist for months to 
years in an asymptomatic, dormant state. The mycobacterial VapCMS1284 is 
proposed to maintain the balance of anabolic and catabolic rates in M. smegmatis 
through its ribonuclease activity (McKenzie 2011). Based on the RNase activity 
that VapCRv0065 and VapCRv0617 display in vitro, and the toxic, bacteriostatic effect 
that their unmasked expression has on mycobacterial cells in vivo, it is possible 
that they play a role in degrading redundant transcripts within the M. tb cell. This 
would serve to correct the metabolic imbalances that can result in the production 
of toxic intermediates (Russell & Cook 1995). Fine-tuning of catabolic and 
anabolic rates would allow conservation of energy, a factor that would be required 
for the M. tb persistence in the dormant state. 
A theory that remains to be explored is the possibility that VapBC complexes 
and/or the VapC proteins are secreted/exported from the M. tb cell, allowing them 
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to act upon the mRNA of the host, i.e. that of the macrophage cell.  Preliminary 
evidence for this theory includes recent studies which report the Rv0617 
(VapCRv0617) (Gomez et al. 2000) and Rv0064 (VapBRv0064) (Malen et al. 2007) 
genes as encoding putative secreted M. tb proteins. 
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4.2 Future Resesarch 
4.2.1 Determine the Toxicity of VapCRv0065 to Mycobacterium smegmatis 
Strains 
The pMind expression constructs for investigating the effect of conditional 
overexpression of VapBCRv0065a/c and VapCRv0065 were created and transformed 
into wild-type M. smegmatis mc
2
155 and knockout M. smegmatis mc
2
155 
ΔvapBC strains. Conducting a growth experiment similar to that done for the 
Rv0617a/c vapBC TA system would allow more comparisons to be drawn 
between the two systems, and would provide greater insight into the role of this 
system in vivo. 
 
4.2.2 Microarray Analysis of VapCRv0065 and VapCRv0617 Overexpression 
In order to identify in vivo transcript targets, it may be of interest to compare the 
transcriptome of M. smegmatis cultures in the presence and absence of VapCRv0065
 
and VapCRv0617 expression through microarray analysis. As activity and 
specificity studies of these two VapC proteins in vitro has revealed a shared 
RNase specificity, it would be interesting to examine whether they would induce 
downregulation of the same sets of transcripts when acting in vivo. Studies 
conducted to investigate factors the leading to activation of either VapC may 
reveal whether these systems are triggered by the same or different stresses. 
 
4.2.3 Further Examine the Specificity of Mycobacterium tuberculosis VapC 
Ribonucleases 
It remains to be determined whether multiple VapC proteins from the same 
organism target shared or exclusive mRNA transcripts in vivo. Therefore, to better 
understand the collective role of VapC proteins in M. tb physiology, efforts should 
be made to express and purify the remaining ~45 VapC M. tb proteins. The 
Pentaprobe system combined with MALDI TOF MS should be applied to each to 
characterise VapC RNA sequence recognition sites. In addition, the influence of 
secondary structure and possibly RNA modifications should be probed further, 
and attempts made to determine what recognition motif(s) are required and where 
these reside in relation to the RNA cut site. 
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4.3 Conclusions 
VapC proteins are present in half of all sequenced prokaryotes and notably so in 
pathogens such as N. gonorrhoeae (Wilbur et al. 2005; Mattison et al. 2006), 
Haemophilus influenzae (Daines et al. 2007; Cline et al. 2012), Leptospira 
interrogans (Zhang et al. 2004)  and M. tb (Miallau et al. 2009; Ramage et al. 
2009). This thesis has outlined the characterisation of proteins encoded by the 
Rv0065a/c and Rv0617a/c vapBC operons of the M. tb genome. Relating back to 
the initial research objectives, the following conclusions can be drawn: 
1) VapCRv0617 is a toxic protein that exhibits an in vivo bacteriostatic effect 
when conditionally expressed in M. smegmatis strains. 
2) VapCRv0065 and VapCRv0617 display the same sequence specificity and 
target GC-rich 4-mers in the RNA. Their activity appears to be 
additionally influenced by the secondary structure of the RNA substrate.  
3) The VapBCRv0617a/c complex binds specifically to a NPIR sequence in the 
putative Rv0617a/c promoter DNA, presumably to fulfil a transcriptional 
autoregulatory role. In contrast, the VapBCRv0065 complex displays no such 
DNA binding activity with putative Rv0065a/c promoter DNA.  
Ultimately, gaining a better understanding of VapC and VapBC protein 
functioning within the M. tb cell may reveal strategies for hindering activity of the 
VapC toxins. Encumbering their RNase action would prevent the ability of cells 
to selectively alter their transcriptome by this means. This would in theory hamper 
the cell’s ability to regulate its growth rate in order to adapt to environmental 
stresses. In turn, the formation of persister cells which lead to latent M. tb 
infections would be prevented, and the efficacy of both antibiotic treatments and 
immune-driven attack would be increased.  
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Appendices 
Appendix A: Reagents 
A1: Bacterial Strains and Plasmids  
Table A1.1 Bacterial Strains 
Strain Description 
E.  coli  
DH5α High plasmid copy number, transformation efficiency and DNA 
yield. fhuA2 Δ(argF-lacZ)U169 phoA glnV44 ф80 Δ(lacZ)M15 
gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
DH10B (TOP10) High plasmid copy number, transformation efficiency and DNA 
yield. F-mcrA Δ(mrr-hsdRMS-mcrBC)ф80 dlacZ ΔM15 ΔlacX74 
deoR recA1 araD139 Δ (ara leu)7697 galU galK rpsL endA1 nupG 
M. smegmatis  
mc
2
155 Electrocompetent lab strain of M. smegmatis  
mc
2
155ΔvapBC 
(JR121) 
mc
2
155ΔvapBC::aphaA-3; Kmr acquired from Jennifer Robson, 
University of Otago (2010) 
mc
2
4517 M. smegmatis expression strain with T7 RNA polymerase, Km
r
 
  
Table A1.2 Plasmids 
Plasmid Description 
pYUB28b Mycobacterium expression vector; Km
r 
Hyg
r 
pMind Tetracycline inducible vector; Km
r 
Hyg
r
 
0065vapBC_pMind Tetracycline inducible vector with 0065a/c operon insert; Km
r 
Hyg
r
 
0065vapC_pMind Tetracycline inducible vector with 0065c gene insert; Km
r 
Hyg
r
 
0617vapBC_pMind Tetracycline inducible vector with 0617a/c operon insert; Km
r 
Hyg
r
 
0617vapC_pMind Tetracycline inducible vector with 0617c gene insert; Km
r 
Hyg
r
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A2: Buffers, Solutions and Media 
Table A2.1 Buffers and Solutions 
Name Composition 
5x DNA Loading 
Dye 
0.05 % (w/v) bromophenol blue 0.25% (w/v) xylene cyanol, 30% 
(v/v) glycerol 
Fairbanks Staining 
Solution A 
0.05% (w/v) coomasie blue R-250, 25% (v/v) isopropanol, 10% 
(v/v) acetic acid 
Fairbanks Staining 
Solution B 
0.005% (w/v) coomasie blue R-250, 10% (v/v) isopropanol, 10% 
(v/v) acetic acid 
Fairbanks Staining 
Solution C 
0.002% (w/v) coomasie blue R-250, 10% (v/v) isopropanol, 10% 
(v/v) acetic acid 
Fairbanks Staining 
Solution D 
10% (v/v) acetic acid 
2 x Formamide 
Loading Buffer 
80% (v/v) formamide, 5 mM EDTA, 0.1% (w/v) bromophenol blue, 
0.1% (w/v) xylene cyanol FF 
GITC 295.4 g guanidine thiocyanate, 2.5 g N-lauroyl sarcosin, 3.9 g tri-
sodium citrate, 3.6 ml 2-mercaptoethanol, 280 ml DEPC H2O (total 
volume 500 ml) 
4 x SDS loading 
Buffer 
200 mM Tris-HCl pH 6.8, 8% (w/v) SDS, 40% (v/v) glycerol, 0.4% 
(w/v) bromophenol blue, 400 mM β-mercaptoethanol 
SDS Resolving Gel 
Layer 
16.5% acrylamide
*
, 0.1 % (w/v) SDS, 0.05% (w/v) APS, 0.05% 
(v/v) TEMED, 375 mM Tris (pH 8.8) 
SDS Stacking Gel 
Layer 
5% acrylamide
*
, 0.1 % (w/v) SDS, 0.05% (w/v) APS, 0.05% (v/v) 
TEMED, 128 mM Tris (pH.6.8) 
SDS running 
Buffer 
25 mM Tris-HCl ph 6.8, 0.1% (w/v) SDS, 190 mM glycine 
TBE Gels 6% acrylamide
*
, 0.05% (w/v) APS, 0.05 % (v/v) TEMED, 15 % 
(v/v) 10 x TBE. 
10 x TBE 0.89 M Tris-HCl, 0.89 M boric acid, 20 mM EDTA 
1 x TBE 100 ml 10 x TBE + 900 ml H2O 
TE 10 mM Tris-HCl pH 8.0, 1 mM EDTA pH 8.0 
*
Acrylamide was added from a 30% acrylamide/bis stock solution 37.5:1 (BioRad 
Laboratories, USA).   
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Table A2.2 Liquid Media 
Name Composition 
7H9/ADC/T Dissolve 0.47 g 7H9 powder (BD) and 0.2% glycerol in 90 ml H2O, 
autoclave, then add 10 ml ADC enrichment and 0.05% Tween-80 
when cool 
Hartmans-de 
Bont 
Add components in the following order: 1 x trace metal stock
*
, 15 
mM (NH4)2SO4, 0.05% (v/v) Tween-80, 0.2% (v/v) glycerol, 50 mM 
MOPS. Autoclave, then add 8.9 M K2HPO4 and 7.08 M NaH2PO4 
LB 1% bactotryptone, 0.5% yeast extract, 1% NaCl pH 8.0 
LBT 1% bactotryptone, 0.5% yeast extract, 1% NaCl, 0.05% Tween-80 
pH 8.0 
Low salt LB 1% bactotryptone, 0.5% yeast extract, 0.5% NaCl pH 8.0 
PA-0.5G 50 mM Na2HPO4, 50 mM KH2PO4, 25 mM (NH4)2SO4, 1 mM 
MgSO4, 0.5% glucose, 0.1 x metals mix
**
, 200 µg/ml each of 17 
amino acids (no Cys, Tyr or Met). Individual components are 
autoclaved or sterile filtered before adding to sterile H2O. 
SOC 2% bactotryptone or bactopeptone, 0.55% yeast extract, 10 mM 
NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose 
ZYP-5052 1% bactotryptone, 0.5% yeast extract, 50 mM Na2HPO4, 25 mM 
KH2PO4, 25 mM (NH4)2SO4, 1 mM MgSO4, 0.5% glycerol, 0.05% 
glucose, 0.2% α-lactose, 1 x metals mix  
*The 100 x trace metals stock for HdB media consisted of: EDTA (0.1 g), MgCl2.gH2O 
(1 g), CaCl2.2H2O (10 mg), NaMoO4.2H2O (2 mg), CoCl2.6H2O (4 mg), MnCl2.2H2O (10 
mg), ZnSO4.7H2O (20 mg), FeSO4.7H2O (50 mg), CuSO4.5H2O to 100 ml 
 
**The 1000x metals mix for PA-0.5G media consisted of sterile components made up to 
the following concentrtaions: 50 µM FeCl3 in 0.12 M HCl (filter sterilized), 20 µM 
CaCl2, 10 µM MnCl2, 10 µM ZnSO4, 2 µM CoCl2, 2 µM CuCl2, 2 µM NiCl2, 2 µM 
Na2MoO4, 2 µM Na2SeO3, 2 µM H3BO3 
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Table A2.3 Solid Media 
Name Composition 
7H10/ADC/T-agar Dissolve 1.9 g 7H10 powder (BD), 0.5% glycerol in 90 ml H2O, 
autoclave, the add 10 ml ADC enrichment and 0.05% Tween-80 
when cool 
LB-agar 1% bactotrypton, 0.5% yeast extract, 1% NaCl, 15 g/L agar pH 8.0 
LBT-agar 1% bactotrypton, 0.5% yeast extract, 1% NaCl, 15 g/L agar, 0.05% 
Tween-80 pH 8.0 
Low salt LB-agar 1% bactotrypton, 0.5% yeast extract, 0.5% NaCl, 15 g/L agar pH 
8.0 
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Appendix B: Sequencing Results 
B1: Perfect IR Mutagenesis  
Sequencing results for two-halves mutagenesis of the perfect IR in the 130 bp Rv0617a/c 
promoter region. Bind 2 represents the upstream half mutated, Bind 3 the downstream 
half mutated, and Bind 4 both halves mutated. Shown for each mutant promoter sequence 
is the sequencing chromatogram results aligned with the wild-type Rv0617a/c 130 bp 
promoter region DNA sequence. IR; inverted repeat. MUT; mutated bases. 
Mutant Sequence 
Bind 2 
 
Bind 3 
 
Bind 4 
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Appendix C: Protein and RNA Information 
C1: Mycobacterium Protein Information 
VapBRv0064 Protein Sequence 
MATIQVRDLPEDVAETYRRRATAAGQSLQTYMRTKLIEGVRGRDKAEAI
EILEQALASTASPGISRETIEASRRELRGG* 
80 amino acids 
Molecular weight of monomer: 8.71 
Theoretical pI: 9.12 
VapCRv0065 Protein Sequence with C-terminal His tag 
VDECVVDAAAVVDALAGKGASAIVLRGLLKESISNAPHLLDAEVGHALR
RAVLSDEISEEQARAALDALPYLIDNRYPHSPRLIEYTWQLRHNVTFYDAL
YVALATALDVPLLTGDSRLAAAPGLPCEIKLVRKLAAALEHHHHHH* 
147 amino acids 
Molecular weight of monomer: 15.8 kDa 
Theoretical pI: 6.34 
VapBCRv0065a/c Protein Complex 
Molecular weight of heterodimer: 24.51 kDa 
VapBRv0616 Protein Sequence 
VRTTIDLPQDLHKQALAIARDTHRTLSETVADLMRRGLAANRPTALSSDP
RTGLPLVSVGTVVTSEDVRSLEDEQ* 
76 amino acids 
Molecular weight of monomer: 8.2 
Theoretical pI: 5.64 
VapCRv0617 Protein Sequence with C-terminal His tag 
VTVLLDANVLIALVVAEHVHHDAAADWLMASDTGFATCPMTQGSLVRF
LVRSGQSAAAARDVVSAVQCTSRHEFWPDALSFAGVEVAGVVGHRQVT
DAYLAQLARSHDGQLATLDSGLAHLHGDVAVLIPTTTKLAAALEHHHHH
H* 
147 amino acids 
Molecular weight of monomer: 15.5 kDa 
Theoretical pI: 6.5 
VapBCRv0617a/c Protein Sequence 
Molecular weight of heterodimer: 23.7 kDa 
 
 
C2: Pyrobaculum Protein Information 
VapCPAE0151 Protein Sequence with pProEX fusion tag 
MSYYHHHHHHDYDIPTTENLYFQGAMKLVVDASAIAALYVPEERSEQAE
RAVSQAQELHTLDLAAYEVANDLWKHARRGLLREDEASNMLEELWEFF
KALKVHSYAEVLKDAFALALKHGVTVYDAAYVALAEKIGGKLLTLDRQ
LAEKFPALVTP* 
156 amino acids 
Molecular Weight: 17.7 kDa 
Theoretical pI: 5.50 
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C3: Pentaprobe RNA and Flanking Sequences 
A representation of the RNA sequence that is transcribed from the T7 promoter. 
Regions highlighted in yellow correspond to the Pentaprobe sequence (McKenzie 
2011) 
AGACCCAAGCTTGGTACCGAGCTCGGATCCACTAGTAACGGCCGCCAG
TGTGCTGGAATTCTGCAGATCTCCAACCTCACACCACATTACACTGGG
GTGATATAATATGATGCCGGGCGGGGGCCGTAACGTAGCACTACATGA
CCCGATACGCTAGGTGGGATTAGGCATCACACTGGCGGCCGCTCGAGC
ATGCATCTAGAGGGCCCTATTCTATAGTGTCACCTAAATGCTAGAGCT
CGCT 
 
C4: Predicted Secondary Structure of 932 RNA Fragments 
 
 
 
Minimum free energy structures predicted using RNAfold (Vienna RNA webservers, 
TBI). 
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C5: Predicted Secondary Structure of 932 RNA Oligonucleotides  
 
 
 
 
Figure taken from Mckenzie (2011)  
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